CYAN-SUBSTITUTED CYCLIC HYDRAZINE DERIVATIVE AND APPLICATION THEREOF

Abstract

The present invention provides a cyano-substituted cyclic hydrazine derivative comprising: a compound represented by the following structural formula or a stereoisomer, a geometric isomer, a tautomer, a racemate, a hydrate, a solvate, a metabolite, and a pharmaceutically acceptable salt or prodrug thereof. The compound is used for the prevention, treatment, or alleviation of autoimmune or proliferative diseases in patients and / or for inhibiting or modulating protein kinase activity. (See Formula).

Description

CYAN-SUBSTITUTED CYCLIC HYDRAZINE DERIVATIVE AND APPLICATION THEREOF nc Lrnn / zznz / B / Yu FIELD OF INVENTION The present invention pertains to the field of drug synthesis and, in particular, the present invention relates to a JAK inhibitor, its method of preparation and its use. BACKGROUND OF THE INVENTION Protein kinases are a class of enzymes that catalyze the phosphorylation of proteins and are key factors in the regulation of cell signals such as cell proliferation and cell differentiation, including cell growth, survival, differentiation, organogenesis, morphogenesis, neovascularization, tissue repair and regeneration, etc. The signal transduction of many cytokines, such as the interferon (IFN) family, the glycoprotein 130 (gpl30) family, the γ-C family (common gamma chain, CD132 family), and the single-chain family, involves the Janus kinase (JAK) family, as well as JAK downstream signal transducers and activators of transcription (STATs). Currently, there are four known members of the JAK family in mammals: JAK1 (also known as Janus kinase-1), JAK2 (also known as Janus kinase-2), JAK3 (also known as Janus kinase-3), and TYK2 (also known as protein tyrosine kinase 2). Blocking JAK signal transduction offers a promising avenue for developing therapeutic approaches for inflammatory diseases, autoimmune diseases, bone marrow proliferative disorders, and cancer. JAK inhibition also contributes to the treatment of immune-mediated skin diseases such as psoriasis and skin sensitization. Toficitinib and baricitinib, which have been launched, are used to treat rheumatoid arthritis; ruxolitinib is used to treat bone marrow fibrosis and acute graft-versus-host disease. However, some JAK inhibitors also have some evident side effects and toxicities. JAK inhibitors can cause immune-related side effects: infection, including pneumonia, viral infection (such as herpes zoster), bacterial infection, actinomycosis (mycobacterial infection), fungal infection, decreased immunity (such as reduced NK cells), and anemia. However, there are also some non-immunological side effects, such as pulmonary embolism (which can be fatal). Studies have shown that existing JAK inhibitors are not selective for members of the JAK kinase family, and their pulmonary embolism side effect is related to JAK2 inhibition. In short, there is an urgent need in this field to develop inhibitors of Janus kinases or related kinases, especially inhibitors with high selectivity for JAK1. nr Lrnn / zznz / E / YiAi BRIEF DESCRIPTION OF THE INVENTION The purpose of the present invention is to provide a novel inhibitor with high activity for JAK1 and high selectivity for JAK2, as well as the method of preparing and using the same. The present invention provides a cyano-substituted cyclic hydrazine derivative, characterized by being a compound represented by the following structural formula or its pharmaceutically acceptable stereoisomer, geometric isomer, tautomer, racemate, hydrate, solvate, metabolite and salt or prodrug; Where, ring A is a heterocyclic group, a fused heterocyclic group and a spiroheterocyclic group; The previous R1 is one or more substituents that are the same or different; The R1 above is selected from hydrogen, hydroxyl, halogen, amino, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl; The above River is selected from a cyano group or a group terminated in cyano; the cyano-terminated group may be saturated or unsaturated in any way; R2 is selected from hydrogen, hydroxyl, halogen, nitro, amino, substituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl; R20 is selected from hydrogen, an amino protecting group. The above ring A is most preferably a heterocyclic group consisting of 4-9 atoms, or a fused heterocyclic group consisting of 6-12 atoms, or a spiroheterocyclic group consisting of 6-12 atoms; Where, there are 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur. The previous ring A can be the structure shown in the following structure or a similar structure: In the present invention, substituted or unsubstituted alkyl refers to: The above unsubstituted alkyl is generally a branched alkyl with 6 or fewer carbon atoms or a branched alkyl; The substituted alkyl above refers to one or more of the hydrogen atoms in the carbon chain of the alkyl being substituted by other groups, and the other groups mentioned herein may be cycloalkyl (substituted in a manner similar to ί / \)θ,1,2,3,4,5,β ί^)θ,1,2,3,4Λ6 / ^0,1,2....... Uji,3.4.5.6 and any hydrogen atom in the cycloalkyl ring may also be substituted by halogen, cyano, alkyl, hydroxyl, carboxyl, etc.), heterocycloalkyl (i.e., on the basis of the above cycloalkyl, at least one carbon atom in the alkyl ring is replaced by oxygen, sulfur, and nitrogen), halogen (F, Cl, Br, I), carboxyl, cyano (-CN), sulfonyl (-SOsRa, Ra is alkyl, aryl, etc.), alkynyl (C^CH, -C^CRb, Rb is alkyl, aryl, etc.), acylamino (-C(O)NRxRy, RxRy is alkyl, aryl, etc.), ester (-C(O)O-Rz, Rz is alkyl, aryl, etc.), aryl, heteroaryl, and other groups; In the present invention, substituted or unsubstituted cycloalkyl refers to: The above unsubstituted cycloalkyl is generally a cycloalkyl with 3-8 carbon atoms; The above substituted cycloalkyl refers to the substitution of one or more hydrogen atoms in the cycloyl ring with other groups, and the other groups mentioned herein may be alkyl, substituted alkyl (ibid.), halogen (F, Cl, Br, I), carboxyl, cyano (-CN), sulfonyl (-SO2Ra, Ra is hydrogen, alkyl, aryl, etc.), alkynyl (-CnCH, -C^CRb, Rb is alkyl, aryl, etc.), acylamino (-C(O)NRxRy, RxRy is alkyl, aryl, etc.), ester (-C(O)O-RZ, Rz is alkyl, aryl, etc.), aryl, heteroaryl, and other groups. In the present invention, substituted or unsubstituted heteroalkyl means that, on the basis of substituted or unsubstituted alkyl, one or more carbon atoms in the carbon chain are replaced by oxygen, sulfur, and nitrogen. In the present invention, substituted or unsubstituted heterocycloalkyl means that, on the basis of substituted or unsubstituted cycloalkyl, one or more carbon atoms in the ring are replaced by oxygen, sulfur, and nitrogen. In the present invention, substituted or unsubstituted alkoxy refers to: The above unsubstituted alkoxy is generally a branched alkoxy with 6 or fewer carbon atoms or a branched alkoxy; The above substituted alkoxy refers to one or more of the hydrogen atoms in the alkyl carbon chain being substituted by other groups, and the other groups mentioned herein may be cycloalkyl (substituted in a manner similar to nr Lrnn / zznz / B / Yi 0,1,2,3,4,6,6 and any hydrogen atom in the cycloalkyl ring may also be substituted by halogen, cyano, alkyl, hydroxyl, carboxyl, etc.), heterocycloalkyl (i.e., on the basis of the above cycloalkyl, at least one carbon atom in the alkyl ring is replaced by oxygen, sulfur, and nitrogen), halogen (F, Cl, Br, I), carboxyl, cyano (-CN), sulfonyl (-SC^Ra, Ra is hydrogen, alkyl, aryl, etc.), alkynyl (C^CH, -C^CRb, Rb is alkyl, aryl, etc.), acylamino (-C(O)NRxRy, RxRy is alkyl, aryl, etc.), ester (-C(O)O-Rz, Rz is alkyl, aryl, etc.), aryl, heteroaryl, and other groups. In the present invention, substituted amino means that one or more hydrogen atoms in the amino (-NH2) are substituted by other groups, and the other groups referred to herein may be alkyl, cycloalkyl, acylamino, ester, and other groups. Furthermore, the present invention provides a cyano-substituted cyclic hydrazine derivative, wherein the structure is as follows: Where, n is selected from a natural number from 1 to 3; The above X is selected from substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, -(CH2)mN(R3)-, -(CH2)mC(O)N(R3)-, -(CH2)mC(O)-; The bond between X and ring A is a single bond or a double bond; R3 is selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl; m is selected from a natural number from 1 to 3. In the present invention, substituted or unsubstituted alkylene means: The unsubstituted alkylene above refers to the form -(CH2)m-; The substituted alkylene above refers to one or more hydrogen atoms in the carbon chain -(CH^m-) being substituted by other groups, and the other groups here can be alkyl, cycloalkyl (substituted in a manner similar to í / ^0,1,2,3,4,5,6 \ / £^0,1,2,3.4,5,6 χ0,1,2....... The hydrogen atom in the cycloalkyl ring may also be substituted by halogen, cyano, alkyl, hydroxyl, carboxyl, etc.), heterocycloalkyl (i.e., on the basis of the cycloalkyl above, at least one carbon atom in the alkyl ring is replaced by oxygen, sulfur, and nitrogen), halogen (F, OI, Br, I), carboxyl, cyano (-CN), sulfonyl (-SC^Ra, Ra is hydrogen, alkyl, aryl, etc.), alkynyl (-ChCH, -C^CRb, Rb is alkyl, aryl, etc.), acylamino (-C(O)NRxRy, RxRy is alkyl, aryl, etc.), ester (-C(O)O-RZ, Rz is alkyl, aryl, etc.), aryl, heteroaryl, and other groups. In the present invention, substituted or unsubstituted heteroalkylene means that one or more carbon atoms of the unsubstituted alkylene are substituted by oxygen, sulfur, and nitrogen. Furthermore, the present invention provides a cyano-substituted cyclic hydrazine derivative, wherein the structure is as follows: x (R1)n NC' 'Ύ^'Λ R2 W Of Ύ HIN Where A, X, R1 and R2 are as defined above; And it is selected from CR4, N; R4 is selected from hydrogen, hydroxyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy. Furthermore, the present invention provides a cyano-substituted cyclic hydrazine derivative, wherein the structure is as follows: nr Lrnn / zznz / B / Yu Where the previous 'a' is 0,1,2,3; The previous River is selected from the group ending in cyano. Furthermore, the present invention provides a cyano-substituted cyclic hydrazine derivative, wherein the structure is as follows: Where Z is selected from substituted or unsubstituted alkylene; R5 is selected from hydrogen, substituted or unsubstituted alkyl, and substituted or unsubstituted heteroalkyl. Furthermore, the present invention also provides a method for preparing the cyano-substituted cyclic hydrazine derivative, wherein the specific reaction equation is as follows: It is produced specifically through the following process steps: S1. Take 11-1 as raw material and nitrosylate the NH group on it to form the nitrous product II-2; S2. convert the nitrous product II-2 into compound II-3 through a reduction reaction; S3. react compound II-3 with compound II-4 under alkaline conditions to obtain compound II-5; S4. Reduce the nitro group in compound II-5 to amino by hydrogenation to obtain compound II-6; S5. subject compound II-6 to a cyclization reaction to obtain compound II-7; S6. Deprotect compound II-7 to obtain the target product. The specific process of the above reaction may be such that the compound shown in formula 11-1 can be obtained directly or by known common synthetic methods. Formula 11-1 can be nitrosated to produce the nitrous product N II-2 to HNO2 (obtained by adding acid to NaNOs) or alkyl nitrite (such as butyl nitrite and isoamyl nitrite). Iron powder, zinc powder, or catalytic hydrogenation can convert the intermediate product II-2 to II-3. II-3 and II-4 (Ar is selected from phenyl or benzyl; see Kulagowski, JJ; et al.; Journal of Medicinal Chemistry (2012) 55, 5901 for the synthesis) are reacted under alkaline conditions (dry NasCOs, anhydrous DMF, heated) to give compound II-5. The nitro group in compound II-5 is reduced to amino by hydrogenation (Pt-C, 1 atmosphere of hydrogen) to obtain II-6. The cyclization reaction can be carried out under a variety of known conditions.Common conditions involve reacting II-6 with the triester ortho-acid (R2(OMe)3, such as triethyl orthoacetate) under acidic conditions; or II-6 and the amide are dehydrated with triethyloxytetrafluoroboric acid or other onium salts. Finally, the aqueous sodium hydroxide solution is deprotected to generate the compound shown in Formula I. Furthermore, the present invention also provides a pharmaceutical composition comprising at least one of the above cyano-substituted cyclic hydrazine derivatives and pharmaceutically acceptable carriers, excipients, diluents, adjuvants or vehicles; Where, the amount of the above cyano-substituted cyclic hydrazine derivative is 0.01-99.9% of the total mass of the pharmaceutical composition. Furthermore, the present invention also provides a pharmaceutical composition, wherein the pharmaceutical composition contains additional therapeutic agents; Additional therapeutic agents are selected from anti-inflammatory drugs, immunomodulatory or immunosuppressive agents, neurotrophic factors, active agents for the treatment of cardiovascular diseases, active agents for the treatment of diabetes, and active agents for the treatment of autoimmune diseases. Furthermore, the compound or pharmaceutical composition provided by the present invention has the following use, where it is used to prevent, manage, treat or alleviate autoimmune diseases or proliferative diseases in patients and / or to inhibit or regulate protein kinase activity. Where autoimmune diseases can be rheumatoid arthritis, psoriasis, type I diabetes, complications caused by organ transplantation, foreign body transplantation, diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disease, ulcerative colitis, Crohn's disease, leukemia and lymphoma; lupus, multiple sclerosis, amyotrophic lateral sclerosis. DETAILED DESCRIPTION OF THE INVENTION nr Lrnn / zznz / B / Yi Specific form of implementation Example 1 -(imidazo[4,5-c(]p¡rrolo[2,3-b]p¡r¡d¡na-1 (6 / - / )-¡l)p¡perídina-4-carbon¡tr¡lo The execution mode is as follows: Dissolve 4-chloro-7-azaindole (50.0 g, 327.8 mmol) in 1 L of dichloromethane and Step A: then add triethylamine (66.3 g, 655.6 mmol), p-toluenesulfonyl chloride (64.4 g, 37.6 mmol) and 4-dimethylaminopyridine (0.4 g, 3.3 mmol) at 0 °C respectively. Stir for 16 h at room temperature. Once the reaction is complete, add 500 ml of water for washing and separate the organic phase; dry and filter; distill the solvent under reduced pressure to obtain the compound 4-chloro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pindine (99.8 g, 99% yield). Step B: Dissolve 4-chloro-1-p-toluenesulfonyl-1H-pyrrolo[2,3-b]pyridine (50.0 g, 163.0 mmol) in 600 mL of dichloromethane. Add tetrabutylammonium nitrate (74.4 g, 244.5 mmol) and trifluoroacetic anhydride (53.1 g, 252.6 mmol) at 0 °C and then react at room temperature for 20 h under nitrogen protection. After the reaction, add 500 mL of saturated aqueous sodium bicarbonate solution to neutralize; separate the organic phases and extract the aqueous phase twice with 1.2 L of dichloromethane. Combine the organic phases and wash with the appropriate amount of water and saturated aqueous sodium chloride solution. Dry the organic phase with anhydrous sodium sulfate, filter, and treat by rotary evaporation. Ultrasonically resuspend the resulting suspension with 80 ml of ethyl acetate, filter, and dry the filter cake to obtain the compound 4-chloro-5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pridine (30.1 g, 52% yield rate.1H NMR (400 MHz, DMSO-d6) δ 9.08 (s, 1H), 8.26 (d, J = 4.0 Hz, 1H), 8.05 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.09 (d, J= 4.0 Hz, 1H), 2.37 (s, 3H). Step C: Add the compound 4-chloro-5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pindine (1.58 g, 4.5 mmol), A / ,A / -disopropylethylamine (1.75 g, 13.5 mmol), and 1-amino-4-pyridinenol (0.58 g, 5.0 mmol) to 50 mL of isopropanol (suspension). Stir the reaction at 95 °C for 16 h. After the reaction, cool to room temperature; add 50 mL of water and extract with ethyl acetate (3 x 50 mL). Combine the organic phases and dry with anhydrous sodium sulfate. Obtain the compound 1-((5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pridine-4-1l)amino)pridine-4-ol (0.91 g, 47% yield) by filtration, centrifugation and purification by column chromatography. LCMS ESI(+)m / z: 432.2(M+1). Step D: Add the compound 1-((5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine-4-yl)amino)pyridine-4-ol (0.91 g, 2.1 mmol) to the mixed solution (suspension) of 15 mL of ethanol and 5 mL of water, and then add solid ammonium chloride (0.45 g, 8.4 mmol) and iron powder (0.59 g, 10.5 mmol) one by one. Heat to 80 °C and stir for 4.5 h. After the reaction, filter the reaction solution and wash the filter residue with an appropriate amount of ethyl acetate. Concentrate the filtrate under reduced pressure and obtain the compound 1-((5-amino-1-p-toluenesulfonyl-1-pyrrolo[2,3-b]pridine-4-1l)amino)pridine-4-1l (0.75 g, yield of 88%) by silica gel column chromatography. LCMS ESI(+)m / z: 402.2(M+1). Step E: Dissolve the compound 1-((5-amino-1-p-toluenesulfonyl-1 / - / -pyrrolo[2,3-]pyridin-4-yl)amino)piperidin-4-ol (750 mg, 1.87 mmol) in 10 ml of acetic acid and add triethyl orthoformate (2.77 g, 18.7 mmol). Heat to 116 °C and stir for 0.5 h. After the reaction, concentrate under reduced pressure and obtain the compound 1-(6-p-toluenesulfonyl imidazo[4,5c(|p¡rrolo[2,3-b]p¡r¡n-1 (6 / - / )-¡l)piper¡n-4-ol (453 mg, yield rate of 59%) by silica gel column chromatography. LCMS ESI(+)m / z: 412.2(M+1). Step F: Dissolve the compound 1-(6-p-toluenesulfonyl imidazo[4,5-c(1-pyrrolo[2,3-b]pyridin-1(6H)1)piperidin-4-ol (150 mg, 0.36 mmol) in 10 mL of dichloromethane and add methylsulfonyl chloride (82 mg, 0.72 mmol) and triethylamine (109 mg, 1.08 mmol). Stir at room temperature for 1 h. After the reaction, concentrate under reduced pressure and obtain the compound 1-(6-ptoluenesulfonyl imidazo[4,5-c]pyrrolo[2,3-b]pyridin-1(6H)-1)piperidin-4-ol methanesulfonate (144 mg, 82% yield) by column chromatography of silica gel. LCMS ESI(+)m / z:490.2(M+1). Step G: Dissolve the compound 1-(6-p-toluenesulfonyl imidazolo[4,5-c(]pyrrolo[2,3-b]pyridin-1(6H)yl)piperidin-4-yl methanesulfonate (95 mg, 0.19 mmol) in 5 mL of 1 / ,1 / 0-dimethylformamide and add sodium cyanide (82 mg, 1.67 mmol). Heat to 80 °C and stir the reaction for 16 h under nitrogen protection. After the reaction, add an appropriate amount of aqueous sodium hydroxide solution and extract with ethyl acetate (3 x 20 mL). Combine the organic phases and dry with anhydrous sodium sulfate. After filtration and centrifugation, obtain the compound 1-(6-p-toluenesulfonyl imidazo[4,5-c(]pyrrolo[2,3-b]pyridin-1 (6H)-yl)pyridine-4carbonitrile (42 mg, 50% yield rate). LCMS ESI(+)m / z: 421.2(M+1). Step H: Dissolve the compound 1-(6-p-toluenesulfonyl imidazo[4,5-c]pyrrolo[2,3-β]pyridin-1(6H)yl)piperidine-4-carbonitrile (42 mg, 0.1 mmol) in 8 ml methanol and add potassium tert-butoxide (56 mg, 0.5 mmol). Stir at room temperature for 6 h. After the reaction, adjust the pH from 7 to 8 with acetic acid and concentrate under reduced pressure. Prepare compound 1 -(imidazo[4,5-c / ]pyrrolo[2,3-¿>]pyridine-1 (6 / - / )-¡l)piper¡dine-4-carbonitrile (12 mg, 45% yield rate) by HPLC.1H NMR (400 MHz, DMSO-cfe) δ 11.86 (s, 1H), 8.56 (s, 1H), 8.49 (s, 1H), 7.46 (t, 1H), 6.84 (dd, J= 3.0, 1.8 Hz, 1H), 3.45 - 3.36 (m, 2H), 3.32 - 3.28 (m, 2H), 3.24 - 3.12 (m, 1H), 2.24 - 2.14 (m, 2H), 2.14 - 2.03 (m, 2H). LCMS ESI(+)m / z: 267.2(M+1). nr Lrnn / zznz / B / Yi Example 2 nr Lrnn / zznz / B / Yi 2-(1 -(imidazo[4,5-c / ]pyrrolo[2,3-£>]pyridin-1 (6^-¡l)p¡pendin-4-¡l)acetonítrile The execution mode is as follows: Step A: Dissolve 1-Boc-4-cyanomethylpiperidine (5.0 g, 22.3 mmol) in 20 ml of dichloromethane and gradually add 20 ml of trifluoroacetic acid at 0 °C. Then stir at room temperature for 2 h. After the reaction, obtain the compound 4-cyanomethylpiperidine trifluoroacetate (5.53 g, 100% yield) by vacuum concentration. Step B: Dissolve the compound 4-cyanomethylpiperidine trifluoroacetate (5.53 g, 20.0 mmol) and sodium nitrite (2.76 g, 40.0 mmol) in 30 mL of water and gradually add 5.0 mL of acetic acid at 0 °C. Stir the reaction at 35 °C for 16 h. After the reaction, adjust the pH of the reaction solution to 8 with sodium carbonate and extract five times with 250 mL of ethyl acetate. Combine the organic phases and dry with anhydrous sodium sulfate; filter and centrifuge to obtain the compound 1-nitroso-4-cyanomethylpiperidine (5.3 g, 70% yield). LCMS ESI(+)m / z: 154.1 (M+1). Step C: Dissolve the compound l-nitroso-4-cyanomethylpiperidine (5.2 g, 20.0 mmol) in 15 mL of methanol, add zinc powder (3.92 g, 60.0 mmol), and gradually add 15 mL of acetic acid at 0 °C. After the addition, stir the reaction at 30 °C for 3 h. After the reaction, filter the reaction solution and obtain the compound l-amino-4-cyanomethylpiperidine (5.3 g, 60% yield) by rotary evaporation of the filtrate. CLEM ESI(+)m / z: 140.1 (M+1). Step D: Add the compound 4-chloro-5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pindine (3.51 g, 10.0 mmol), / V. / V-diisopropylethylamine (7.75 g, 60.0 mmol), and 1-amino-4-cyanomethylpiperidine (2.09 g, 15.0 mmol) to 200 mL of isopropanol (suspension). Stir the reaction at 95 °C for 16 h. After the reaction, cool to room temperature and add 200 mL of water; extract with ethyl acetate (3 x 250 mL) and combine the organic phases; wash with 300 mL of saturated saline solution and dry with anhydrous sodium sulfate; filter and treat by rotary evaporation. Purify by silica gel column chromatography to obtain the compound 2-(1((5-nitro-1-p-toluenesulfonyl-1H-pyrrolo[2,3-b]pridine-4-yl)amino)pperidine-4-yl)acetonitrile (2.02 g, 44% yield rate). LCMS ESI(+)m / z: 455.1 (M+1). Step E: Add the compound 2-(1-((5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine-4-yl)amino)piperidine-4-yl)acetonitrile (1.37 g, 3.0 mmol) to the mixed solution (suspension) of 60 mL of ethanol and 20 mL of water, and then add solid ammonium chloride (0.64 g, 12.0 mmol) and iron powder (0.67 g, 12.0 mmol) one at a time. Heat to 80 °C and stir for 2.5 h. After the reaction, filter the reaction solution and wash the filter residue with 50 mL of ethyl acetate. Add the filtrate to 50 mL of water and extract with ethyl acetate (3 x 70 mL). Combine the organic phases, wash with 150 ml of saturated saline solution, and dry with anhydrous sodium sulfate. Filter by suction and concentrate the filtrate under reduced pressure to obtain the compound 2-(1-((5-amino-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine-4-yl)amino)piperidin-4-yl)acetonitrile (1.02 g, 80% yield). LCMS ESI(+)m / z: 425.1 (M+1). Step F: Dissolve the compound 2-(1-((5-amino-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-4-yl acetonitrile (424 mg, 10 mmol) in 10 mL of acetic acid and add triethyl orthoformate (1.48 g, 10 mmol). Heat to 116 °C and stir for 0.5 h. After the reaction, concentrate under reduced pressure and obtain the compound 2-(1-(6-p-toluenesulfonyl imidazo[4,5-c]pyrrolo[2,3-β]pyridin-1(6-β)-β)piperidin-4-β)acetonitrile (256 mg, 59% yield) by gel column chromatography. silica. LCMS ESI(+)m / z: 435.2(M+1). Step G: Dissolve the compound 2-(1-(6-p-toluenesulfonyl imidazo[4,5-c(1-pyrrolo[2,3-b]pyridin-1(6-p)-1)piperidin-4-1)acetonitrile (95 mg, 1.0 mmol) in 10 mL of tetrahydrofuran and add 60% sodium hydrogen (40 mg, 1.0 mmol). Stir at room temperature for 1 h. After the reaction, adjust the pH from 7 to 8 with acetic acid and concentrate under reduced pressure. Prepare the compound 2-(1-(imidazo[4,5-c]pyrrolo[2,3-p]pyridin-1(6-p)-1)piperidin-4-1)acetonitrile (24 mg, 42% yield) %) by silica gel column chromatography and HPLC.1H NMR (400 MHz, CDCI3) δ 10.07 (s, 1H), 8.81 (s, 1H), 8.13 (s, 1H), 7.40 (s, 1H), 6.80 (s, 1H), 3.56 - 3.19 (m, 4H), 2.48 (d, J = 6.4 Hz, 2H), 2.13 - 2.08 (m, 2H), 2.07 -1.94 (m, 1 H), 1.91 -1.75 (m, 2H). LCMS ESI(+)m / z: 281.2(M+1). Example 3 nr Lrnn / zznz / B / Yi 2-(1-(methylim¡dazo[4,5-c(]pyrrolo[2,3-b]pyr¡din-1 (6H)-yl)p¡perid¡n-4-¡l)aceton¡trilo The execution mode is as follows: Dissolve triethyl oxyomborum tetrafluoride (190 mg, 1.0 mmol) and acetamide (59 mg, 1.0 mmol) in 10 mL of tetrahydrofuran and stir at room temperature for 2 h. Concentrate under reduced pressure to obtain the colorless oil and dissolve it in 5 mL of absolute ethanol; add this to 5 mL of absolute ethanol to dissolve the compound 2-(1-((5-amino-1-ptoluenesulfonyl-1 / 7-pyrrolo[2,3-b]pridin-4-1)amino)pridin-4-1)acetonitrilo (212 mg, 0.5 mmol). Heat to 75 °C and stir the reaction for 1 h. After the reaction, neutralize with saturated aqueous sodium bicarbonate solution and add 30 mL of water; Extract with ethyl acetate (3 x 30 ml) and combine the organic phases; wash with 50 ml of saturated saline solution and dry with anhydrous sodium sulfate.Filter by suction and concentrate the filtrate under reduced pressure; obtain the compound 2-(1-(2-methyl-6-p-toluenesulfonyl imidazo[4,5c(|p¡pyrolo[2,3-¿)]p¡r¡n-1 (6 / - / )-¡l)piper¡n-4-¡l)acetonitrilo (180 mg, yield rate of 80%) by silica gel column chromatography. LCMS ESI(+)m / z: 448.1 (M+1). Step B: Dissolve the compound 2-(1-(2-methyl-6-p-toluenesulfonyl imidazo[4,5-c(]pyrrolo[2,3 b]pyridin-1 (6 / - / )-1)piperidin-4-1)acetonitrile (180 mg, 0.4 mmol) in 9 ml of methanol and add 4 ml of 1 N sodium hydroxide. Stir at room temperature for 16 h. After the reaction, adjust the pH from 7 to 8 with acetic acid and concentrate under reduced pressure; Prepare the compound 2-(1-(2-methylimidazol[4,5-c]pyrrolo[2,3-t]pyridin-1(6-)-1l)piperidin-4-1l)acetonitrile (70 mg, yield rate of 60%) by silica gel column chromatography and HPLC.1H NMR (400 MHz, DMSO-d6) δ 11.86 (s, 1H), 8.46 (s, 1H), 7.48 (t, J=3.0 Hz,1H), 6.70 (dd, J = 3.2 Hz, 1.6 Hz, 1H), 3.57 (t, J = 10.2 Hz, 2H), 3.13 (d, J = 10.2 Hz, 2H), 2.64 (d, J= 6.4 Hz, 2H), 2.52 (s, 3H), 2.15 - 2.04 (m, 1H), 2.00 - 1.89 (m, 2H), 1.68 - 1.56 (m, 2H). LCMS ESI(+)m / z:295.2(M+1). Example 4 nr Lrnn / zznz / B / Yi Step A: Dissolve triethyl oxyomborum tetrafluoride (190 mg, 1.0 mmol) and propionamide (73 mg, 1.0 mmol) in 10 mL of tetrahydrofuran and stir at room temperature for 2 h. Concentrate under reduced pressure to obtain the colorless oil and dissolve it in 5 mL of absolute ethanol; add this to 5 mL of absolute ethanol to dissolve the compound 2-(1-((5-amino-1-ptoluenesulfonyl-1 / - / -pyrrolo[2,3-β]pyridine-4-yl)amino)piperidine-4-yl)acetonitrile (212 mg, 0.5 mmol). Heat to 75 °C and stir the reaction for 1 h. After the reaction, neutralize with saturated aqueous sodium bicarbonate solution and add 30 mL of water; Extract with ethyl acetate (3 x 30 ml) and combine the organic phases; wash with 50 ml of saturated saline solution and dry with anhydrous sodium sulfate.Filter by suction and concentrate the filtrate under reduced pressure; obtain the compound 2-(1-(2-ethyl-6-p-toluenesulfonyl imidazo[4,5c(|p¡rrolo[2,3-b]p¡r¡n-1 (6 / - / )-¡l)piper¡n-4-¡l)acetonitrilo (180 mg, yield rate of 78%) by silica gel column chromatography. LCMS ESI(+)m / z: 462.1 (M+1). Step B:. nr Lrnn / zznz / B / Yi Dissolve the compound 2-(1-(2-ethyl-6-p-toluenesulfonyl imidazo[4,5-d]pyrrolo[2,3-b]p¡prid¡n1 (6 / - / )-¡l)p¡pendin-4-¡l)acetonitrilo (180 mg, 0.39 mmol) in 9 ml of methanol and add 4 ml of 1 N sodium hydroxide. Stir at room temperature for 16 h. After the reaction, adjust the pH from 7 to 8 with acetic acid and concentrate under reduced pressure; Prepare the compound 2-(1-(2-ethylimidazol[4,5-c / |pyrrolo[2,3-b]pyridin-1(6 / - / )-1)pependin-4-1)acetonitrile (75 mg, yield rate of 62%) by silica gel column chromatography and HPLC.1H NMR (400 MHz, DMSO-d6) δ 11.86 (s, 1H), 8.49 (s, 1H), 7.48 (t, J = 3.0 Hz, 1H), 6.71 (dd, J = 3.2 Hz, 1.6 Hz, 1H), 3.59 (t, J = 10.2 Hz, 2H), 3.12 (d, J = 10.2 Hz, 2H), 2.92 (q, J = 7.5 Hz, 2H), 2.65 (d, J = 6.4 Hz, 2H), 2.16-2.05 (m, 1H), 2.00-1.91 (m, 2H), 1.68- 1.56 (m, 2H), 1.31 (t, J = 7.5 Hz, 3H). LCMS ESI(+)m / z: 309.2(M+1). Example 5 2-(1-(2-(hydroxy¡met¡l)im¡dazo[4,5-c(]pyrrolo[2,3-b]p¡r¡d¡n-1(6 / - / )-¡l)p¡perídin-4-¡l)aceton¡trilo The execution mode is as follows: Step A: Dissolve triethyl oxyomborum tetrafluoride (135 mg, 0.71 mmol) and hydroxyacetamide (53 mg, 0.71 mmol) in 10 mL of tetrahydrofuran and stir at room temperature for 2 h. Concentrate under reduced pressure to obtain the colorless oil and dissolve it in 5 mL of absolute ethanol; add this to 5 mL of absolute ethanol to dissolve the compound 2-(1-((5-amino-1-ptoluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine-4-1)amino)pyridine-4-1)acetonitrile (100 mg, 0.24 mmol). Heat to 75 °C and stir the reaction for 1 h. After the reaction, neutralize with saturated aqueous sodium bicarbonate solution and add 30 mL of water; Extract with ethyl acetate (3 x 30 ml) and combine the organic phases; wash with 50 ml of saturated saline solution and dry with anhydrous sodium sulfate.Filter by suction and concentrate the filtrate under reduced pressure; obtain the compound 2-(1-(2-(hydroxymethyl)-6-p-toluenesulfonyl imidazo[4,5c(|p¡rrolo[2,3-b]p¡r¡n-1 (6 / - / )-¡l)piper¡n-4-¡l) acetonitrile (80 mg, yield rate of 72%) by silica gel column chromatography. LCMS ESI(+)m / z: 465.1 (M+1). Step B: Dissolve the compound 2-(1-(2-(hydroxymethyl)-6-p-toluenesulfonyl imidazo[4,5-c(pyrrolo[2,3-b]pyridine-1 (6 / - / )-1)piperidin-4-1)acetonitrile (80 mg, 0.17 mmol) in 9 ml of methanol and add 3 ml of 1 N sodium hydroxide. Stir at room temperature for 16 h. After the reaction, adjust the pH from 7 to 8 with acetic acid and concentrate under reduced pressure; prepare the compound 2-(1-(2-(hydroxymethyl)imidazo[4,5-c(]pyrrolo[2,3-b]pyridine-1 (6F / )-1)piperidin-4-1)acetonitrile (20 mg, yield rate 38%) by silica gel column chromatography and HPLC.1H NMR (400 MHz, DMSO-cfe) δ 11.92 (s, 1H), 8.54 (s, 1 H), 7.50 (t, J = 3.0 Hz, 1H), 6.73 (dd, J=3.2, 1.8 Hz, 1H), 5.31 (t, J = 6.0 Hz,1H), 5.16 (q, J=6.6 Hz, 1H), 4.70 (d, J = 6.0 Hz, 2H), 3.57 (t, J = 10.2 Hz,2H), 3.15 (dd, J = 10.2Hz, 2H), 2.64 (d, J = 6.4 Hz, 2H), 2.152.04 (m, 1H), 1.98 - 1.89 (m, 2H), 1.72 - 1.60 (m, 2H). LCMS ESI(+)m / z: 311.2(M+1). Example 6 nr Lrnn / zznz / B / Yi 2-(1 -(2-(2-hydroxyethyl)imidazo[4,5-c / ]pyrrolo[2,3-¿?]pyridin-1 (6 / - / )-¡l)piper¡din-4-¡l)aceton¡trilo The execution mode is as follows: Step A: Dissolve triethyl oxyomborum tetrafluoride (135 mg, 0.71 mmol) and 3-hydroxypropanamide (64 mg, 0.71 mmol) in 10 mL of tetrahydrofuran and stir at room temperature for 2 h. Concentrate under reduced pressure to obtain the colorless oil and dissolve it in 5 mL of absolute ethanol; add this to 5 mL of absolute ethanol to dissolve the compound 2-(1((5-amino-1-p-toluenesulfonyl-1-Hpyrolo[2,3-b]pyridine-4-1)amino)pyridine-4-1)acetonitrile (100 mg, 0.24 mmol). Heat to 75 °C and stir the reaction for 1 h. After the reaction, neutralize with saturated aqueous sodium bicarbonate solution and add 30 mL of water; Extract with ethyl acetate (3 x 30 ml) and combine the organic phases; wash with 50 ml of saturated saline solution and dry with anhydrous sodium sulfate.Filter by suction and concentrate the filtrate under reduced pressure; obtain the compound 2-(1-(2-(hydroxyethyl)-6-p-toluenesulfonyl imidazo[4,5-c / |pyrrolo[2,3-b]pridine-1 (6 / - / )-1)piperidin-4-1)acetonitrile (60 mg, yield rate of 52%) by silica gel column chromatography. LCMS ESI(+)m / z: 479.1 (M+1). Step B: Dissolve the compound 2-(1-(2-(hydroxyethyl)-6-p-toluenesulfonyl imidazo[4,5-c(]pyrolo[2,3b]pyridin-1(6H)-1)pyridin-4-1)acetonitrile (60 mg, 0.13 mmol) in 9 mL of methanol and add 3 mL of 1 N sodium hydroxide. Stir at room temperature for 16 h. After the reaction, adjust the pH from 7 to 8 with acetic acid and concentrate under reduced pressure; prepare the compound 2-(1-(2-(hydroxyethyl)imidazo[4,5-c(]pyrolo[2,3b]pyridin-1(6H)-1)pyridin-4-1)acetonitrile (20 mg, 48% yield) by silica gel column chromatography and HPLC.1H NMR (400 MHz, DMSO-d6) δ 11.87 (s, 1H), 8.49 (s, 1H), 7.48 (d, J = 3.4 Hz, 1H), 6.71 (d, J = 3.4, 1.8 Hz, 1H), 4.80 (brs, 1H), 3.84 (t, J = 7.0 Hz,2H), 3.59 (t, J = 10.4Hz, 2H), 3.16-3.06 (m, 4H), 2.65 (d, J = 6.4 Hz, 2H), 2.15-2.04 (m, 1H), 1.98- 1.89 (m, 2H), 1.72 - 1.60 (m, 2H). LCMS ESI(+)m / z: 325.1 (M+1). Example 7 nr Lrnn / zznz / B / Yi ( / 7)-2-(1 -(2-(1 -hydroxyethyl)¡m idazo[4,5-c / ]pyrrolo[2,3 -b]pyrid¡n-1 (6 / - / )-¡l)piper¡din-4¡l)acetonitrile The execution mode is as follows: Step A: Dissolve triethyl oxyomborum tetrafluoride (251 mg, 1.32 mmol) and R-lactamide (118 mg, 1.32 mmol) in 8 mL of tetrahydrofuran and stir the reaction at room temperature for 2 h. Concentrate under reduced pressure to obtain the colorless oil and dissolve it in 5 mL of absolute ethanol; add this to 5 mL of absolute ethanol to dissolve the compound 2-(1-((5-amino-1-ptoluenesulfonyl-1 / - / -pyrrolo[2,3-t>]pyridin-4-yl)amino)piperidine-4-yl)acetonitrile (189 mg, 0.44 mmol). Heat to 75 °C and stir the reaction for 1 h. After the reaction, neutralize with aqueous sodium bicarbonate solution and add 30 mL of water. Extract with ethyl acetate (3 x 30 ml) and combine the organic phases; wash with 50 ml of saturated saline solution and dry with anhydrous sodium sulfate.Filter by suction and concentrate the filtrate under reduced pressure; obtain the compound ( / 7)-2-(1 -(2-(1 -hydroxyethyl)-6-p-toluenesulfonyl imidazo[4,5-c(|p¡rrolo[2,3b]pyridin-1(6 / 7)-1l) piperidin-4-yl)acetonitrile (110 mg, yield rate of 52%) by silica gel column chromatography. LCMS ESI(+)m / z: 479.1 (M+1). nr Lrnn / zznz / B / Yi Step B: Dissolve the compound ( / 7)-2-(1-(2-(1-hydroxyethyl)-6-p-toluenesulfonyl imidazo[4,5c(1-pyrrolo[2,3-b]pyridine-1(6 / - / )-1)piperidin-4-yl)acetonitrile (110 mg, 0.23 mmol) in 9 ml of methanol and add 3 ml of 1 N sodium hydroxide. Stir at room temperature for 16 h. After the reaction, adjust the pH from 7 to 8 with acetic acid and concentrate under reduced pressure; prepare the compound ( / 7)-2-(1-(2-(1-hydroxyethyl)-imidazo[4,5-d]pyrrolo[2,3-b]pyridine-1(6 / 7)-1)piperidin-4-yl)acetonitrile (30 mg, 40% yield rate) by silica gel column chromatography and HPLC.1H NMR (400 MHz, DMSO-d6) δ 11.92 (s, 1H), 8.55 (s, 1H), 7.50 (d, J = 3.4 Hz, 1 H), 6.73 (d, J = 3.4 Hz, 1H), 5.31 (s, 1 H), 5.16 (q, J = 6.6 Hz, 1H), 3.65 3.53 (m, 2H), 3.15 (dd, J= 30.2, 10.0 Hz, 2H), 2.64 (d, J = 6.4 Hz, 2H), 2.17 - 2.04 (m, 1H), 1.98 - 1.89 (m, 2H), 1.72 - 1.60 (m, 2H), 1.56 (d, J = 6.6 Hz, 3H). LCMS ESI(+)m / z: 325.0(M+1). Example 8 (S)-2-(1 -(2-(1 -hydroxyethyl)imidazo[4,5-c / ]pyrrolo[2,3 -b]pyridine-1 (6 / - / )-1l)piperidin-4yl)acetonitrile The execution mode is as follows: Step A: Dissolve triethyl oxyomborum tetrafluoride (298 mg, 1.56 mmol) and S-lactamide (140 mg, 1.56 mmol) in 10 mL of tetrahydrofuran and stir the reaction at room temperature for 2 h. Concentrate under reduced pressure to obtain the colorless oil and dissolve it in 5 mL of absolute ethanol; add this to 5 mL of absolute ethanol to dissolve the compound 2-(1-((5-amino-1-ptoluenesulfonyl-1 / 7-pyrrolo[2,3-b]pridin-4-1)amino)pridin-4-1)acetonitrile (222 mg, 0.52 mmol). Heat to 75 °C and stir the reaction for 1 h. After the reaction, neutralize with saturated aqueous solution of sodium bicarbonate and add 30 ml of water; extract with ethyl acetate (3 x 30 ml) and combine the organic phases; wash with 50 ml of saturated saline solution and dry with anhydrous sodium sulfate.Filter by suction and concentrate the filtrate under reduced pressure; obtain the compound (S)-2-(1-(2-(1-hydroxyethyl)-6-p-toluenesulfonyl imidazo[4,5-c / ]pyrolo[2,3-¿>]pr¡n-1 (6 / - / )-¡l) piperidin-4-yl)acetonitrile (160 mg, yield rate of 64%) by silica gel column chromatography. LCMS ESI(+)m / z: 479.1 (M+1). Step B: Dissolve the compound (S)-2-(1-(2-(1-hydroxyethyl)-6-p-toluenesulfonyl imidazo[4,5-d|pyrolo[2,3-b]pyridin-1(6A7)-yl)piperidin-4-yl)acetonitrile (160 mg) in 9 mL of methanol and add 3 mL of 1 N sodium hydroxide. Stir at room temperature for 16 h. After the reaction, adjust the pH from 7 to 8 with acetic acid and concentrate under reduced pressure; prepare the compound (S)-2-(1-(2-(1-hydroxyethyl)-imidazo[4,5-d|pyrolo[2,3-b]pyridin-1(6A7)-yl)piperidin-4-yl)acetonitrile (44.6 mg, yield rate of 41 %) by silica gel column chromatography and HPLC.1H NMR (400 MHz, DMSO-d6) δ 11.92 (s, 1H), 8.55 (s, 1H), 7.50 (d, J= 3.4 Hz, 1H), 6.73 (d, J= 3.4 Hz, 1H), 5.31 (s, 1H), 5.16 (q, J = 6.6 Hz, 1H), 3.65 - 3.53 (m, 2H), 3.15 (dd, J = 30.2, 10.0 Hz, 2H), 2.64 (d, J = 6.4 Hz, 2H), 2.17 - 2.04 (m, 1H), 1.98 - 1.89 (m, 2H), 1.72 - 1.60 (m, 2H), 1.56 (d, J = 6.6 Hz, 3H). LCMS ESI(+)m / z: 325.0(M+1). Example 9 2-(1 -(2-amino¡m¡dazo[4,5-c(|p¡rrolo[2,3-b]p¡r¡d¡n-1 (6 / - / )-¡l)p¡per¡din-4-¡l)aceton¡trilo nr Lrnn / zznz / B / Yi The execution mode is as follows: Step A: Dissolve 4-hydroxymethylpiperidine (3.01 g, 26.1 mmol) and sodium nitrite (2.76 g, 40.0 mmol) in 30 mL of water and gradually add 4.0 mL of acetic acid at 0 °C. Stir the reaction at 30 °C for 16 h. Adjust the pH of the reaction solution to 8 with saturated aqueous sodium bicarbonate solution and extract five times with 250 mL of ethyl acetate. Combine the organic phases and dry with anhydrous sodium sulfate; filter and obtain 1-nitroso-4-hydroxymethylpiperidine (2.87 g, 76% yield) by rotary evaporation. LCMS ESI(+)m / z: 145.1 (M+1). Step B: Dissolve the compound 1-nitroso-4-hydroxymethylpiperidine (2.87 g, 20.0 mmol) in 15 mL of methanol, add zinc powder (5.23 g, 80.0 mmol), and gradually add 15 mL of acetic acid at 0 °C. After the addition, stir the reaction at room temperature for 16 h. Filter the reaction solution and obtain the crude compound 1-amino-4-hydroxymethylpiperidine (3.02 g, 65% yield) by rotary evaporation of the filtrate. LCMS ESI(+)m / z: 131.1 (M+1). Step C: Add the compound 4-chloro-5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pindine (2.32 g, 6.6 mmol), A / V-diisopropylethylamine (3.41 g, 26.4 mmol) and 1-amino-4-hydroxymethylpiperidine (1.03 g, 7.9 mmol) to 60 mL of isopropanol (suspension). Stir the reaction at 95 °C for 16 h. After the reaction, cool to room temperature and add 100 mL of water; extract with ethyl acetate (3 x 100 mL) and combine the organic phases; Dry with anhydrous sodium sulfate and obtain the compound (1-((5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine-4-1)amino)pyridine-4-1)methanol (2.11 g, 71% yield) by filtration, spin drying, and purification by column chromatography. LCMS ESI(+)m / z: 446.2(M+1). Step D: Dissolve the compound (1-((5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine-4-yl)amino)pyridine-4-yl)methanol (1.02 g, 3.37 mmol) in 30 mL of anhydrous dichloromethane and add triethylamine (1.02 g, 10.1 mmol) at 0 °C; add methanesulfonyl chloride (465 mg, 4.06 mmol) dropwise and react at room temperature for 18 h under nitrogen protection. After the reaction, add water to neutralize at 0 °C and extract with dichloromethane (3 x 80 mL); combine the organic phases and dry with anhydrous sodium sulfate; The compound 1-((5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3b]pindin-4-1)amino)piperidina-4-1)methyl methanesulfonate (1.6 g, 91% yield) was obtained by filtration, spin drying and purification by column chromatography. LCMS ESI(+)m / z: 524.1 (M+1). Step E: Suspend the compound 1-((5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-β]pyridin-4-yl)amino)piperidin-4-yl)methyl methanesulfonate (300 mg, 0.57 mmol), iron powder (193 mg, 3.44 mmol) and ammonium chloride (61 mg, 1.15 mmol) in a mixture of 9 ml of ethanol and 3 ml of water and stir at 75 °C under nitrogen protection for 2 h. After the reaction, obtain the product 1-((5-amino-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3β]pyridin-4-β)amino)piperidin-4-yl)methyl methanesulfonate (85 mg, 30% yield rate) by filtration, centrifugation and purification. LCMS ESI(+)m / z: 494.1 (M+1). Step F: Dissolve the compound 1-((5-amino-1-p-toluenesulfonyl-1-Hpyrolo[2,3-b]pyridin-4-1)amino)pyridin-4-1)methyl methanesulfonate (80 mg, 0.16 mmol) and hydrogen bromide (0.08 ml) in 10 ml of methanol. Add to a sealed tube and shake at 30 °C for 20 h. After the reaction, obtain the product 1-(2-amino-6-p-toluenesulfonyl imidazo[4,5-c(|pyrrolo[2,3-b]pridine-1 (6 / - / )-1)piperidin-4-1)methyl methanesulfonate (90 mg, 100% yield rate) by spin drying and purification by column chromatography. LCMS ESI(+)m / z: 519.1 (M+1). Step G: Dissolve the compound 1-(2-amino-6-p-toluenesulfonyl imidazo[4,5c(|pyrolo[2,3-γ)]pridine-1 (6 / - / )-γ)pridine-4-γ)methyl methanesulfonate (80 mg, 0.31 mmol), trimethylcyanosilane (31 mg, 0.31 mmol) and potassium carbonate in LA / . / V-dimethylformamide 10 and stir at room temperature under nitrogen protection for 20 h. After the reaction, add 20 ml of water and extract with ethyl acetate (3 x 20 ml); Combine the organic phases and dry with anhydrous sodium sulfate to obtain the compound 2-(1-(2-amino-6-p-toluenesulfonyl imidazo[4,5c(]pyrrolo[2,3-b]pridina-1(6 / - / )-1)peridina-4-1)acetonitrile (60 mg, 87% yield) by filtration, spin drying, and purification by column chromatography. LCMS nr Lrnn / zznz / B / Yi ESI(+)m / z: 450.1 (M+1). Step H: Dissolve the compound 2-(1-(2-amino-6-p-toluenesulfonyl imidazo[4,5-c(|pyrolo[2,3-b]pyridine-1(6 / - / )-1)piperidin-4-1)acetonitrile (60 mg, 0.13 mmol) in the mixed solution of dichloromethane (10 mL) and methanol (10 mL) and add potassium carbonate (301 mg, 2.18 mmol); stir at room temperature for 18 h under nitrogen protection. After the reaction, filter and add 20 mL of water; extract with ethyl acetate (5 x 50 mL) and combine the organic phases; dry with anhydrous sodium sulfate and the compound 2-(1-(2-aminoimidazo[4,5-c(|pyrolo[2,3-b]pyridine-1 (6 / - / )-¡l)piper¡n-4-¡l)aceton¡trilo (20 mg, 51% yield rate) by filtration, spin drying and purification by column chromatography.1H NMR (400 MHz, DMSO-d6) δ 11.50(s, 1H), 8.11 (s, 1H), 7.37 (t, J = 3.2 Hz, 1H), 6.54 (dd, J = 3.2, 2.0 Hz, 1H), 6.24 (s, 1H), 3.49 (t, J = 10.2 Hz, 2H), 3.04 (d, J = 10.2 Hz, 2H), 2.61 (d, J = 6.8 Hz, 1H), 2.03 - 1.96 (m, 1H), 1.91 - 1.88 (m, 2H), 1.72 - 1.68 (m, 2H). LCMS ESI(+)m / z: 296.1 (M+1). Example 10 nc Lrnn / zznz / B / Yu Λ / -((1 -(4-(cyanomet¡l)p¡perid¡n-1 -il)-1,6-dih idroimidazol[4,5-c / ]pirrolo[2,3 -b]pirid¡n-2¡l)metil)metanosulfonamida The ejection mode and the siguiente: Paso A: Add Boc-glycinamide (328 mg, 1.88 mmol) and triethyloxyonium tetrafluoroboric acid (358 mg, 1.88 mmol) to 15 mL of anhydrous tetrahydrofuran under nitrogen and stir at 30 °C for 2 h. Concentrate the reaction solution under reduced pressure. Dissolve the residue in 15 mL of ethanol and add 2-(1-((5-amino-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine-4-yl)amino)piperidine-4-yl)acetonitrile (160 mg, 0.38 mmol) under nitrogen; stir at 75 °C for 1 h. Concentrate the reaction solution under reduced pressure. Add saturated sodium bicarbonate solution (10 mL) and ethyl acetate (15 mL) and stir for 5 min. Separate the organic phases and extract the aqueous phase with 45 ml of ethyl acetate 3 times.Combine the organic phases and wash with 10 ml of water; wash with 10 ml of saturated salt and dry with anhydrous sodium sulfate; concentrate under reduced pressure and obtain the compound tert-butyl-((1-(4-(cyanomethyl)piperidine-1-yl)-6-p-toluenesulfonyl-1,6-dihydroimidazol[4,5-d-pinOlo[2,3-b]pridin-2-yl)methyl)carbamate (200 mg, 90% yield) by silica gel column chromatography. LCMS ESI(+)m / z: 564.2(M+1). Step B: Dissolve the compound tert-butyl-((1-(4-(cyanomethyl)piperidin-1-yl)-6-p-toluenesulfonyl-1,6-dihydroimidazol[4,5-c(]pyrrolo[2,3-β]pyridine-2-1)methyl)carbamate (100 mg, 0.18 mmol) in 3 mL of dichloromethane and add trifluoroacetic acid (1 mL) dropwise in an ice bath. Heat to room temperature and stir for 4 h under nitrogen protection. Concentrate the reaction solution under reduced pressure. Add 5 mL of saturated sodium bicarbonate solution and stir for 5 min. Extract with 15 mL of dichloromethane 3 times. Combine the organic phases, wash with 5 mL of saturated saline solution, and dry with anhydrous sodium sulfate. Filter by suction and concentrate the filtrate to Reduced pressure to obtain the compound 2-(1(2-(aminomethyl)-6-p-toluenesulfonyl imidazol[4,5-c / ]pyrrolo[2,3-b]pridina-1 (6 / - / )-1l)piperidin-4yl)acetonitrile (82 mg, 100% yield rate). LCMS ESI(+)m / z: 464.1 (M+1). Step C: Dissolve 2-(1-(2-(aminomethyl)-6-p-toluenesulfonyl midazol[4,5-d]pyrrolo[2,3-b]pyridin-1(6-1)-1)pyridin-4-1)acetonitrile (82 mg, 0.53 mmol) in 3 ml of dichloromethane and add triethylamine (54 mg, 0.53 mmol) and methanesulfonyl chloride (30 mg, 0.27 mmol) under an ice bath and nitrogen protection. Shake for 2 h in an ice bath. Add saturated sodium bicarbonate solution (10 ml) and shake at room temperature for 30 min. Extract with 15 ml of dichloromethane 3 times and combine the organic phases; wash with 3 ml of saturated saline solution and dry with anhydrous sodium sulfate; Concentrate under reduced pressure and obtain the compound N-((1-(4-(cyanomethyl)piperidine-1-yl)-6-p-toluenesulfonyl-1,6-dihydroimidazol[4,5-c(]pyrrolo[2,3-b]pridin-2-yl)methyl)methanesulfonamide (30 mg, yield rate of 71%) by silica gel column chromatography. LCMS ESI(+)m / z: 542.1 (M+1). Step D: nr Lrnn / zznz / B / Yi Dissolve the compound N-((1-(4-(cyanomethyl)pyridine-1-1)-6-p-toluenesulfonyl-1,6-dihydroimidazol[4,5-cy]pyrrolo[2,3-β]pyridine-2-yl)methyl)methanesulfonamide (16 mg, 0.03 mmol) in 3 mL of methanol and add 1 N sodium hydroxide solution (1 mL, 1.0 mmol). Stir at 35 °C for 6 h. Dilute the reaction solution with 9 mL of water and remove the methanol by distillation under reduced pressure. Extract the residue three times with 15 mL of ethyl acetate. Combine the organic phases and dry with anhydrous sodium sulfate; filter by suction and evaporate the solvent under reduced pressure. Prepare the compound N-((1-(4-(cyanomethyl)p¡per¡din-1-¡l)-1,6dihydroimidazole[4,5-c / ]pyrrolo[2,3-£>]pyridin-2-yl)methyl)methanesulfonamide (48 mg, 51% yield rate) from the residue by HPLC.1H NMR (400 MHz, DMSO-ó6) δ 11.96 (s, 1H), 8.57 (s, 1H), 7.60 (s, 1H), 7.52 (t, J = 2.6 Hz, 1 H), 6.75 (d, J = 2.6 Hz, 1 H), 4.52 (s, 2H), 3.57 (t, J = 10.2 Hz, 2H), 3.23 - 3.19 (m, 2H), 2.99 (s, 3H), 2.63 (d, J = 6.5 Hz, 2H), 2.15 - 2.06 (m, 1H), 1.98-1.91 (m,2H), 1.74 - 1.62 (m, 2H). LCMS ESI(+)m / z: 388.1 (M+1). Example 11 nr Lrnn / zznz / B / Yi 2-(1-(¡midazo[4,5-c(|p¡rrolo[2,3-b]p¡r¡d¡n-1 (6 / - / )-¡l)piper¡d¡na-4-¡l)prop¡on¡tr¡lo The execution mode is as follows: Step A: Dissolve 4-piperidine ethanol (21.1 g, 100 mmol) in 200 mL of water and 90 mL of acetic acid, and dissolve sodium nitrite (41.4 g, 600 mmol) in 200 mL of water. At 0 °C, gradually add an aqueous solution of sodium nitrite to the reaction system and allow the reaction to proceed at room temperature for 16 h. After the reaction, extract three times with 150 mL of ethyl acetate. Combine the organic phases and dry with anhydrous sodium sulfate; filter and concentrate under reduced pressure; obtain the compound 1-nitroso-4-piperidine ethanol (9.5 g, 60% yield) by silica gel column chromatography. LCMS ESI(+)m / z: 159.1 (M+1). Step B: Dissolve the compound 1-nitroso-4-piperidine ethanol (8.0 g, 50.1 mmol) in 40 mL of methanol and add zinc powder (3.14 g, 48.0 mmol); add 8 mL of acetic acid dropwise at room temperature. After the addition, stir the mixture at 30 °C for 15 min. After the reaction, filter the reaction solution and obtain the crude compound 1-amino-4-piperidine ethanol (4.37 g, 60% yield) by rotary evaporation of the filtrate. LCMS ESI(+)m / z: 145.1 (M+1). Step C: Add the compound 4-chloro-5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine (2.46 g, 7.0 mmol), A / ,A / -diisopropylethylamine (4.5 g, 35.0 mmol) and 1-amino-4-piperidine ethanol (2.20 g, 2.20 g) to 200 mL of isopropanol (suspension). Stir the reaction at 95 °C for 16 h. After the reaction, cool to room temperature and add 300 mL of water; extract with ethyl acetate (3 x 250 mL) and combine the organic phases; Dry with anhydrous sodium sulfate and obtain the compound (1-((5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine-4-yl)amino)piperidine-4-yl)ethanol (1.97 g, 61% yield rate) by filtration, spin drying and purification by column chromatography. LCMS ESI(+)m / z: 460.2(M+1). Step D: Dissolve the compound 2-(1-((5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-4-yl)ethanol (1.17 g, 2.55 mmol)) in 50 ml of dichloromethane and add methanesulfonyl chloride (876 mg, 7.65 mmol) and triethylamine (1.28 g, 12.75 mmol) and stir at room temperature for 2 h. After the reaction, obtain the crude compound 2-(1-((5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-4-yl)ethyl methanesulfonate (1.37 g, 100% yield) by vacuum concentration. LCMS ESI(+)m / z: 518.2(M+1). Step E: Add the compound 2-(1-((5-nitro-1-p-toluenesulfonyl-1-pyrrolo[2,3-]pyridin-4-yl)amino)piperidine-4-yl)ethyl methanesulfonate (1.37 g, 3.0 mmol) to the mixed solution (suspension) of 45 mL of ethanol and 15 mL of water, and then add solid ammonium chloride (0.64 g, 12.0 mmol) and iron powder (0.67 g, 12.0 mmol) one by one. Heat to 80 °C and stir for 3 h. After the reaction, filter the reaction solution and wash the filter residue with an appropriate amount of ethyl acetate. Add 50 mL of water to the filtrate and extract with ethyl acetate (3 x 50 mL). Combine the organic phases and dry with anhydrous sodium sulfate; obtain the compound 2-(1-(5-amino-1-p-toluenesulfonyl-1 / - / pyrrolo[2,3-b]pindin-4-1)amino)pyridine-4-1)ethyl methanesulfonate (1.26 g, 97% yield) by filtration, spin drying and purification by column chromatography. LCMS ESI(+)m / z: 430.2(M+1). Step F: Dissolve the compound 2-(1-((5-amino-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-4-yl ethyl methanesulfonate (582 mg, 1.35 mmol) in 25 mL of acetic acid and add triethyl orthoformate (1.00 g, 6.75 mmol). Heat to 116 °C and stir the reaction for 1 h. After the reaction, concentrate under reduced pressure and obtain the compound 2-(1-(6-ptoluenesulfonyl imidazo[4,5-c(]pyrrolo[2,3-b]pyridin-1(6H)-yl)piperidin-4-yl)ethyl methanesulfonate (253 mg, 42% yield) using silica gel Column chromatography. LCMS ESI(+)m / z: 440.2(M+1). Step H: Dissolve the compound 2-(1-(6-p-toluenesulfonyl imidazo[4,5-c(]pyrrolo[2,3-b]pyridine(6-p)-1)pyridine-4-1)ethyl methanesulfonate (253 mg, 1.35 mmol) in 16 mL of N,N-dimethylformamide and add potassium carbonate (187 mg, 1.35 mmol) and trimethylcyanosilane (134 mg, 1.35 mmol), respectively. Heat to 100 °C and stir the reaction for 20 h under nitrogen protection. After the reaction, add the appropriate amount of aqueous sodium hydroxide solution and extract with ethyl acetate (3 x 100 mL); combine the organic phases and dry with anhydrous sodium sulfate; obtain the compound 3-(1-(6-p-toluenesulfonyl imidazo[4,5-o]pyrolo[2,3-t>]pridin-1 (6 / - / )-i)pperidin-4-i)proponithlo (97 mg, yield rate of 48%) by filtration, centrifugal drying and purification by column chromatography. LCMS ESI(+)m / z: 449.2(M+1). Step H: Dissolve the compound 3-(1-(6-p-toluenesulfonyl imidazo[4,5-c(]pyrrolo[2,3-b]pᵣdin-1(6H)-1)piperıdin-4-1)propionitrile (97 mg, 0.22 mmol) in 9 mL of methanol and add 3 mL of 1 N aqueous sodium hydroxide solution; stir the reaction at room temperature for 16 h. After the reaction, adjust the pH from 7 to 8 with acetic acid and concentrate under reduced pressure. Prepare the compound 2-(1-(imidazo[4,5-c(]pyrrolo[2,3-b]pᵣdin-1(6H)-1)piperıdin-4-1)propionitrile (30 mg, 48% yield) by gel column chromatography silica and HPLC.1H NMR (400 MHz, DMSO-ó6) δ 11.82 (s, 1H), 8.58 (s, 1H), 8.55 (s, 1 H), 7.44 (t, J = 2.8 Hz, 1H), 6.73 (dd, J = 3.1, 1.9 Hz, 1H), 3.36 - 3.33 (m, 1H), 3.31 - 3.26 (m, 3H), 2.61 (t, J = 7.0 Hz, 2H), 1.96 - 1.90 (m, 2H), 1.71-1.46 (m, 5H). LCMS ESI(+)m / z: 295.2(M+1). nr Lrnn / zznz / B / Yi nr Lrnn / zznz / B / Yi 6-(midazo[4,5-c / ]pyrrolo[2,3-¿>]pyridin-1 (6 / - / )-¡l)-6-azaspiro[2,5]octane-1 -carbonitrile The execution mode is as follows: Step A: Dissolve diethyl (cyanomethyl)phosphonate (3.72 g, 21.0 mmol) in 30 mL of anhydrous tetrahydrofuran and add 60% sodium hydride (0.84 g, 21 mmol) at 0 °C; react at this temperature for half an hour and then add dropwise to a lithium tetrahydroaluminum solution (10 mL) containing tert-butyl 4-oxopiperidine-1-carboxylate (2.09 g, 10.5 mmol); react at room temperature for 3 h under nitrogen protection. After the reaction, add water at 0 °C to neutralize and extract with ethyl acetate (240 mL) three times; Obtain the tert-butyl ester product of 4-(cyanomethylene)pyridine-1-carboxylic acid (2.2 g, 94% yield rate) by drying, centrifugation and purification.1H NMR (400 MHz, CDCh) δ 5.19 (s, 1H), 3.54 - 3.48 (m, 4H), 2.56 (t, J = 6.0 Hz, 1 H), 2.33 (t, J = 6.0 Hz, 1 H). Step B: Dissolve potassium tert-butoxide (1.11 g, 9.9 mmol) in 20 ml of dimethyl sulfoxide and gradually add trimethyl sulfoxide iodide (2.18 g, 9.9 mmol); react at room temperature for 1.5 hours and add a solution of dimethyl sulfoxide containing tert-butyl ester of 4-(cyanomethylethylene)piperidine-1-carboxylic acid (2.0 g, 9.0 mmol) to this reaction solution; heat to 45 °C under nitrogen protection and stir for 16 h. After the reaction, inactivate with aqueous ammonium chloride solution and extract with ethyl acetate (240 ml) three times; Obtain the tert-butyl ester product of 1-cyano-6-azaspiro[2,4]octane-6-carboxylic acid (1.8 g, 85% yield) by drying, centrifugation and purification. LCMS ESI(+)m / z: 237.1 (M+1). nr Lrnn / zznz / B / Yu Step C: Dissolve the tert-butyl ester of 1-cyano-6-azaspiro[2,4]octane-6-carboxylic acid (1.8 g, 7.6 mmol) in 20 mL of dichloromethane and add trifluoroacetic acid (2 mL) dropwise in an ice bath; heat to 75 °C and stir for 18 h. After the reaction, obtain the crude product 6-aza-spiro[2,5]octane-1-carboxylic acid trifluoroacetate (1.0 g, 97% yield) by centrifugation drying. LCMS ESI(+)m / z: 137.1 (M+1). Step D: Dissolve the 6-aza-spiro[2,5]octane-1-carbonitrile trifluoroacetate compound (1.0 g, 7.4 mmol) in 10 mL of water and 1 mL of glacial acetic acid and add dropwise the aqueous solution containing sodium nitrite (1.0 g, 14.7 mmol) under an ice bath; stir at room temperature for 20 h. After the reaction, inactivate with aqueous sodium bicarbonate solution and extract with ethyl acetate (240 mL) three times; obtain the 6-nitroso-6-aza-spiro[2,5]octane-1-carbonitrile compound (0.6 g, 50% yield) by centrifugation and purification. LCMS ESI(+)m / z: 166.1. Step E: Suspend 6-nitroso-6-aza-spiro[2,5]octane-1-carbonyl (0.3 g, 1.8 mmol) and zinc powder (1.17 g, 18 mmol) in methanol (5 mL) and acetic acid (0.5 mL), and stir at room temperature for 2 h under nitrogen protection. After the reaction, obtain the product 6-amino-6-azaspiro[2,5]octane-1-carbonyl (274 mg, 100% yield) by filtration and centrifugation. LCMS ESI(+)m / z: 152.1 (M+1) Step F: Add the compound 4-chloro-5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine (634 mg, 1.8 mmol), A / V-diisopropylethylamine (2.32 g, 18 mmol) and 6-amino-6-azaspiro[2,5]octane-1-methylonitrile (274 mg, 1.8 mmol) to 10 mL of isopropyl alcohol (suspension). Stir the reaction at 95 °C for 18 h. After the reaction, cool to room temperature and add 100 mL of water; extract with ethyl acetate (3 x 100 mL) and combine the organic phases; Dry with anhydrous sodium sulfate and obtain the compound 6-((5-nitro-1-p-toluenesulfonyl-1 / - / -pyrrolo[2,3b]pyridin-4-yl) by filtration, spin drying and purification by column chromatography. LCMS ESI(+)m / z: 467.1 (M+1). Step G: Add the compound 6-((5-nitro-1-p-toluenesulfonyl-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)6-azaspiro[2,5]octane-1-carbonitrile (430 mg, 0.92 mmol) to the mixed solution (suspension) of 20 mL of ethanol and 4 mL of water, and then add solid ammonium chloride (99 mg, 1.84 mmol) and iron powder (300 mg, 5.54 mmol) one at a time. Heat to 80 °C and stir for 3 h. After the reaction, filter the reaction solution and wash the filter residue with an appropriate amount of ethyl acetate. Add 20 mL of water to the filtrate and extract with ethyl acetate (3 x 20 mL); combine the organic phases and dry with anhydrous sodium sulfate. The compound 6-((5-amino-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-Δ]pyridin-4-α)amino)-6-azaspiro[2,5]octane-1-carbonitrile (347 mg, yield rate of 62%) was obtained by filtration, spin drying and purification by column chromatography. LCMS ESI(+)m / z: 437.1 (M+1). Step H: Dissolve the compound 6-((5-amino-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pridine-4-yl)amino)-6-azaspiro[2,5]octane-1-carbonyl (230 mg, 2.65 mmol) in 5 ml of acetic acid and add triethyl orthoformate (392 mg, 2.65 mmol). Heat to 116 °C and stir the reaction for 1 h. After the reaction, concentrate under reduced pressure and obtain the compound 6-(6-ptoluenesulfonyl imidazo[4,5-c(]pyrolo[2,3-b]pridin-1(6H)-1)-6-azaspiro[2,5]octane-1-carbonyl (120 mg, 51% yield) by silica gel column chromatography. LCMS ESI(+)m / z: 446.1 (M+1). Step I: Dissolve the compound 6-(6-p-toluenesulfonyl imidazo[4,5-pyro[2,3-b]pyridine-1(6H)-1)6-azaspiro[2,5]octane-1-carbonitrile (110 mg, 0.25 mmol) in a mixed solution of 10 mL of methanol and 10 mL of dichloromethane and add potassium carbonate (681 mg, 4.9 mmol); stir at room temperature for 18 h under nitrogen protection. After the reaction, filter and add 20 mL of water; extract with ethyl acetate (5 x 50 mL) and combine the organic phases; dry with anhydrous sodium sulfate and filter. Centrifuge and prepare the compound 6-(¡midazo[4,5c(|pyrrolo[2,3-b]p¡r¡d¡n-1 (6 / - / )-¡l)-6-azaspiro[2,5]octane-1-carbonítrile (20 mg, 28% yield rate) by HPLC.1H NMR (400 MHz, DMSO-d6) δ 11.86(s, 1H), 8.59 (s, 1H), 8.57 (s, 1H), 7.47 (t, J = 3.0 Hz, 1H), 6.77 (dd, J = 3.2, 2.0 Hz, 1H), 3.41 -3.32 (m, 4H), 2.09 - 1.78 (m, 5H), 1.27 - 1.19 (m, 2H). ESI(+)m / z: 293.1 (M+1). Example 13 nr Lrnn / zznz / B / Yi 6-(2-((F?)-1 -hydroxyethyl¡l)¡m¡dazo[4,5-d|pyrrolo[2,3-b]p¡r¡d¡n-1 (6 / - / )-¡l)-6azaspiro[2,5]octane-1 - carbonitrile The execution mode is as follows: nr Lrnn / zznz / B / Yi Step A: Dissolve triethyl oxyomborum tetrafluoride (1.31 g, 6.9 mmol) and R-lactamide (612 mg, 6.9 mmol) in 20 mL of tetrahydrofuran and stir the reaction at room temperature for 2 h. Concentrate under reduced pressure to obtain the colorless oil and dissolve it in 10 mL of absolute ethyl alcohol; add to 10 mL of absolute ethanol to dissolve the compound 6-((5-amino-1p-toluenesulfonyl-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-6-azaspiro[2,5]octane-1-carbonitrile (504 mg, 1.11 mmol). Heat to 75 °C and stir the reaction for 1 h. After the reaction, neutralize with aqueous sodium bicarbonate solution and add 30 mL of water. Extract with ethyl acetate (3 x 100 ml) and combine the organic phases; wash with 200 ml of saturated saline solution and dry with anhydrous sodium sulfate.Filter by suction and concentrate the filtrate under reduced pressure; obtain the compound 6-(2-(( / 7)-1-hydroxyethyl) 6-p-toluenesulfonyl imidazo[4,5-c(|pyrrolo[2,3-b]pridine-1 (6 / - / )-l)-6-azaspiro[2,5]octane-1-carbonitrile (590 mg, yield rate of 52%) by silica gel column chromatography. LCMS ESI(+)m / z: 490.1 (M+1). Step B: Dissolve the compound 6-(2-(( / 7)-1-hydroxyethyl) 6-p-toluenesulfonyl imidazo[4,5c(|pyrrolo[2,3-b]pridine-1 (6 / - / )-1)-6-azaspiro[2,5]octane-1-carbonitrile (290 mg, 0.59 mmol) in 15 ml of methanol and add 5 ml of 1 N aqueous sodium hydroxide solution; stir the reaction at 30 °C for 6 h. After the reaction, adjust the pH from 7 to 8 with acetic acid and concentrate under reduced pressure; prepare the compound 6-(2-(( / 7)-1 -hydroxyethylimidazo[4,5-c / ]pyrrolo[2,3¿>]pyridin-1(6 / 7)-i)-6-azaspiro[2,5]octane-1-carbonitrile (80 mg, 28% yield rate) by silica gel column chromatography and HPLC.1H NMR (400 MHz, DMSO-ds) δ 12.18 (s, 1H), 8.64 (s, 1H), 7.64 (t, J = 2.8 Hz, 1 H), 7.47 (d, J = 8.0 Hz, 1H), 6.68 (dd, J = 3.3, 1.8 Hz, 1H), 5.26 (q, J = 6.4 Hz, 1H), 3.78 - 3.62 (m, 2H), 3.33-3.16 (m, 2H), 2.43 - 2.22 (m, 2H), 1.60 (d, J = 6.6 Hz, 3H), 1.49 (d, J = 13.8 Hz, 1H), 1.40 - 1.21 (m, 4H). LCMS ESI(+)m / z: 337.1 (M+1). Example 14 nr Lrnn / zznz / E / YiA 2-(1 -(imidazo[4,5-c / ]pyrrolo[2,3-¿>]pyridin-1 (6H)-¡l)p¡pendina-4-¡l)-2-methyl propionitrile The execution mode is as follows: Step A: Dissolve 1-Boc-4-cyanomethylpiperidine (4.5 g, 20.0 mmol) in 130 mL of anhydrous tetrahydrofuran and pour into a sodium bis(trimethylsilyl)amine tetrahydrofuran solution (2 M, 30 mL, 60.0 mmol) under an ice bath and nitrogen protection. After the addition is complete, stir for 10 min in an ice bath and dilute methyl iodide (6.53 g, 46.0 mmol) with 20 mL of anhydrous tetrahydrofuran and gradually pour into the reaction solution. After the addition is complete, stir the reaction for 16 h under nitrogen protection at room temperature. Neutralize the reaction solution with the appropriate amount of saturated ammonium chloride solution and add 150 mL of water; extract three times with 600 mL of ethyl acetate. Combine the organic phases and dry with anhydrous sodium sulfate. Filter and concentrate under reduced pressure to obtain the crude compound tert-butyl ester of 4-(2-cyanopropyl2-11)piperidine-1-carboxylic acid (4.02 g, yield rate of 79%). Step B: Dissolve the tert-butyl ester of 4-(2-cyanopropyl-2-yl)piperidin-1-carboxylic acid (4.02 g, 15.0 mmol) in 30 ml of dichloromethane and gradually add 15 ml of trifluoroacetic acid at 0 °C. Stir at room temperature for 4 h. Concentrate under reduced pressure to obtain the compound 2-methyl-2-(piperidin-4-yl)propionitrile trifluoroacetate (3.79 g, 100% yield). Step C: Dissolve the compound 2-methyl-2-(piperidine-4-yl)propionitrile trifluoroacetate (3.79 g, crude product, 15.0 mmol) and sodium nitrite (1.55 g, 22.5 mmol) in 50 mL of water and gradually add 2.6 mL of acetic acid at 0 °C. Stir the reaction at 35 °C for 16 h. Adjust the pH of the reaction solution to 8 with sodium carbonate and extract five times with 250 mL of ethyl acetate. Combine the organic phases and dry with anhydrous sodium sulfate; filter and obtain the compound 2-(1-nitrosopiperidine-4-yl)-2-methylpropionitrile (2.01 g, 74% yield) by rotary evaporation. LCMS ESI(+)m / z: 182.1 (M+1). Step D: Dissolve the compound 2-(1-nitrosopiperidine-4-yl)-2-methylproponitrile (1.00 g, 5.0 mmol) in 30 mL of methanol and add zinc powder (4.71 g, 88.0 mmol) and 6 mL of acetic acid, respectively; stir at 30 °C for 25 min. After the reaction, filter the reaction solution and concentrate the filtrate under reduced pressure to obtain the compound 2-(1-aminopiperidine-4-yl)-2-methylproponitrile (4.73 g, 80% yield). LCMS ESI(+)m / z: 168.2(M+1). Step E: Add the compound 4-chloro-5-nitro-1-p-toluenesulfonyl-1 / - / -pyrrolo[2,3-t]pyridine (2.11 g, 6.0 mmol), / V / V-diisopropylethylamine (3.88 g, 30.0 mmol) and 2-(1-aminopiperidina-4-1)-2-methylproponitrile (1.01 g, 6.0 mmol) to 150 mL of isopropanol (suspension). Stir the reaction at 95 °C for 16 h. After the reaction, cool to room temperature and add 250 mL of water; extract with ethyl acetate (3 x 250 mL) and combine the organic phases; wash with 300 mL of saturated saline solution and dry with anhydrous sodium sulfate; filter and treat by rotary evaporation. Purify by silica gel column chromatography to obtain the compound 2-methyl-2-(1-((5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine-4-yl)amino)pyridine-4-yl)propionitrile (1.47 g, 50% yield rate). LCMS ESI(+)m / z: 483.1 (M+1). Step F: Add the compound 2-methyl-2-(1-((5-nitro-1-p-toluenesulfonyl-1 / - / -pyrrolo[2,3-b]pyridine4-yl)amino)piperidine-4-yl)propionitrile (1.47 g, 3.0 mmol) to the mixed solution (suspension) of 75 mL of ethanol and 25 mL of water, and then add solid ammonium chloride (0.64 g, 12.0 mmol) and iron powder (0.67 g, 12.0 mmol) one by one. Heat to 80 °C and stir for 2 h. After the reaction, filter the reaction solution and wash the filter residue with 50 mL of ethyl acetate. Add 50 mL of water to the filtrate and extract with ethyl acetate (3 x 150 mL). Combine the organic phases and wash with 150 ml of saturated saline solution; dry with anhydrous sodium sulfate. Filter by suction and concentrate the filtrate under reduced pressure to obtain the crude compound 2-methyl-2-(1-((5-amino-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine-4-l)amino)pyridine-4-l)propionitril (1.74 g). LCMS ESI(+)m / z: 453.1 (M+1). Step G: Dissolve the compound 2-methyl-2-(1-((5-amino-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3b]pindin-4-1)amino)properidine-4-1)proponitrile (540 mg, 1.2 mmol) in 30 ml of acetic acid and add triethyl orthoformate (890 mg, 6.00 mmol). Heat to 116 °C and stir the reaction for 45 min. After the reaction, concentrate under reduced pressure and obtain the compound 2-methyl2-(1-(6-p-toluenesulfonyl imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1 piperidin-4-yl)propionitrile (301 mg, yield rate of 54%) by silica gel column chromatography. LCMS ESI(+)m / z: 463.1 (M+1). Step H: Dissolve the compound 2-methyl-2-(1-(6-p-toluenesulfonyl imidazo[4,5-cy]pyrrolo[2,3b]pyridin-1 (6 / - / )-1l)piperidin-4-1l)propionitril (301 mg, 0.65 mmol) in 12 ml of methanol and 6 ml of tetrahydrofuran, and add 4 ml of 1 N aqueous sodium hydroxide solution; stir the reaction at 35 °C for 6 h. After the reaction, adjust the pH from 7 to 8 with acetic acid and concentrate under reduced pressure. Prepare the compound 2-(1-(midazo[4,5-irrolo[2,3-b]pridine(6 / - / )-1)piperidine-4-1)-2-methylpropionitrile (71 mg, 35% yield) by silica gel column chromatography and HPLC.1H NMR (400 MHz, DMSO-d6) δ 11.85 (s, 1H), 8.56 (s, 1H), 8.53 (s, 1H), 7.46 (t, J = 2.9 Hz, 1H), 6.74 (dd, J = 3.3, 1.9 Hz, 1H), 3.40 - 3.33 (m, 4H), 2.09 - 1.99 (m, 2H), 1.76 - 1.60 (m, 3H), 1.38 (s, 6H). LCMS ESI(+)m / z: 309.0(M+1). Example 15 nr Lrnn / zznz / B / Yi ( / 7)-2-(1 -(2-(1 -hydroxyethyl)im idazo[4,5-c(|pyrrolo[2,3 -b]pyridína-1 (6 / - / )-¡l)piper¡dina-4-¡l)-2 methyl propionitrile The execution mode is as follows: Step A: Dissolve triethyl oxyomborum tetrafluoride (633 mg, 3.33 mmol) and R-lactamide (297 mg, 3.33 mmol) in 10 mL of tetrahydrofuran and stir the reaction at room temperature for 2 h. Concentrate under reduced pressure to obtain the colorless oil and dissolve it in 5 mL of absolute ethanol; add this to 10 mL of absolute ethanol to dissolve the compound 2-methyl-2-(1-((5-amino-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3C]pyridine-4-1)amino)pyridine-4-1)propionitrile (504 mg, 1.11 mmol). Heat to 75 °C and stir the reaction for 1 h. After the reaction, neutralize with aqueous sodium bicarbonate solution and add 50 ml of water; extract with ethyl acetate (3 x 50 ml) and combine the organic phases; wash with 100 ml of saturated saline solution and dry with anhydrous sodium sulfate.Filter by suction and concentrate the filtrate under reduced pressure; obtain the compound (fi)-2-(1-(2-(1-hydroxyethyl)-6-p-toluenesulfonyl imidazo[4,5-c(]pyrrolo[2,3-b]pridine-1 (6 / - / )-1) piperidin-4-1)-2-methyl propionitrile (289 mg, yield rate of 57%) by silica gel column chromatography. LCMS ESI(+)m / z: 507.2(M+1). Step D: Dissolve the compound (77)-2-(1-(2-(1-hydroxyethyl)-6-p-toluenesulfonyl imidazo[4,5cdpyrrolo[2,3-b]puridin-1 (6 / - / )-1l) piperidin-4-1l)-2-methylproponitrile (289 mg, 0.57 mmol) in 15 ml of methanol and add 5 ml of 1 N sodium hydroxide. Stir the reaction at 30 °C for 6 h. After the reaction, adjust the pH from 7 to 8 with acetic acid and concentrate under reduced pressure; Prepare the compound ( / 7)-2-(1-(2-(1-hydroxyethyl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin1(6 / 7)-yl)piperidin-4-yl)-2-methylproponitrile (110 mg, yield rate of 54%) by silica gel column chromatography and HPLC.1H NMR (400 MHz, DMSO-cfe) δ 11.92 (s, 1H), 8.55 (s, 1H), 7.50 (t, J = 3.0 Hz, 1H), 6.74 (dd, J = 3.3, 1.8 Hz, 1H), 5.30 (d, J = 6.3 Hz, 1H), 5.21 - 5.13 (m, 1H), 3.66 - 3.51 (m, 2H), 3.20 (dd, J= 30.4, 10.2Hz, 2H), 2.02 (d, J= 10.7 Hz, 2H), 1.88 (t, J = 12.0 Hz, 1H), 1.74 - 1.61 (m, 2H), 1.57 (d, J = 6.6 Hz, 3H), 1.40 (s, 6H). LCMS ESI(+)m / z: 353.2(M+1). nr Lrnn / zznz / E / YiAi 2-(1 -(imidazo[4,5-c(|p¡rrolo[2,3-b]p¡r¡d¡n-1 (6F / )-yl)p¡per¡d¡n-4-¡lídene)aceton¡trile The execution mode is as follows: nr Lrnn / zznz / E / YiA Step A: Suspend Deiss-Martin (2.5 g, 6 mmol) in 50 mL of dichloromethane and add the compound 1-(6-p-toluenesulfonylimidazo[4,5-c(]pyrrolo[2,3-b]piridine-1(6H)-1)piperidin-4-ol (1.2 g, 3 mmol). Stir at room temperature for 3 h under nitrogen protection. After the reaction, obtain the compound 1-(6-p-toluenesulfonylimidazo[4,5-d]pyrrolo[2,3-b]piridine-1(6H)-1)piperidin-4-one (550 mg, 45% yield) by centrifugation drying and purification by column chromatography. LCMS ESI(+)m / z: 410.1 (M+1). Step B: Dissolve the compound 1-(6-p-toluenesulfonyl imidazo[4,5-c(|pyrolo[2,3-b]pridin-1(6H)-1)yl)piperidin-4-one (110 mg, 0.27 mmol) in 12 mL of methanol and add aqueous sodium hydroxide solution (2 N, 3 mL) at 0 °C; stir at room temperature for 16 h under nitrogen protection. After the reaction, add 20 mL of water and extract with dichloromethane (5 x 50 mL); combine the organic phases and dry with anhydrous sodium sulfate; obtain the compound 1-(imidazo[4,5-c(|pyrolo[2,3-b]pridin-1(6H)-1)piperidin-4-one (50 mg, 73% yield) by filtration. centrifugation and purification.1H NMR (400 MHz, DMSO-ó6) δ 11.86 (s, 1H), 8.62 (s, 1 H), 8.56 (s, 1 H),7.47 (t, J = 3.0 Hz,1 H), 6.92 (dd, J = 3.6, 2.0 Hz, 1 H),3.64 - 3.26 (m, 4H), 2.72 - 1.88 (m, 4H).LCMS ESI(+)m / z: 256.1 (M+1). Step C: Dissolve ethyl cyanomethyl phosphate (53 mg, 0.3 mmol) in 2 ml of anhydrous tetrahydrofuran and add 60% sodium hydrogen (24 mg, 0.6 mmol) at 0 °C under nitrogen protection; stir for 30 min. Dissolve the compound 1-(imidazo[4,5-c(pyrolo[2,3-b]pridine-1(6H)1l)piperidin-4-one (37 mg, 0.15 mmol) in 1 ml of anhydrous tetrahydrofuran and add to the reaction solution; stir the reaction at room temperature for 3 h under nitrogen protection. After the reaction, add the appropriate amount of saturated aqueous ammonium chloride solution and extract with ethyl acetate (3 x 10 ml); combine the organic phases and dry with anhydrous sodium sulfate; obtain the compound 2-(1-(imidazo[4,5-c(]pyrolo[2,3b]pridine-1(6H)1l)piperidin-4-lydeno)acetonitrile (15 mg, 39% yield) by filtration, centrifugation, and purification.1H NMR (400 MHz, DMSO-cfe) δ 11.84(s, 1H), 8.60 (s, Η), 8.56 (s, 1 Η), 7.45 (d, J = 3.2 Hz, 1H), 6.79 (d, J = 3.2 Hz, 1H), 5.74 (s, 1H), 3.42 - 3.33 (m, 4H), 2.86 - 2.83 (m, 2H), 2.74 - 2.71 (m, 2H). LCMS ESI (+) m / z: 279.1 (M+1). Example 17 nr Lrnn / zznz / E / YiAi Dissolve the 4-methyl-4-pyridine carboxylate hydrochloride compound (2.0 g, 9.6 mmol) in 10 mL of water. At 0 °C, add sodium nitrite (1.66 g, 24.1 mmol) and acetic acid (1.16 g, 19.2 mmol). Stir at 30 °C overnight. After the reaction, cool the reaction solution to 0 °C and adjust the pH to between 7 and 8 with sodium bicarbonate. Extract with ethyl acetate (2 x 20 mL) and combine the organic phases. Wash with brine (40 mL) and dry with anhydrous sodium sulfate. Filter, centrifuge, and obtain the yellow oily compound 1-nitroso-4-methyl-4-pyridine carboxylate (1.91 g, 99% yield). LCMS ESI (+) m / z: 201.1 (M+1). Step B: Dissolve the compound 1-nitroso-4-methyl-4-piperidinecarboxylate (1.91 g, 9.5 mmol) in 50 mL of tetrahydrofuran. At 0 °C, gradually add a 2.5 M lithium tetrahydroaluminum solution (11.4 mL, 28.6 mmol). Stir at room temperature for 3 h under a nitrogen atmosphere. After the reaction, cool the reaction solution to 0 °C and gradually add water (1.1 mL); add 15% sodium hydroxide (1.1 mL) and water (3.3 mL) and stir at room temperature for 15 min; obtain the compound 1-amino-4-methyl-4-hydroxymethylpiperidine (1.15 g, 80% yield) by filtration, spin drying, and purification by column chromatography. LCMS ESI (+) m / z: 145.1 (M+1). Step C: Dissolve the compound 1-amino-4-methyl-4-hydroxymethylpyridine (806 mg, 5.6 mmol), the compound 4-chloro-5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-δ]pyridine (966 mg, 2.8 mmol) and A / ,A / -diisopropylethylamine (2.13 g, 16.5 mmol) in 50 ml of isopropanol and stir the reaction solution at 88 °C overnight. After the reaction, centrifuge the reaction solution and obtain the yellow solid compound (4-methyl-1-((5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3b]pyridine-4-yl)amino)pyridine-4-yl)methanol (787 mg, yield rate of 62%) by purification by column chromatography. LCMS ESI (+) m / z: 460.1 (M+1). Step D: Dissolve the compound (4-methyl-1-((5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyr¡din-4¡l)amino)p¡perdina-4-¡l)methanol (2.69 g, 5.9 mmol) in 30 ml of dichloromethane and then add triethylamine (1.19 g, 11.7 mmol) and methanesulfonyl chloride (805 mg, 7.0 mmol); stir at room temperature for 4 h. After the reaction, centrifuge the reaction solution and obtain the yellow solid compound (4-methyl-1-((5-nitro-1-p-toluenesulfonyl-1 / 7pyrrolo[2,3-b]pyridine-4-yl methanesulfonate of)amino)piperidin-4-yl)methyl (3.06 g, 97% yield) by purification by column chromatography. LCMS ESI (+) m / z: 538.0 (M+1). Step E: Dissolve the compound (4-methyl-1-((5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine-4-yl)amino)piperidin-4-yl)methyl methanesulfonate (2.96 g, 5.5 mmol) in 90 ml of ethanol and then add iron powder (2.46 g, 44.1 mmol) and ammonium chloride (2.36 g, 44.1 mmol) dissolved in water (30 ml) and stir at 80 °C for 2 h. After the reaction, filter the reaction solution and obtain the solid compound (4-methyl-1-((5-amino-1-p-toluenesulfonyl1 / 7-pyrrolo[2,3-b]pridine-4-yl)amino methanesulfonate of)piperidine-4-yl)methyl (2.14 g, yield rate of 77%) by spin drying and purification by column chromatography. LC-MS: m / z508.1 (M+1). Step F: Dissolve the compound (4-methyl-1-((5-amino-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-Δ]pyridine4-λ)amino)pyridine-4-λ)methyl methanesulfonate (1.3 g, 2.5 mmol) in 40 ml of acetic acid and add triethyl orthoformate (1.85 g, 12.5 mmol); heat to 116 °C and stir for 45 min. After the reaction, centrifuge the reaction solution and obtain the solid compound (4methyl-1-(6-p-toluenesulfonyl imidazo[4,5-c]pyrrolo[2,3-β]pyridine-1-(6 / 7)methanesulfonato-yl)piperidin-4-yl)methyl (1.24 g, 94% yield) by purification by LCMS column chromatography. LCMS ESI (+) m / z: 518.0 (M+1). Step G: Dissolve the compound (4-methyl-1-(6-p-toluenesulfonyl imidazo[4,5-c]pyrrolo[2,3-β]pyridin1(6 / 7)-β1)piperidin-4-β1)methyl methanesulfonate (100 mg, 0.97 mmol) in 5 ml of N,N-dimethylformamide and add sodium cyanide (47 mg, 0.97 mmol). Stir for 16 h at 120 °C. After the reaction, centrifuge the reaction solution and obtain the compound 2-(1(imidazo[4,5-c(|pyrrolo[2,3-b]pridin-1(6 / - / )-1)-4-methylpyridine-4-1)acetonitrile (28 mg, 49% yield) by purification by column chromatography.1H NMR (400 MHz, CDCI3) δ 9.72 (s, 1 H), 8.80 (s, 1 H), 8.17 (s, 1 H), 7.38 (t, J = 2.8 Hz, 1 H), 6.82 (dd, J = 3.1, 2.1 Hz, 1 H), 3.52-3.36 (m, 2 H), 3.36-3.24 (m, 2 H), 2.49 (s, 2H), 2.04-1.98(m, 2H), 1.90-1.82 (m, 2H), 1.37 (s, 3H). LCMS ESI (+) m / z: 295.1 (M+1). nr Lrnn / zznz / B / Yi ( / 7)-2-(1 -(2-(1 -hydroxyethyl)¡m idazo[4,5-c / ]pyrrolo[2,3 -¿>]pyridin-1 (6 / - / )-¡l)-4-methylp¡perina-4¡lo)acetonítrile The execution mode is as follows: Step A: Dissolve R-lactamide (263 mg, 2.96 mmol) and triethyloxonium tetrafluoroboric acid (561 mg, 2.96 mmol) in 10 ml of tetrahydrofuran and stir at 28 °C for 2 h. Dissolve the dry oil and the compound (4-methyl-1-((5-amino-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine-4-yl)amino)pyridine-4-yl) methyl methanesulfonate (500 mg, 0.99 mmol) in ethanol (30 ml) and stir at 75 °C for 2 h. After the reaction, centrifuge the reaction solution and obtain the solid compound ( / 7)-(1 -(2-(1 -hydroxyethyl)-6-p-toluenesulfonyl imidazo[4,5-G(]pyrrolo[2,3methanesulfonate b]pyridin-1 (6 / - / )-1l)-4-methylpyridin-4-1l)methyl (337 g, 60% yield rate) by purification by column chromatography. LCMS ESI (+) m / z: 548.0 (M+1). Step B: Dissolve the compound ( / 7)-(1-(2-(1-hydroxyethyl)-6-p-toluenesulfonyl imidazo[4,5o]pyrolo[2,3-b]pyridine-1 (6 / - / )-1)-4-methylpyridine-4-1)methylmethanesulfonate (200 mg, 0.36 mmol), trimethylcyanosilane (106 mg, 1.07 mmol) and potassium carbonate (148 mg, 1.07 mmol) in 10 ml of A / ,Ndimethylformamide and stir the reaction solution at 120 °C for 72 h. After the reaction, add 30 ml of water and extract with dichloromethane (3 x 30 ml); combine the organic phases and wash the organic phases with saline solution (100 ml); dry with anhydrous sodium sulfate. Prepare the compound ( / 7)-2-(1-(2-(1-hydroxyethyl)imidazo[4,5-d]pyrrolo[2,3-b]pyridine1 (6 / 7)-1)-4-methylpyridine-4-1)acetonitrile (48 mg, 40% yield rate) by filtration and centrifugation.1H NMR (400 MHz, DMSO-cfe) or 11.95 (s, 1H), 8.55 (s, 1H), 7.55 (t, J = 3.0 Hz, 1H), 6.64 (dd, J= 3.2, 2.0 Hz, 1H), 5.28 (d, J= 6.0 Hz, 1H), 5.20 - 5.14 (m, 1H), 3.65 - 3.60 (m, 2H), 3.60 - 3.55 (m, 2H), 2.68 (s, 2H), 1.96 - 1.94 (m, 2H), 1.88 - 1.80 (m, 2H), 1.35 (s, 3H). LCMS ESI (+) m / z: 339.1 (M+1). Example 19 OH / V^CN / / -N' H 2-(4-hydroxy-1 -(imidazo[4,5-c / ]pyrrolo[2,3-¿>]pyridin-1 (6 / 7)-¡l)-piper¡dina-4-¡l)acetonítrilo The execution mode is as follows: nc Lrnn / zznz / B / Yu Step A: Add diisopropylaminolithium (2 M, 50 mL, 100.0 mmol) to 150 mL of tetrahydrofuran and add acetonitrile (4.10 g, 100.0 mmol) under nitrogen protection at -78 °C; stir for 1 h at -78 °C. Then, dissolve N-Boc-4-piperidone (10.0 g, 50.0 mmol) in 50 mL of tetrahydrofuran and add it to the reaction system. After the addition is complete, gradually heat to room temperature and maintain the reaction for 1 h. After the reaction, neutralize with an appropriate amount of saturated aqueous ammonium chloride solution and add 150 mL of water; extract three times with 600 mL of ethyl acetate. Combine the organic phases, wash with 300 mL of saturated saline solution, and dry with anhydrous sodium sulfate. Filter by suction and concentrate the filtrate under reduced pressure; obtain the compound N-Boc-4-cyanomethyl-4-hydroxypiperidine (6.2 g, 52% yield) by silica gel column chromatography. LCMS ESI(+)m / z: 241.2(M+1). Step B: Dissolve the compound N-Soc-4-cyanomethyl-4-hydroxypiperidin (6.2 g, 25.8 mmol) in 60 mL of dichloromethane and add 15 mL of trifluoroacetic acid at 0 °C. After the addition is complete, stir the reaction at room temperature for 5 h. After the reaction, concentrate the reaction solution under reduced pressure to obtain the compound 4(cyanomethyl)-4-hydroxypiperidin trifluoroacetate (5.12 g, 97% yield). LCMS ESI(+)m / z: 141.1 (M+1). Step C: Dissolve 4-(cyanomethyl)-4-hydroxypyridine trifluoroacetate (5.12 g, 25.0 mmol) in 30 mL of water and 50 mL of acetic acid, and dissolve sodium nitrite (2.59 g, 37.5 mmol) in 15 mL of water. At 0 °C, gradually add an aqueous solution of sodium nitrite to the reaction system and stir the reaction at room temperature for 16 h. After the reaction, concentrate the reaction solution under reduced pressure and obtain nitroso-4-(cyanomethyl)-4-hydroxypyridine (2.60 g, 61% yield) by silica gel column chromatography. LCMS ESI(+)m / z: 170.1 (M+1). Step D: Dissolve the compound 1-nitroso-4-(cyanomethyl)-4-hydroxypyridine (2.30 g, 13.5 mmol) in 100 mL of methanol and add zinc powder (17.8 g, 272.0 mmol); add 20 mL of acetic acid dropwise at room temperature. After the addition, stir the mixture at 30 °C for 15 min. After the reaction, filter the reaction solution and obtain the crude compound 1-amino-4-(cyanomethyl)-4-hydroxypyridine (1.78 g, 85% yield) by rotary evaporation of the filtrate. LCMS ESI(+)m / z: 156.1 (M+1). Step E: Add the compound 4-chloro-5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine (4.02 g, 11.4 mmol), A / ,A / -diisopropylethylamine (5.89 g, 45.6 mmol), and 1-amino-4-(cyanomethyl)-4-hydroxypiperidine (1.78 g, 11.4 mmol) to 150 mL of isopropanol (suspension). At 95 °C (oil bath temperature), stir the reaction for 16 h. After the reaction, cool to room temperature and add 200 mL of water; extract three times with 600 mL of ethyl acetate. Combine the organic phases and dry with anhydrous sodium sulfate. Filter and obtain the compound 2-(4-hydroxy-1-(5-nitro-1-p-toluenesulfonyl-1 / 7-pyrolo[2,3-b]pyridine-4-yl)amino)pyridine-4-yl)acetonitrile (3.25 g, 60% yield rate) by rotary evaporation and purification. LCMS ESI(+)m / z: 471.2(M+1). Step F: Add the compound 2-(4-hydroxy-1-((5-nitro-1-p-toluenesulfonyl-1 / - / -pyrrolo[2,3b]pyridine-4-1)amino)pyridine-4-1)acetonitrile (3.25 g, 3.9 mmol) to the mixed solution (suspension) of 90 mL of ethanol and 30 mL of water, and then add solid ammonium chloride (0.88 g, 16.55 mmol) and iron powder (0.92 g, 16.55 mmol) one by one. Heat to 80 °C and stir for 2.5 h. After the reaction, filter the reaction solution and wash the filter residue with 50 mL of ethyl acetate. Add 50 mL of water to the filtrate and extract three times with 240 mL of ethyl acetate. Combine the organic phases, wash with 100 ml of saturated saline solution, and dry with anhydrous sodium sulfate. Filter by suction and concentrate the filtrate under reduced pressure; obtain the compound 2-(1-((5-amino-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3b]pridine-4-yl)amino)4-hydroxypridine-4-yl)acetonitrile (1.88 g, 62%) by silica gel column chromatography. LCMS ESI(+)m / z: 441.2(M+1). Step G: Dissolve the compound 2-(1-((5-amino-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine-4-yl)amino)4-hydroxypiperidine-4-yl)acetonitrile (562 mg, 1.28 mmol) in 25 ml of acetic acid and add triethyl orthoformate (948 mg, 6.40 mmol). Heat to 116 °C and stir for 1 h. Cool to room temperature and concentrate under reduced pressure; Obtain the compound 2-(4-hydroxy-1 (6-p-toluenesulfonyl imidazo[4,5-cf|pyrolo[2,3-£>]pridine-1 (6F / )-yl)-pyridine-4-yl)acetonitrile (360 mg, yield rate of 62%) by silica gel column chromatography. LCMS ESI(+)m / z:426.2(M+1). Step H: Dissolve 2-(4-hydroxy-1-(6-p-toluenesulfonyl imidazo[4,5-c(]pyrrolo[2,3-b]pyridin-1(6H)-β)piperidine-4-yl)acetonitrile (360 mg, 0.80 mmol) in 15 mL of methanol and 5 mL of tetrahydrofuran. Add 5 mL of 2 N aqueous sodium hydroxide solution and stir the reaction for 16 h at room temperature. Adjust the reaction solution to a pH of 8 to 9 with acetic acid and concentrate under reduced pressure; obtain the compound 2-(4-hydroxy-1-(imidazo[4,5-c(]pyrrolo[2,3-b]pyridin-1(6A7)-yl)piperidine-4-yl)acetonitrile (60 mg, 26% yield) by purification by silica gel column chromatography.1H NMR (400 MHz, DMSO-de) δ 11.86 (s, 1H), 8.76 - 8.16 (m, 2H), 7.48 (s, 1H), 6.90 (s, 1H), 5.45 (s, 1H), 3.85 - 3.54 (m, 2H), 3.08 (d, J = 9.9 Hz, 2H), 2.81 (s, 2H), 2.03 - 1.91 (m, 2H), 1.86 (d, J= 12.2 Hz, 2H). LCMS nr Lrnn / zznz / B / Yi ESI(+)m / z: 297.1 (M+1). Example 20 nr Lrnn / zznz / B / Yi 2-(8-(¡midazo[4,5-^¡rrolo[2,3-b]p¡r¡d¡n-1 (67 / )-¡l)-8-azabicyclo[3.2.1 ]octan-3 ¡lidene)acetonítrilo The specific implementation methods are as follows: Step A: Dissolve nortropine (3.01 g, 26.13 mmol) in 80 mL of water. Then, add 80 mL of concentrated hydrochloric acid at 0 °C and add sodium nitrite (43.5 g, 630.2 mmol) in parts at 30 °C. Continue stirring at 30 °C and react for 16 h. After the reaction, perform time-extraction with 600 mL of ethyl acetate. Mix the organic phase, dry with anhydrous sodium sulfate, filter, rotate, and evaporate the filtrate. The compound 8-nitroso-8-azabicylchloro[3.2.1]octane-3-ol (8.62 g, 70% yield) is obtained by purification using silica column chromatography. LCMS ESI(+)m / z:157.1 (M+1). Step B: Dissolve the compound 8-nitroso-8-azabicyclo[3.2.1]octan-3-ol (7.0 g, 44.8 mmol) in 150 mL of methanol, add zinc powder (29.3 g, 448.0 mmol), and then add 30 mL of acetic acid dropwise at 0 °C. After the addition, stir at 30 °C and react for 20 min. Then filter the reaction liquid. Stir and evaporate the filtrate to obtain the crude compound 8-amino-8-azabicyclo[3.2.1]octan-3-ol (3.43 g, 54% yield). LCMS ESI(+)m / z:143.1(M+1). Step C: Add the compound 4-chloro-5-nitro-1-p-toluene sulfoyl-1 / 7-pyrrolo[2,3-b]pyridine (3.52 g, 10.0 mmol), A / ,A / -diisopropylethylamine (5.17 g, 40.0 mmol), and 8-amino-8-azabicyclo[3.2.1]octan-3-ol (1.72 g, 12.0 mmol) to 150 mL of isopropyl alcohol (suspension). Stir at 95 °C and react for 16 h. After the reaction, cool to room temperature, add 300 mL of water, extract with ethyl acetate (3 x 250 mL), mix the organic phase, dry with anhydrous sodium sulfate, filter, and dry by centrifugation. A purification by column chromatography is carried out to obtain the compound 8-((5-nitro-1-ptoluene-1 H-pyrrolo[2,3-b]pridina-4-base)amino)8-azabicyl[3.2.1]octane-3-ol (3.17 g, 70% yield). LCMS ESI(+)m / z: 458.2(M+1). Step D: Add the compound 8-((5-nitro-1-p-toluene sulfonyl-1 / 7-pyrrolo[2,3-b]pindine-4base)amino)8-azabicyl[3.2.1]octane-3-ol (3.17 g, 7.0 mmol) to a mixed solution of 120 mL of ethanol and 40 mL of water (suspension), followed by the addition of solid ammonium chloride (1.50 g, 28.0 mmol) and iron powder (1.56 g, 28.0 mmol). Then, heat to 80 °C and stir for 2 h. After the reaction, filter the reaction liquid with an appropriate amount of ethyl acetate, washing the residue from the filter. Then, add 200 mL of water to the filtrate and perform the extraction with ethyl acetate (3 x 250 mL). Next, the organic phase was fused, dried with anhydrous sodium sulfate, filtered, and dried by centrifugation. Purification by column chromatography was carried out to obtain the compound 8-((5-nitro-1-ptoluene-1 / 7-pyrrolo[2,3-b]pyridine-4-base)amino)8-nitrogen azabicyclo[3.2.1]octane-3-alcohol (yield ratio of 3.02 g, 100%). LCMS ESI(+)m / z:428.2(M+1). Step E: Dissolve the compound 8-((5-amino-1-p-toluene sulfonyl-1 / 7-pyrrolo[2,3-b]pyridine-4-l)amino)8-azabicyclo[3,2,1]octane-3-ol (2.95 g, 6.9 mmol) in 80 ml of acetic acid and add triethyl orthoformate (5.11 g, 34.5 mmol). When the temperature rises to 116 °C, stir and react for 1 h. After the reaction, perform concentration and decompression. Next, the compound 8-(6-p-toluene sulfonyl imidazo[4,5-c(|pyrrolo[2,3b]pyridin-1 (6 / - / )-1)-8-azabicyclo[3.2.1 ]octane-3 -ol (2.31 g, 77% yield) is obtained by silica column chromatography. LCMS ESI(+)m / z: 438.2(M+1). Step F: Dissolve Dess-Martin Periodinane (3.01 g, 7.1 mmol) in 80 mL of dichloromethane. Dissolve the compound 8-(6-p-toluene sulfonyl imidazo[4,5-dipyrrolo[2,3-b]]pridin-1 (6 / - / )-1)-8azabicyclo[3.2.1]octane-3-ol (2.05 g, 4.7 mmol) in 20 mL of dichloromethane and add to the reaction solution. Stir at room temperature for 2 h. After the reaction, wash the reaction solution with 60 mL of saturated aqueous sodium bicarbonate solution and 60 mL of saturated aqueous sodium chloride solution, respectively. Next, obtain the compound 8-(6-toluene sulfonyl imidazo [4,5-c(|p¡pyrlo[2,3-b]p¡r¡n-1 (6 / - / )-¡l)-8azabicyclo[3.2.1]octane-3-ketone (1.3 g, 64% yield) by drying with anhydrous sodium sulfate, filtration, concentration and decompression and by silica column chromatography. LCMS ESI(+)m / z: 436.2(M+1). Step G: Dissolve diethyl cyanomethyl phosphate (798 mg, 4.5 mmol) in 30 mL of anhydrous tetrahydrofuran under nitrogen protection. Then add 60% sodium hydrogen (180 mg, 4.5 mmol) at 0 °C and stir for 30 min. Dissolve the compound 8-(6-toluene sulfonyl imidazoli[4,5-d]pinOlo[2,3-t]pridine-1 (6 / - / )-1)-8-azabicyclo[3.2.1]octane-3-ketone (1.31 g, 3.0 mmol) in 15 mL of anhydrous tetrahydrofuran, add it to the reaction solution, and then stir for 2 h under nitrogen protection at room temperature. After the reaction, add an appropriate amount of saturated aqueous ammonium chloride solution, extract with ethyl acetate (3 x 50 ml) and fuse the organic phases. After that, obtain the compound 2-(8-(6-p-toluene sulfonyl imidazo[4,5-c(]pyrrolo[2,3-b]pridine-1(6H)-1)8-azabicilo[3.2.1]octan-3-ylidene)acetonitril (879 mg, 64% yield) by drying with anhydrous sodium sulfate, filtration, dry centrifugation and purification by silica column chromatography. LCMS ESI(+)m / z: 459.2(M+1). Step H: Dissolve 2-(8-(6-p-toluene sulfonyl imidazo[4,5-c(|p¡pyrlo[2,3-b]p¡r¡n-1(6 / - / )-¡l)-8azabic¡clo[3.2.1]octan-3-¡liden)acetonithol in 24 mL of methanol and 8 mL of tetrahydrofuran, then add 8 mL of 1 N aqueous sodium hydroxide solution. Stir at 35 °C and react for 16 h. After the reaction, adjust the pH to 8–9 with acetic acid, concentrate and decompress, and perform silica column chromatography to obtain the compound 2-(8-(¡midazo[4,5-c(|pyrrolo[2,3-b]p¡r¡din-1(6 / - / )-¡l)-8-azab¡cyclo[3.2.1]octan3-ylidene)acetonitrile (302 mg, 55% yield).1H NMR (400 MHz, DMSO-d6) δ 11.81 (s, 1H), 8.55 (s, 1H), 8.26 (s, 1H), 7.43 (t,J = 2.9 Hz, 1H), 6.90 (dd, J = 3.2, 1.9 Hz, 1H), 5.76 (s, J = 2.0 Hz,1 H), 3.98 (d, J = 20.5 Hz, 2H), 3.00 (d, J = 14.7 Hz, 2H), 2.79 (d, J = 15.0 Hz, 1H), 2.57 (d, J = 15.2 Hz, 1H), 2.36 - 2.22 (m, 2H), 1.83 - 1.64 (m, 2H). LCMS ESI(+)m / z: 305.2(M+1). Example 21 nr Lrnn / zznz / B / Yi J8-(imidazo[4,5-c / ]pyrrolo[2,3-£>]pyridin-1 (6H)-yl)-8-azabicyclo[3.2.1 ]octan-3-yl)acetonitrile The specific implementation methods are as follows: nr Lrnn / zznz / B / Yi Dissolve the compound 2-(8-(imidazo[4,5-c(pyrrolo[2,3-b]pridin-1(6 / - / )-l)-8azabicyclo[3.2.1]octan-3-lydeno)acetonitrile (100 mg, 0.33 mmol) in 10 mL of methanol and add palladium on carbon (106 mg, 0.10 mmol). Then, stir under hydrogen conditions at room temperature and react for 16 h. After that, filter the reaction solution, wash the filter residue with an appropriate amount of methanol, then concentrate and decompress the filtrate and perform high-performance liquid chromatography, which helps to prepare the compound 1H NMR DMSO-d6) δ 11.80 (s, 1H), 8.53 (s, 1H), 8.24 (s, 0.38H), 8.20 (s, 0.62H), 7.45 - 7.42 (m, 1H), 6.89 (dd, J = 3.2, 2.0 Hz, 0.38H), 6.81 (dd, J = 3.2, 2.0 Hz, 0.62H), 3.82 (s, 2H), 2.75 (d, J = 8.1 Hz, 1.24 H), 2.63 (d, J = 8.1 Hz, 0.76 H), 2.59 - 2.57 (m, 0.38H), 2.41 - 2.34 (m, 0.62H), 2.34 - 2.10 (m, 3H), 1.98 - 1.84 (m, 3H), 1.84 - 1.70 (m, 0.76H), 1.641.58 (m, 1.24H). LCMS ESI(+)m / z: 307.2(M+1). Example 22 2-(8-(2-((fí)-1-hydroxy¡ethyl)¡m¡dazo[4,5-c(|pyrrolo[2,3-b]p¡r¡d¡n-1(6 / - / )-¡l)-8azabic¡clo[3.2.1]octane-3-¡lidene)aceton¡thlo The specific implementation methods are as follows: Step A: Dissolve Dess-Martin perioddinane (7.30 g, 17.1 mmol) in 70 mL of dichloromethane and dissolve 8-((5-nitro-1-p-toluene sulfonyl-[2,3-b]pyrrole and pyridine-4-base)amino) 8azabicyclo[3.2.1]octane-3-alcohol (5.20 g, 11.4 mmol) in 50 mL of dichloromethane and add it dropwise to the reaction solution. Then stir and react at room temperature for 3 h. After the reaction, add the appropriate amount of saturated aqueous ammonium chloride solution and extract with dichloromethane (3 x 250 mL). Then combine the organic phase and wash with 500 mL of saturated aqueous sodium chloride solution. Dry with anhydrous sodium sulfate, filter, concentrate and decompress the filtrate and purify by silica column chromatography to obtain the compound 8-((5-nitro-1-p-toluene sulfonyl1 / 7-pyrrolo[2,3-b]pridina-4-i)amino)8-azabicyclo[3.2.1]octane-3-ketone (5.6 g, 72% yield). LCMS ESI(+)m / z: 456.2(M+1). Step B: Dissolve diethyl cyanomethyl phosphate (3.27 g, 18.5 mmol) in 100 mL of nitrogen-protected anhydrous tetrahydrofuran. Add 60% sodium hydrogen (738 mg, 60%, 18.5 mmol) at 0 °C and stir for 30 min. Dissolve 8-((5-nitro-1-p-toluene sulfonyl-1-Hpyrrolo[2,3-b]pyrrole and pyridine-4-1)amino)-8-azabicyl[3.2.1]octane-3-ketone (5.6 g, 12.3 mmol) in 100 mL of anhydrous tetrahydrofuran and then add the reaction solution. Stir and react under nitrogen protection at room temperature for 3 h. After the reaction, add saturated aqueous ammonium chloride solution and extract with ethyl acetate (3 x 250 ml), fuse the organic phase. Dry with anhydrous sodium sulfate, filter, concentrate by rotary evaporation and perform silica column chromatography to obtain the compound 2-(8-(((5-nitro-1-p-toluene sulfonyl-1 / 7-pyrrolo[2,3-b])pyridin-4-yl)amino) azabicilo[3.2.1]octane-3-ylidene)acetonitrilo (4.37 g, 74% yield). LCMS ESI(+)m / z: 479.2(M+1). Step C: Add the compound 2-(8-((5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine-4-1)amino) 8-azabicyclo[3,2,1]octane-3-lydene) acetonitrile (2.37 mg, 5.0 mmol) to the solvent mixture of 120 mL of ethyl alcohol and 40 mL of water (suspension). Then, add solid ammonium chloride (1.32 g, 24.8 mmol) and iron powder (1.38 g, 24.8 mmol) successively. Heat to 80 °C and stir for 2 h. After the reaction, filter the reaction solution and wash the filter residue with an appropriate amount of ethyl acetate. Next, add 200 ml of water to the filtrate, extract with ethyl acetate (3 x 250 ml) and fuse the organic phase. Dry the filtrate with anhydrous sodium sulfate, filter, concentrate and decompress and perform silica gel column chromatography to obtain the compound 2-(8-((5-amino-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-o]pyridine-4-yl)amino)8 nr Lrnn / zznz / E / YiAi azabicyclo[3.2.1 ]octane-3-ylidene)acetonitril (1.58 g, 65% yield).LCMS ESI(+)m / z: 449.2(M+1). Paso D: Dissolve triethyloxyboron tetrafluoride (661 mg, 3.48 mmol) and R-lactamide (310 mg, 3.48 mmol) in 20 mL of tetrahydrofuran, stir, and react at room temperature for 2 h. Then, obtain the colorless oily substance by decompression and concentration. After that, dissolve the substance in 15 mL of absolute ethyl alcohol used to dissolve the compound 2-(8-((5-amino-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3-b]pyridine-4-1)amino)8azabicyl[3.2.1]octane-3-ylidene)acetonitrile (520 mg, 1.16 mmol). Heat to 75 °C, stir, and react for 1 h. After the reaction, neutralize with aqueous sodium bicarbonate solution, add 50 ml of water, extract with ethyl acetate (3 x 50 ml), mix the organic phase, wash with 100 ml of saturated salt water, dry with anhydrous sodium sulfate.Next, perform suction filtration, decompress and concentrate the filtrate and perform silica column chromatography to obtain the compound 2-(8-(2((R)-1-hydroxyethyl-6-p-toluenesulfonyl imidazol[4,5-c / ]pyrrolo[2,3-bjpyridin-1 (6 / - / )-il)-8azabiciiclo[3.2.1]octane-3-ylidene)acetonitrilo (480 mg, 82% yield). LCMS ESI(+) M / z: 503.2(m+1). Step F: Dissolve the compound 2-(8-(2-(( / 7)-1-hydroxyethyl-6-p-toluenesulfonyl imidazol(4,5-d)pyrrole and [2,3-b]pyridine-1 (6 / 7)-ilo)-8-azabichloro[3.2.1]octane-3-ylidene)acetonitrile (360 mg, 0.71 mmol) in 9 mL of methanol. Add 3 mL of 1 N sodium hydroxide solution and stir at 35 °C and allow to react for 8 h. After the reaction, adjust the pH to 8-9 with acetic acid and decompress the concentration. Then, perform silica column chromatography to obtain the compound 2-(8-(2-(( / 7)-1-hydroxyethyl)imidazol[4,5-c]pyrrole[2,3-?]pyridine in -1 (6Λ7)-yl)-8azabicyclo[3.2.1 ]octan-3-ylidene)acetonítrilo (32 mg, 12% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.77 (d, J = 26.3 Hz, 1H), 8.49 (d, J = 5.7 Hz, 1H), 7.46 - 7.30 (m, 1H), 6.95 (dd, J = 115.2, 2.4 Hz, 1H), 5.47 (s, 1H), 4.98 - 4.80 (m, 1H), 4.31 - 3.72 (m, 2H), 2.73 (d, J = 7.0 Hz, 1H), 2.70 - 2.54 (m, 3H), 2.38 - 1.73 (m, 6H), 1.64 (d, J = 6.2 Hz, 3H), 1.57 - 1.44 (m, 1H). LCMS ESI(+)m / z: 326.2(M+1). Example 23 nr Lrnn / zznz / B / Yi 2-(8-(2-(( / 7)-1-hydroxyethyl¡l)¡m¡dazo[4,5-c(|pyrrolo[2,3-b]pyrid¡n-1(6 / 7)-¡l)-8azabicyclo[3.2.1]octan-3-¡l)aceton¡trilo The specific implementation methods are as follows: nr Lrnn / zznz / B / Yu Step A: Dissolve the compound 2-(8-(2-(( / 7)-1-hydroxyethyl-6-p-toluenesulfonyl imidazole[4,5-c(|pyrrolo [2,3-£>]pyridin-1 (6 / 7)-1)-8-azabicyclo[3.2.1]octane-3-ylidene) acetonitrile (480 mg, 0.96 mmol) in 35 ml of methanol. Add palladium over carbon (202 mg, 0.19 mmol) and stir at room temperature for 16 h under hydrogen. Filter the reaction solution, wash the filter residue with an appropriate amount of methanol, concentrate, and decompress to obtain the crude compound 2-(8-(2-(( / 7)-1-hydroxyethyl-6-p-toluenesulfonyl imidazole [4,5-c(]pyrrolo[2,3-b]pyridine-1 (6 / 7)-1)-8azabicyclo[3.2.1]octane-3-1)acetonitrile (360 mg, 74% yield). LCMS ESI (+) m / z: 505.2 (M+1). Step B: Dissolve the compound 2-(8-(2-(( / 7)-1-hydroxyethyl-6-p-toluenesulfonyl imidazol(4,5d)pyrrolo[2,3-b]pyridin-1(6 / 7)-1)-8-azabicyclo[3.2.1]octane-3-1)acetonitrile (360 mg, 0.71 mmol) in 9 ml of methanol. Add 3 ml of 1 N aqueous sodium hydroxide solution, stir at 35 °C and react for 8 h. After the reaction, adjust the pH to 8-9 with acetic acid, concentrate and decompress, and perform silica column chromatography to obtain the compound 2-(8-(2-(( / 7)-1-hydroxyethyl)imidazol[4,5-c(]pyrrolo[2,3 -£>]pi rid in -1 (6 / 7)-¡l)-8azabicyclo[3.2.1]octane-3-¡l)acetonítrilo (diastereoisomer, 32 mg, 12% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.80 (s, 1H), 11.73 (s, 1H), 8.49 (s, 1 H), 8.48 (s, 1H), 7.43(t, J = 2.4 Hz, 1H), 7.35 (t, J = 2.5 Hz, 1H), 7.09 (d,J = 2.1 Hz,1 H), 6.80 (d, J = 2.7 Hz, 1H), 5.55 5.45 (m, 1H), 5.45 - 5.35 (m, 1H), 4.98 - 4.88 (m, 1H), 4.88 - 4.78 (m, 1H), 4.25 (t, J = 6.4 Hz, 1H), 4.05 - 4.00 (m, 1H), 3.84 (t, J = 6.4 Hz, 1H), 3.80 - 3.75 (m, 1H), 2.73 (d, J = 7.0 Hz, 2H), 2.66 (d, J = 5.8 Hz, 2H), 2.64 - 2.52 (m, 4H), 2.38), 1.73 (s. 1, 12H). (s, 3H), 1.56 - 1.50 (m, 1 H), 1.50 - 1.44 (m, 1H). LCMS ESI(+)m / z: 326.2(M+1). Example 24 / —CN or N~-Z TV” 3-(4-(imidase[4,5-c / ]pyrrolol[2,3-¿>]pyridin-1 (6 / - / )-yl)piperazine-1 -yl)acetonitrile The specific embodiments are as follows: nr Learn / sell / B / Yi Step A: Dissolve 1-Boc-piperazine (1.86 g, 10.0 mmol) in 20 mL of water and 9 mL of acetic acid, and dissolve sodium nitrite (4.14 g, 60.0 mmol) in 20 mL of water. Gradually add the aqueous sodium nitrite solution dropwise to the reaction system at 0 °C, stir, and allow to react at room temperature for 16 h. After the reaction, add 150 mL of ethyl acetate three times for extraction. Then, fuse the organic phase with the organic phase, dry with anhydrous sodium sulfate, filter, concentrate, and decompress. Finally, perform silica column chromatography to obtain the compound 1-Boc-4-nitrosopiperazine (1.46 g, 68% yield). LCMS ESI(+)m / z: 159.1 (M+1). Step B: 1-Boc-4-aminopiperazine Dissolve 1-Boc-4-nitrosopiperazine (1.46 g, 6.8 mmol) in 10 mL of methanol at room temperature, add zinc powder (2.20 g, 33.8 mmol), cool to 0 °C, and gradually add acetic acid (20 mL) dropwise. Heat to room temperature and stir for 2 h under nitrogen protection. After the reaction, filter and adjust the pH to 910 with a saturated aqueous solution of sodium bicarbonate. Add 40 mL of water, extract three times with 180 mL of dichloromethane, and combine the organic phases. Dry with anhydrous sodium sulfate, filter, centrifuge, and purify to obtain 1-Boc-4-aminopiperazine (1.18 g, 86% yield). Step C: Add the compound 4-chloro-5-nitro-1-p-toluene sulfonyl-1 / - / -pyrrolo[2,3-b]pyridine (1.18 g, 5.87 mmol), A / ,A / -disopropylethylamine (7.10 mg, 55 mmol), and 1-Boc-4-aminopiperazine (1.18 g, 5.87 mmol) to 60 mL of isopropyl alcohol (suspension). Stir at 100 °C for 16 h under nitrogen protection. After the reaction, cool to room temperature and add ethyl ether, which will precipitate a large amount of the yellow solid. Next, filter the solution, recover the solid and dry it to obtain the product 1-Boc-4-((5-nitro-1-p-toluene sulfonyl-1 / 7-pyrolo[2,3-b]pyridine-4-yl)amino)perazine (2.16 g, 76% yield). LCMS ESI(+)m / z: 517.1 (M+1). Step D: Dissolve the compound 1-Boc-4-((5-nitro-1-p-toluene sulfonyl-1 / 7-pyrrolo[2,3-b]pindin-4-yl)amino)piperazine (1.8 g, 3.49 mmol) in 45 ml of ethyl alcohol. Successively add iron powder (1.17 g, 20.9 mmol), ammonium chloride (0.37 g, 6.98 mmol) and 15 ml of water, then raise the temperature to 75 °C and stir for 2 h. After the reaction, filter, centrifuge and purify by column chromatography to obtain the compound 1-Boc-4-((5-amino-1-p-toluene sulfonyl-1 / 7-pyrrorolo [2,3-b]pyridine-4-1l)amino)perazine (930 mg, 54% yield). LCMS ESI(+) M / z: 487.1 (m +1). Step E: Dissolve 1-Boc-4-((5-amino-1-p-toluene sulfonyl-1 / 7-pyrrorolo [2,3-t>]pyridin-4-yl)amino)piperazine in 30 mL of methylbenzene. Then, successively add triethyl orthoformate (2 mL) and pyridine hydrochloride (23 mg, 0.2 mmol). Subsequently, raise the temperature to 115 °C under nitrogen protection and stir for 3 h. After the reaction, centrifuge and purify by column chromatography to obtain the product 1-Boc-4-(6-p-toluene sulfonyl imidazo[4,5-c(|p¡rrolo[2,3-b]p¡r¡na-1 (67 / )-¡l)piperazine (760 mg, 80% yield). LCMS ESI(+)m / z: 497.1. Step F: Dissolve the compound 1-Boc-4-(6-p-toluene sulfonyl imidazo[4,5-c(]pyrolyl[2,3-b]pyridine-1(6H)-1)piperazine (200 mg, 0.4 mmol) in 5 mL of 1,4-dioxane. Under an ice bath, add 1,4-dioxane solution (4 N, 2 mL) of hydrogen chloride and stir the mixture at room temperature for 16 h under nitrogen protection. After the reaction, centrifuge the reaction solution to obtain the compound 4-(6-p-toluene sulfonyl imidazo[4,5-c(]pyrolyl[2,3-b]pyridine-1(6H)-1)piperazine hydrochloride (180 mg, 100% yield). LCMS ESI (+) m / z: 397.1 (M+1). Step G: Dissolve the compound 4-(6-p-toluene sulfonyl imidazo[4,5-c(]pyrrolo[2,3-b]pyridine-1(6 / 7)I) piperazine hydrochloride (200 mg, 0.51 mmol) in 10 mL of methanol. Add aqueous sodium hydroxide solution (2 N, 3 mL) at 0 °C and stir at room temperature for 16 h under nitrogen protection. After the reaction is complete, add 20 mL of water, extract with dichloromethane (3 x 80 mL), fuse the organic phases, dry with anhydrous sodium sulfate, filter, centrifuge, and purify by column chromatography to obtain the compound 1(piperazine-1-I)-1,6-dihydroimidazo[4,5-c(]pyrrolo[2,3-b]pyridine (120 mg, 97% yield). %). nr Lrnn / zznz / B / Yi LCMS ESI(+)m / z: 243.1 (M+1) . Step H: nr Lrnn / zznz / B / Yi Dissolve the compound 1-(piperazine-1-yl)-1,6-dihydro¡midazol[4,5-d]pyrrolo[2,3-¿>]pyridine (48 mg, 0.2 mmol), bromoacetonitrile (31 mg, 0.26 mmol) and triethylamine (61 mg, 0.6 mmol) in 5 ml of N, N-dimethylformamide and stir at room temperature for 16 h under nitrogen protection. After the reaction, add 40 mL of water, extract with ethyl acetate (3 x 40 mL), combine the organic phases, dry with anhydrous sodium sulfate, filter, centrifuge, and finally apply HPLC to prepare the compound 3-(4-(imidazo[4,5-c(]pyrrolo[2,3-b]pridine(6 / - / )-1)piperazine-1-yl)acetonitrile (8 mg, 16% yield). 1H NMR (400 MHz, DMSOd6) δ 12.18(s, 1H), 8.93 (s, 1H), 8.74 (s, 1H), 7.57 (t, J = 3.2 Hz, 1H), 6.81 (dd, J = 3.2 Hz, 2.0 Hz, 1H), 3.91 (s, 2H), 3.41 - 3.39 (m, 4H), 2.87 - 2.81 (m, 4H). LCMS ESI(+)m / z: 282.1 (M+1. 3-(4-(¡midazo[4,5-c(|pyrrolo[2,3-b]p¡r¡d¡n-1 (6H)-yl)piperaz¡n-1 -yl)propanonitrile The specific implementation methods are as follows: Dissolve the compound 1-(piperazine-1-yl)-1,6-dihydroimidazol[4,5-d]pyrrolo[2,3-b]pridine (52 mg, 0.22 mmol), triethylamine (108 mg, 1.1 mmol) in 3 ml of 3-allylonitrile. Stir at 100 °C for 1 h under nitrogen protection. Once the reaction is complete, filter, add 20 mL of water, extract with ethyl acetate (5 x 40 mL), combine the organic phases, dry with anhydrous sodium sulfate, filter, centrifuge, and prepare by HPLC to obtain the compound 3-(4-imidazo[4,5-c(pyrrolo[2,3-b]pridine-1(6 / - / )-1)piperazine-1-1-yl)propionitrile (32 mg, 48% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.84 (s, 1H), 8.61 (s, 1H), 8.56 (s, 1H), 7.45 (s, 1H), 6.74 (d, J = 2.4 Hz, 1H), 3.34 (s, 4H), 2.78 - 2.71 (m, 8H). LCMS ESI(+)m / z: 296.1 (M+1) . Example 26 nr Lrnn / zznz / B / Yi 3-(4-(imidazo[4,5-c / ]pyrrorolo[2,3-¿>]pyridin-1 (6 / - / )-¡l)piperazin-1 -yl)oxypropionitrile The specific implementation methods are as follows: Dissolve the compound 1-(piperazine-1-1)-1,6-dihydroimidazol[4,5-d]pyrrolo[2,3-b]pridine (70 mg, 0.29 mmol), HATU (165 mg, 0.43 mmol), 2-cyanoacetic acid (30 mg, 0.35 mmol) and A / ,AAdiisopropylethylamine (112 mg, 0.87 mmol) in 5 ml of A / ,A / -dimethylformamide. Then stir for 16 h at room temperature under nitrogen protection. Once the reaction is complete, add 20 mL of water, extract with ethyl acetate (3 x 60 mL), fuse the organic phases, dry with anhydrous sodium sulfate, filter, centrifuge, and purify to obtain the compound 3-(4-(imidazo[4,5-c(]pyrrolo[2,3-b]pyridine-1(6H)-yl)piperazine-1l)oxopropionitril (30 mg, 33% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.85 (s, 1H), 8.57 (s, 1H), 8.56 (s, 1H), 7.45 (t, J = 2.8 Hz, 1H), 6.78 (dd, J = 3.2, 2.0 Hz, 1H), 4.19 (s, 2H), 3.85-3.70 (m, 4H), 3.33-3.30 (m, 4H). LCMS ESI(+)m / z: 310.1 (M+1) . Example 27 2-(1 -(2-(( / 7)-1 -hydroxyethyl)imidazo[4,5-cflpyrrolo[2,3 -b]pyridín-1(6 / 7)-yl)-6-azepan-453 yl)acetonitrile nr Lrnn / zznz / B / Yi The specific implementation methods are as follows: Step A: Dissolve hydroxylamine hydrochloride (6.12 g, 88.1 mmol) in 25 mL of water, add sodium acetate (9.64 g, 118 mmol), and stir at room temperature for 10 min. Add p-cyclohexanone ethylcarboxylate (10.0 g, 58.8 mmol) dropwise to the reaction and stir the mixture at 45 °C for 16 h. Subsequently, extract the solution three times with 50 mL of ethyl acetate, merge the organic phases, and wash with 20 mL of water and 20 mL of saturated brine. Next, dry with anhydrous sodium sulfate, concentrate and decompress and finally apply silica column chromatography to obtain the compound 4-ethyl formate cyclohexanone oxime (10.9 g, 100% yield).1H NMR (400 MHz, CDCI3) δ 8.02 (brs, 1H), 4.19 - 4.09 (m, 2H), 3.20 - 3.10 (m, 1H), 2.60 - 2.51 (m, 1H), 2.49 - 2.40 (m, 1H), 2.21 - 2.00 (m, 4H), 1.82 - 1.66(m, 2H), 1.26 (t, J= 7.1 Hz, 3H). Step B: Dissolve the compound ethyl 4-oxocyclohexanecarboxylate (3.32 g, 12.9 mmol) in pyridine (15 ml) and add p-toluenesulfonyl chloride (4.10 g, 21.5 mmol) under nitrogen protection at -15 °C. Then, stir at -15 °C under nitrogen protection for 2 h. Pour into 60 ml of ice water, stir for 20 min, filter by suction, and wash with 30 ml of water. Subsequently, recover the filter mass and perform dry depression to obtain the compound 4-((p-toluene sulfonyloxy)amino)cyclohexane-1-ethyl formate (4.87 g, 80% yield).1H NMR (400 MHz, CDCI3) δ 7.85 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 4.13 (q, J = 7.1 Hz, 2H), 3.07 - 2.97 (m, 1H), 2.58 - 2.46 (m, 2H), 2.45 (s, 4H), 2.28 - 2.12 (m, 2H), 2.11 - 1.96 (m, 2H), 1.85 - 1.64 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H). Step C: Dissolve the compound 4-((p-toluene sulfonyloxy)amino)cyclohexane-1-ethyl formate (16.6 g, 45.9 mmol) in 35 mL of acetic acid and stir at room temperature for 16 h. After that, concentrate and decompress the reaction solution. Then, add 40 mL of saturated aqueous sodium bicarbonate solution, stir for 15 min with 150 mL of ethyl acetate, extracting the aqueous phase 3 times. Next, combine the organic phase, wash it with 50 ml of saturated salt water, dry with anhydrous sodium sulfate, perform decompression and concentration, and finally apply silica column chromatography to obtain 7-oxynitrogen heterocyclic heptane-4-ethyl formate (5.33 g, 63% yield).1H NMR (400 MHz, CDCI3) δ 6.30 (s, 1H), 4.15 (q, J = 7.1 Hz, 2H), 3.41 - 3.29 (m, 1H), 3.29 - 3.17 (m, 1H), 2.68 - 2.52 (m, 2H), 2.52 - 2.39 (m, 1H), 2.15 - 2.00 (m, 2H), 1.92 - 1.76 (m, 2H), 1.37- 1.18(m, 3H). Step D: Dissolve the compound 7-oxoazepane-4-ethylcarboxylate (3.72 g, 20.1 mmol) in 50 mL of tetrahydrofuran and add lithium aluminum hydride (3.81 g, 100 mmol) dropwise to the tetrahydrofuran solution (300 mL) under nitrogen protection in an ice bath. Stir at room temperature for 2 h and stir for 4 h at 60 °C. Then, heat to 0 °C and add dropwise successively water (4 mL), 15% sodium hydroxide solution (4 mL), and water (8 mL). Stir at room temperature for 3 h. Filter through diatomaceous earth and wash with 50 mL of tetrahydrofuran. Next, decompress and concentrate the solution to obtain the compound 4-hydroxymethyl nitrogen heptane heterocyclic (2.31 g, 89% yield).1H NMR (400 MHz, CDCI3) δ 3.56 - 3.45 (m, 2H), 3.08 - 2.72 (m, 4H), 1.94 - 1.73 (m, 4H), 1.66- 1.52 (m, 1H), 1.50- 1.35 (m, 2H). Step E: Dissolve the heterocyclic compound 4-hydroxymethyl nitrogen heptane (2.31 g, 17.9 g) in 100 ml of dichloromethane and successively add sodium nitrite (3.70 g, 53.6 mmol) at room temperature and p-toluenesulfonic acid monohydrate (10.2 g, 53.6 mmol). Shake at 35 °C for 2 h, decompress and concentrate the reaction solution and apply silica column chromatography to obtain the compound 1-nitroso-4-hydroxymethyl nitrogen heterocyclic heptane (2.19 g, 77% yield).1H NMR (400 MHz, CDCh) δ 4.83 - 4.63 (m, 1H), 4.12 - 3.96 (m, 1H), 3.92 - 3.70 (m, 1H), 3.68 - 3.43 (m, 3H), 2.30 - 2.14 (m, 1H), 2.09 - 1.79 (m, nr Lrnn / zznz / B / Yi 3Η), 1.78-1.40 (m,3H), 1.27 - 1.00 (m, 1 Η). Step F: Dissolve the heterocyclic compound 1-nitroso-4-hydroxymethyl nitrogen heptane (1.10 g, 6.95 mmol) in 20 mL of dichloromethane and dropwise add triethylamine (1.19 g, 10.4 mmol) and methylsulfonyl chloride (1.19 g, 10.4 mmol) under nitrogen protection in an ice bath. Stir in an ice bath for 2 h. Add water (10 mL) and stir at room temperature for 15 min. Then add ethyl acetate (100 mL), separate the organic phases, wash twice with water (30 mL each) and then with saturated saline solution (30 mL). Next, dry with anhydrous sodium sulfate, filter by suction, decompress and concentrate to obtain the compound methyl methanesulfonate (1-nitro-nitrogen heterocyclic heptane-4-yl) (1.64 g, 100% yield). Step G: Dissolve the heterocyclic compound 1-nitroso-nitrogen heptane-4-yl) methyl methanesulfonate (1.64 g, 6.94 mmol) in 10 mL of anhydrous A / ,A / -dimethylformamide and add sodium cyanide under nitrogen conditions (1.02 g, 20.8 mmol). Stir at 80 °C for 5 h. Then decompress and concentrate. Subsequently, pour the reaction solution into 20 mL of water and extract three times with 40 mL of ethyl acetate. Combine the organic phases and wash with water (20 mL) and saturated saline solution (20 mL). Then dry with anhydrous sodium sulfate, filter by suction, decompress, and concentrate. Finally, silica column chromatography was applied to obtain the compound 1-nitroso-4-cyanomethyl nitrogen heptane heterocyclic (1.09 g, 94% yield). Step H: Dissolve the compound 1-nitroso-4-cyanomethyl nitrogen heptane heterocyclic (600 mg, 3.59 mmol) in 20 mL of methanol. Successively add zinc powder (4.69 g, 71.8 mmol) at room temperature and add acetic acid dropwise (5 mL). Stir at 35 °C for 15 min. Extract the reaction solution, wash with 20 mL of methanol, and concentrate the filtrate, from which the oily substance 1-amino-4-cyanomethyl azacyclic heptane is used directly for the next step of the reaction. Step I: Dissolve the crude azacyclic 1-amino-4-cyanomethyl heptane compound from the previous step in 25 ml of isopropanol, followed by the addition of A / V-diisopropylethylamine (2.20 ml, 17.1 mmol) and 4-chloro-5-nitro-1-toluene sulfonyl-1 / 7-pyrrolo[2,3-b]pridine (1.00 g, 2.84 mmol). Heat to 85 °C under nitrogen protection, stir, and react for 16 h. Next, concentrate the reaction solution and apply silica column chromatography to obtain the compound 2-(1-((5-nitro-1-toluene sulfonyl-1 / 7-pyrrolo[2,3-b]p¡r¡n-4-1l)amino)azacycloheptane4-1l)acetonitrile (450 mg, 34% yield). nr Lrnn / zznz / B / Yi Step J: Add the compound 2-(1-((5-nitro-1-toluene sulfonyl-1 / 7-pyrrolo[2,3-b]pyridine-4-yl)amino)azepam-4-yl)azacycloheptane (527 mg, 1.12 mmol) to 25 ml of ethanol, successively add iron powder (1.26 g, 22.5 mmol) and saturated ammonium chloride (1.5 ml) at room temperature, and stir at 75 °C and react for 5 min. Filter with hot diatomaceous earth, wash with 20 ml of methanol and concentrate the filtrate. Finally, apply silica column chromatography (ethyl acetate) to obtain the compound 2-(1-((5-amino-1-toluene sulfonyl-1 / 7-pyrolo[2,3-Σ>]pyridin-4-α)amino)azacycloheptane-4-α)acetonitril (200 mg, 41% yield). Step K: Add R-lactamide (107 mg, 1.23 mmol) and triethyloxonium tetrafluoroboric acid (234 mg, 1.24 mmol) to 8 mL of dry tetrahydrofuran under nitrogen and stir at 30 °C for 2 h. Then decompress and concentrate the reaction solution. Dissolve the residue in 3 mL of dry ethanol and add the compound 2-(1-((5-amino-1-toluene sulfonyl-1 / 7-pyrrorolo[2,3]pyridin-4-1I)amino)azacycloheptane-4-yl)acetonitrile (180 mg, 0.41 mmol). Then stir at 75 °C and react for 1 h, decompress, and concentrate the reaction solution. Add saturated solution of sodium bicarbonate (10 ml) and ethyl acetate (15 ml) and stir for 5 min. Separate the organic phases and extract the aqueous phase with 15 ml of ethyl acetate three times.Next, fuse the organic phases and wash with 10 ml of water and 10 ml of salt-saturated water, dry with anhydrous sodium sulfate, decompress and concentrate, and finally apply silica column chromatography to obtain the compound 2-(10(2-(( / 7)1 -hydroxyethyl)-6-p-toluene sulfonyl imidazolide[4,5-c / ]pyrrolo[2,3 -b]pyridin-1 (6H)1l)azacycloheptane-4-1l)acetonitril (980 mg, yield 49%). Step L: Dissolve the compound 2-(1-(2-(( / 7)-1-hydroxyethyl)-6-p-toluene sulfonyl imidazo[4,5c(|pyrrolo[2,3-b]pridina-1 (6 / 7)-1)azacycloheptane-4-1)acetonitrile (98 mg, 0.2 mmol) in 3 mL of methanol and add 1 N sodium hydroxide solution (1 mL, 1.0 mmol). Stir at 35 °C for 7 h. Subsequently, dilute the reaction solution with 40 mL of dichloromethane, dry with anhydrous sodium sulfate, filter by suction, decompress, and evaporate to remove the solvent. After that, prepare the residue by TLC to obtain the compound 2-(1-(2-((F?)-1 hydroxy¡ethyl)¡m¡dazo[4,5-d]pyrrolo[2,3-¿)]pyr¡dina-1 (6 / 7)-¡l)-6-azacycloheptane-4-¡l)aceton¡trilo (40 mg, 59% yield).1H NMR (400 MHz, DMSO-d6) δ 11.87 (s, 1H), 8.59 - 8.47 (m, 1H), 7.52 - 7.44 (m, 1H), 6.76 - 6.64 (m, 1H), 5.36 - 5.25 (m, 1H), 5.25 - 5.14 (m, 1H), 3.90 - 3.62 (m, 2H), 3.28 - 3.01 (m, 2H), 2.69 - 2.59 (m, 2H), 2.12 - 1.63 (m, 7H), 1.58 (d, J= 6.5 Hz, 3H). LCMS ESI(+)m / z: 339.1 (M+1) . Example 28 nc Lrnn / zznz / E / YiAi nr Lrnn / zznz / E / YiA 3-(4-ethyl-3-(imidazo[4,5-c(]pyrrolo[2,3-¿j]pyrid¡ne(6 / - / )-yl)imidazolin-1 -yl)-3-oxopiOpionitrile The specific implementation methods are as follows: Ts Step A: Add the compound 4-chloro-5-nitro-1-p-toluene sulfonyl-1 / - / -pyrrolo[2,3-]pyridine (4.80 g, 13.7 mmol), tert-butylcarbazate (1.98 g, 15.0 mmol), Λ / , / V-diisopropylethylamine (3.81 ml, 27.3 mmol) to 100 ml of isopropyl alcohol. Stir at 85 °C under nitrogen protection for 16 h. After the reaction, decompress and evaporate the solvent. Next, the residues are subjected to silica column chromatography to obtain the compound 2-(5-nitro-1-ptoluene sulfonyl-1 H-pyrrolo[2,3-b]-4-1)tert-butyl carbazate (4.56 g, 75% yield).1H NMR (400 MHz, CDCI3) δ 9.73 (s, 1H), 9.11 (s, 1 H), 8.06 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 4.1 Hz, 1H), 7.31 (d, J = 8.1 Hz, 2H), 6.96 (d, J = 4.1 Hz, 1H), 6.68 (S, 1H), 2.40 (s, 3H), 1.46 (s, 9H). LCMS ESI(+)m / z: 448.1 (M+1). Step B: Dissolve the compound 2-(5-nitro-1-p-toluene sulfonyl-1H-pyrrolo[2,3-b]-4yl) tert-butyl carbazate (4.56 g, 10.2 mmol) in 250 mL of methanol and add 10% palladium on carbon (2.78 g) under nitrogen conditions. Stir the mixture at room temperature in a hydrogen atmosphere for 16 h. Then filter the reaction solution and wash twice with methanol (20 mL). Decompress and evaporate the filtrate to remove the solvent, through which the compound 2-(5-amino-1-p-toluene sulfonyl1 / 7-pyrrorolo[2,3-b]-4-1l)tert-butyl carbazate can be obtained (4.25g, 100% yield).1H NMR (400 MHz, CDCI3) δ 7.99 (d, J = 8.3 Hz, 2H), 7.87 (s, 1H), 7.49 (d, J = 4.1 Hz, 1H), 7.23 (d, J = 8.2 Hz, 3H), 6.69 (d, J = 4.1 Hz, 1 H), 6.56 (s, 2H), 2.36 (s, 4H), 1.43(s, 9H). LCMS ESI(+)m / z: 418.1 (M+1). Step C: Add the compound 2-(5-amino-1-p-toluene sulfonyl-1H-pyrrolo[2,3-b]4-l)tert-butyl carbazate (4.25 g, 10.2 mmol), triethyl orthoformate (1.81 g, 12.2 mmol), and pyridine hydrochloride (116 mg, 1.0 mmol) to 150 mL of methylbenzene. Heat to 115 °C under nitrogen conditions and stir for 2 h. After the reaction, decompress and evaporate the reaction solution to remove the solvent. Next, the residues are subjected to silica column chromatography to obtain the compound tert-butyl(6-toluenesulfonylmidazo[4,5c(|pyrrolo[2,3-i)]pridine-1 (6 / - / )-i)carbamate (4.35 g, 100% yield).1H NMR (400 MHz, CDCI3) δ 8.77 (s, 1H), 8.05 (d, J = 8.3 Hz, 2H), 7.91 (s, 1H), 7.91 (s, 1H), 7.58 (d, J = 2.8 Hz, 1H), 7.25 (d, J = 8.4 Hz, 1H), 6.58 (d, J = 2.8 Hz, 1H), 2.35 (s, 3H), 1.49 (s, 9H). LCMS ESI(+)m / z: 428.1 (M+1). Step D: Dissolve the compound tert-butyl(6-p-toluene sulfonyl imidazo[4,5-c(]pyrrolo[2,3-b]pyridine(6H)-1)carbamate (3.69 g, 8.63 mmol) in 400 mL of acetone, add sodium hydroxide powder (726 mg, 13.0 mmol), and stir at room temperature for 10 min. Add ethyl 2-bromobutyrate (5.05 g, 25.9 mmol) to the reaction solution, followed by stirring at room temperature for 1.5 h. Then, perform suction filtration of the reaction solution and wash the filter media with dichloromethane (50 mL). Decompress and concentrate the filtrate, and subject the residues to silica column chromatography to obtain the ethyl compound. 2-(tert-butoxycarbonyl)(6-p-toluene sulfonyl imidazo[4,5c(|pyrrorolo[2,3-í)]pyrdina methyl ester of -1 (6 / - / )-íl)amino)butyrate (4.08 g, 87% yield).1H NMR (400 MHz, CDCI3) δ 8.89 (s, 1H), 8.38 (s, 1H), 8.14 (d, J = 8.4 Hz, 2H), 7.78 (d, J = 4.0 Hz, 1H), 7.29 (d, J = 8.3 Hz, 2H), 6.69 (d, J = 3.9 Hz, 1 H), 4.98 - 4.79 (m, 1H), 4.33 (q, J = 7.1 Hz, 2H), 2.38 (s, 3H), 1.59 - 1.48 (m, 2H), 1.36 (t, J = 9.2, 5.1 Hz, 3H), 1.33-1.12 (m, 9H), 0.81 (t, J = 7 A Hz, 3H). LCMS ESI(+)m / z: 542.2(M+1). Paso E: Dissolve the compound 2-(tert-butoxycarbonyl)(6-p-toluenesulfonylimidazolo[4,5d]pyrrolo[2,3-b]pyridin-1(6H)-yl)amino)methylbutyrate (4.08 g, 7.53 mmol) in 33 mL of dichloromethane and methanol mixed solvent (with a volume ratio of 10 to 1). Then add 15 mL of 4 N hydrogen chloride dioxane solution under an ice bath. Stir at room temperature under nitrogen protection for 16 h. Concentrate and decompress the reaction solution. Add 80 mL of saturated sodium bicarbonate solution and stir for 5 min. Subsequently, extract with ethyl acetate (3 x 50 ml), fuse the organic phases, wash with 50 ml of salt-saturated water, and dry with anhydrous sodium sulfate. Finally, perform suction filtration, decompress, and concentrate the filtrate to obtain the compound ethyl 2-((6-toluene sulfonyl imidazolo[4,5-c(]pyrrolo[2,3b]pyridine-1 (6 / - / )-1)amino)methylbutyrate (3.10 g, 93% yield).1H NMR (400 MHz, CDCI3) δ 8.85 (s, 1H), 8.10 (d, J = 8.4 Hz, 2H), 8.03 (s, 1H), 7.77 (d, J = 3.9 Hz, 1H), 7.27 (s, 1H), 7.25 (s, 1H), 6.91 (d, J = 4.0 Hz, 1H), 5.74 (d, J = 7.8 Hz, 1H), 4.33 - 4.16 (m, 2H), 3.85 3.76 (m, 1H), 2.35 (s, 3H), 1.92 - 1.82 (m, 2H), 1.26 (t, J = 7.2 Hz, 3H), 1.14 (t, J = 7.4 Hz, 3H). LCMS ESI(+)m / z: 442.1 (M+1). Paso F: Dissolve the compound 2-((6-toluene sulfonyl imidazo[4,5-d]pyrrolo[2,3-b]pridin-1(6H)yl)amino)methylbutyrate (3.10 g, 7.02 mmol) in 200 mL of ethanol. In addition, add sodium borohydride (797 mg, 21.1 mmol) under an ice bath and nitrogen protection, and stir at room temperature for 48 h. Pour a 1 N dilute hydrochloric acid solution into the reaction solution at 0 °C and adjust the reaction solution to neutral. Add 50 mL of water and stir at room temperature. Adjust the 1 N hydrochloric acid to neutral, decompress, and evaporate the solvent. Next, extract with ethyl acetate (3 x 50 ml), fuse the organic phase and wash with 30 ml of saturated salt water, dry with anhydrous sodium sulfate, decompress and evaporate the solvent. Finally, apply silica column chromatography to obtain the compound 2-((6-toluene sulfonyl imidazo[4,5-c(1-pyrrolo[2,3b]pyridine-1 (6 / - / )-1)amino)butyl-1-ol (1.97 g, 69% yield).1H NMR (400 MHz, DMSOd6) δ 8.69 (s, 1H), 8.30 (s, 1 H), 8.02 (d, J = 8.4 Hz, 2H), 7.92 (d, J = 4.0 Hz, 1H), 7.40 (d, J = 8.1 Hz, 2H), 7.16 (d, J = 4.0 Hz, 1H), 6.95(d, J = 2.7 Hz, 1 H), 4.89 (t, J = 5.0 Hz, 1 H), 3.54 3.44 (m, 1H), 3.37 - 3-.34 (m, 1H), 3.23 - 3.15 (m, 1H), 2.33 (s, 3H), 1.42 - 1.32 (m, 2H), 0.83 (t, J = 7.5 Hz,3H). LCMS ESI(+)m / z: 400.1 (M+1). Paso G: Under ice bath cooling and nitrogen protection, add the compound 2-((6-p-toluene sulfonyl imidazo[4,5-c(]pyrrolo[2,3-b]pyridine-1 (6 / - / )-(1)amino)butyl-1-ol (1.72 g, 4.31 mmol), DBU (3.28 g, 21.5 mmol), and DPPA (3.55 g, 12.9 mmol) to 120 mL of methylbenzene. Heat to 75 °C and stir for 16 h. Then, decompress and concentrate the reaction solution. Finally, subject the residues to silica column chromatography to obtain the compound N-(1-azidine2-1)-6-p-toluene sulfonyl imidazo[4,5-c(]pyrrolo[2,3-b] pyridin-1 (6 / - / )-¡l)-amine (1.10 g, 60% yield).1H NMR (400 MHz, CDCI3) δ 8.88 (s, 1H), 8.12 (d, J = 8.4 Hz, 2H), 7.96 (s, 1 H), 7.81 (d, J = 4.0 Hz, 1H), 7.27 (d, J = 8.4 Hz, 2H), 7.01 (d, J= 4.0 Hz, 1H), 5.41 (s, 1H), 3.68 (dd, J = 12.0, 2.8 Hz, 1H), 3.47-3.34 (m, 2H), 1.52 -1.41 (m, 2H), 0.91 (t, J = 7.5 Hz, 3H). LCMS ESI(+)m / z: 425.1 (M+1). nr Lrnn / zznz / B / Yi Step H: Dissolve the compound N-(1-azidin-2-1l)-6-p-toluene sulfonyl imidazo[4,5-c(]pyrrolo[2,3b]phdin-1 (6 / - / )-1l)-amine (1.10 g, 2.59 mmol) in 200 ml of methanol. Add 10% palladium on carbon (220 mg) under nitrogen protection. Replace the hydrogen and stir at room temperature in a hydrogen atmosphere for 6 h. Then, perform suction filtration and wash the filter mass with 20 ml of methanol. Subsequently, decompress and concentrate the filtrate to obtain the compound A / 2-(6-toluene sulfonimidazo[4,5-cf]pyrrolo[2,3-δ)]prdidin-1 (6 / - / )-δ-1,2-butanediamine (1.03 g, 100% yield).1H NMR (400 MHz, CDCI3) δ 8.88 (s, 1H), 8.12 (d, J = 8.4 Hz, 2H), 7.97 (s, 1H), 7.76 (d, J = 3.9 Hz, 1H), 7.27 (d, J = 8.0 Hz, 2H), 7.12 (d, J = 4.0 Hz, 1 H), 5.99 (d, J = 2.0 Hz, 1H), 3.15 (s, 1 H), 3.09 (dd, J = 13.1,3.3 Hz, 1 H), 2.64 (dd, J= 13.1,8.8 Hz, 1 H), 2.36 (s, 3H), 1.44 -1.27 (m, 3H), 0.83 (t, J = 7.5 Hz, 3H). LCMS ESI(+)m / z: 399.1 (M+1). Step I: Dissolve the compound / ^-(e-toluene sulfonimidazo[4,5-c / ]pyrrorolo[2,3-¿>]pyridin-1 (6H)yl)butane-1,2-diamine (1.03 g, 2.58 mmol) in 50 ml of methanol and add paraformaldehyde (101 mg, 3.36 mmol). Heat to 70 °C and stir for 16 h. Cool to room temperature, filter by suction and wash with 10 ml of methanol. Next, decompress and evaporate the filtrate to remove the solvent to obtain the compound ethyl imidazole 1-(5-alkyl-1-yl)-6-p-toluene sulfonyl-1,6-dihydro imidazole [4,5-d-pyrrolo[2,3-ε]pyridine (1.06 g, 100% yield). 1H NMR (400 MHz, CDCh) δ 8.94 - 8.77 (m, 1H), 8.13 - 8.07 (m, 2H), 7.79 - 7.67 (m, 1H), 7.28 - 7.24 (m, 1H), 7.08 (m, 1H), 4.53 - 3.97 (m, 2H), 3.80 - 3.37 (m, 3H), 2.42 - 2.30 (m, 3H), 1.83 - 1.59 (m, 2H), 0.96 - 0.74 (m, 3H). LCMS ESI(+)m / z: 411.1 (M+1). Step J: Dissolve the compound 1-(5-ethylimidazolane-1-yl)-6-p-toluene sulfonyl-1,6-dihydroimidazo[4,5-c]pyrrolo[2,3-t]pyridine (60 mg, 0.15 mmol) in 3 mL of methanol and add 2 N sodium hydroxide solution (1.0 mL, 2.0 mmol). Stir at room temperature for 16 h. Dilute the reaction solution with 10 mL of water and remove the methanol by decompression and evaporation. Then extract with ethyl acetate, combine the organic phases, wash with 5 mL of salt-saturated water, dry with anhydrous sodium sulfate, filter by suction, decompress, and evaporate to remove the solvent. Finally, the crude compound 1-(5-ethylimidazolan-1-yl)-1,6-dihydroimidazolidazol[4,5-c(|pyrrolo[2,3-b]pridine (50 mg, crude yield 100%) is obtained. LCMS ESI(+)m / z: 257.1 (M+1). Step K: Dissolve the compound 1-(5-ethyl imidazolan-1-1)-1,6-dihydroimidazolidazol[4,5c(1-pyrrolo[2,3-b]pridine] (50 mg, 0.2 mmol) in 4 ml of dichloromethane. Then, under nitrogen protection and an ice bath, successively add cyanoacetic acid (20 mg, nr Lrnn / zznz / E / YiAi 0.24 mmol), HOBT (37 mg, 0.27 mmol), 4-dimethylaminopyridine (38 mg, 0.31 mmol), 4-dimethylaminopyridine (38 mg, 0.31 mmol) and EDCI (60 mg, 0.31 mmol). Shake at room temperature for 16 h. Then, decompress and concentrate the mixture. Finally, silica column chromatography and HPLC were applied to prepare the compound 3-(4-ethyl-3(imidazo[4,5-c]pyrrolo[2,3-b]pyridine-1(6- / )-1l)imidazolin-1-1l)-3-oxypropionitrile (20 mg, 32% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.90 (s, 1H), 8.75 - 8.17 (m, 2H), 7.47 (s, 1H), 6.70 (s, 1H), 5.03 - 4.68 (m, 2H), 4.24 - 3.85 (m, 4H), 3.54 - 3.42 (m, 1H), 1.51 - 1.28 (m, 2H), 0.82 - 0.69 (m, 3H). LCMS ESI(+)m / z: 324.1 (M+1). nr Lrnn / zznz / B / Yi Example 29 3-(4-ethyl¡n-3-(¡m¡dazo[4,5-c / ]pyrrolo[2,3-¿>]pyr¡d¡n-1 (6 / - / )-¡l)im¡dazol¡din-1 -yl)propionitrile Step A: Dissolve the compound 1-(5-ethylimidazolane-1-1)-6-p-toluene sulfonyl-1,6-dihydroimidazolidinedazol[4,5-cy]pyrrolo[2,3-b]pridine (70 mg, 0.17 mmol) and triethylamine (86 mg, 0.85 mmol) in 3 ml of acrylonitrile. Stir at 120 °C for 16 h. Then decompress and evaporate to remove the solvent. Finally, silica column chromatography was applied to obtain the compound 3-(4-ethyl-3-(6-toluene sulfonyl imidazolo[4,5-c(|pyrrolo[2,3-b]pridina1 (6 / - / )-1l)imidazolidina-1 -yl)propionitrile (50 mg, 63% yield). LCMS ESI(+)m / z: 464.1 (M+). Step O: Dissolve the compound 3-(4-ethyl-3-(6-toluene sulfonyl imidazo[4,5-c(]pyrrolo[2,3-b]pridin(6 / - / )-1)propionyl (50 mg, 0.11 mmol) in 5 mL of anhydrous tetrahydrofuran. Add 60% sodium hydroxide (22 mg, 0.11 mmol) in an ice bath. Stir at room temperature for 4 h. Pour the reaction solution into 15 mL of saturated aqueous ammonium chloride solution. Neutralize the reaction solution, decompress, and concentrate to remove the solvent. Finally, use silica column chromatography to obtain the compound. 3-(4-ethyl-3-(¡m¡dazo[4,5-c(|p¡rrorolo[2,3-b]pyr¡dina-1 (6H)¡l)im¡dazolidin-1 -yl)proonitrile (150 mg, 48% yield).1H NMR (400 MHz, DMSO-cfe) δ 11.03 (s, 1H), 8.06 - 7.99 (m, 2H), 7.85 - 7.81 (m, 2H), 7.75 - 7.64 (m, 2H), 7.49 (d, J = 8.4 Hz, 2H), 7.29 (dd, J = 6.1, 2.5 Hz,1H), 6.16 - 6.10 (m, 2H), 5.18 (s, 2H), 2.01 (s, 1H), 0.86 - 0.76 (m,4H). LCMS ESI(+)m / z: 310.1 (M+1) . nr Lrnn / zznz / B / Yi 3-(4-methyl-3-(¡m¡dazo[4,5-c(|pyrrolo[2,3-¿>]pyr¡din-1(6 / - / )-¡l)¡m¡dazol¡na-1-yl)-3oxopropionitrile The specific implementation methods are as follows: Step A: Dissolve tert-butyl carbamate (6-toluene sulfonimidazo[4,5-c(1-pyrrolo[2,3b]pyridine-1) (3.60 g, 8.42 mmol) in 400 mL of acetone and then add sodium hydroxide (709 mg, 12.6 mmol) powder. Stir at room temperature for 10 min. Subsequently, add ethyl 2-bromopropionate (4.57 g, 25.3 mmol) to the reaction solution and stir the mixture at room temperature for 1.5 h. Then, perform suction filtration of the reaction solution and wash the filter media with dichloromethane (50 mL). After that, decompress and concentrate the filtrate. Finally, subject the residues to silica column chromatography to obtain the compound 2-(tert-butylcarbonyl)(6-p-toluene methyl sulfonyl im idazo[4,5-c / |pyrrorolo[2,3-b]pihdine-1 (6 / - / )-¡l-amino) propionate (2.85 g, 64% yield).1H NMR (400 MHz, CDCh) δ 8.92 (s, 1H), 8.39 (s, 1H), 8.15 (d, J = 8.2 Hz, 2H), 7.80 (d, J = 3.9 Hz, 1H), 7.30 (d, J = 8.3 Hz, 2H), 6.71 (d, J= 4.0 Hz,1H), 5.24 - 5.04 (m, 1H), 4.29 (q, J = 7.0 Hz, 2H), 2.38 (s, 3H), 1.40-1.14 (m, 15H). LCMS ESI(+)m / z: 528.2(M+1). Paso B: Dissolve the compound 2-(tert-butoxycarbonyl)(6-p-toluene sulfonimidazo[4,5c(|pyrrolo[2,3-]]pyridine-1-amino) methyl propionate (2.85 g, 5.4 mmol) in 30 mL of a dichloromethane / methanol mixture (10:1 by volume). Add dropwise 4 N hydrogen chloride dioxane solution (10 mL) under an ice bath. Stir the mixture at room temperature under nitrogen protection for 16 h. Then, decompress and concentrate the reaction solution. Subsequently, add 30 mL of saturated sodium bicarbonate solution and stir for 5 min, extract with ethyl acetate (3 x 50 mL), fuse the organic phases, wash with 50 mL of salt-saturated water, and dry with anhydrous sodium sulfate. By suction filtration, decompression, and concentration of The solution yields the compound 2-((6-toluene sulfonimidazo[4,5-G(]pyrlo[2,3-b]pridine-1 (6H)1)amino)methyl ethyl propionate (2.12 g, 92% yield).1H NMR (400 MHz, CDCI3) δ 8.86 (s, 1H), 8.11 (d, J = 8.4 Hz, 2H), 8.05 (s, 1H), 7.78 (d, J = 3.9 Hz, 1H), 7.26 (d, J = 8.0 Hz, 2H), 6.90 (d, J= 3.9 Hz,1H), 5.80 (d, J= 6.1 Hz, 1H), 4.32 - 4.18 (m, 2H), 4.00 - 3.91 (m, 1H), 2.35 (s,3H), 1.43 (d,J= 7.1 Hz, 3H), 1.27 (t, J= 7.1 Hz, 3H). LCMS ESI(+)m / z: 428.0(M+1). Paso C: Dissolve the compound 2-((6-p-toluene sulfonylmidazo[4,5-d]pyrolo[2,3-b]pyrdin-1(6H)1)amino)methyl propionate (2.12 g, 4.96 mmol) in 50 mL of ethanol and add sodium borohydride (563 mg, 14.9 mmol) in an ice bath under nitrogen protection. Then, stir the mixture at room temperature for 16 h. Add 1N dilute hydrochloric acid solution to the reaction solution at 0 °C, adjust the reaction solution to neutrality, and remove the solvent by decompression and concentration. Extract the solution with ethyl acetate, fuse the organic phases, and wash with 30 mL of saturated saline solution. Subsequently, dry with anhydrous sodium sulfate and remove the solvent by decompression and concentration. Finally, apply silica column chromatography to obtain the compound 2-((6-toluene sulfonyl imidazo[4,5-c(|p¡rrorolo[2,3-b]p¡r¡n-1 (6 / - / )-¡l)amino)propyl-1 -ol (1.48 g, 77% yield).1H NMR (400 MHz, DMSO-cfe) δ 8.70 (s, 1 H), 8.29 (s, 1H), 8.02 (d, J = 8.4 Hz, 2H), 7.92 (d, J = 4.0 Hz, 1 H), 7.40 (d, J = 8.2 Hz, 2H), 7.15 (d, J = 4.0 Hz, 1 H), 7.03(s, 1 H), 4.94 (d, J = 5.2 Hz, 1H), 3.46 - 3.33 (m, 4H), 2.32 (s, 3H), 0.90 (d, J = 5.7 Hz, 3H). nr Lrnn / zznz / B / Yi LCMS ESI(+)m / z: 386.1 (M+1). Paso D: Add the compound 2-((6-toluene sulfonyl imidazo[4,5-c(|pyrrolo[2,3-b]pridine-1 (6 / 7)yl)amino) propyl-1-ol (1.68 g, 4.36 mmol), DBU (3.32 g, 3.36 mmol, 21.8 mmol), and DPPA (3.60 g, 13.1 mmol) to 100% methylbenzene under ice bath cooling and nitrogen protection. Heat to 100 °C and stir for 4 h. Then, decompress and concentrate the reaction solution. Finally, subject the residues to silica column chromatography to obtain the compound N-(1-azida-2-base)-6-p-toluene sulfonyl imidazo[4,5-c(]pyrrolo[2,3-¿>]pyr¡dina-1 (6 / 7)-¡l)-amine (1.26 g, 67% yield). 1H NMR (400 MHz, CDCI3) 1H), 7.80 (d, J = 4.0 Hz, 1H), 7.28 (d, 2H), 6.98 (d, J = 4.0 Hz, 1H), 5.49 (s, 1H), 3.68 - 3.52 (m, 2H), 3.49 - 3.37 (m, 1H), 2.36 (s, 3H), 1.84- 1.53 (m, 2H), 1.04 (d, J = 6.1 Hz, 3H). LCMS ESI(+)m / z: 411.1 (M+1). Step E: Dissolve the compound N-(1-azida-2-yl)-6-p-toluene sulfonyl imidazo[4,5-c(]p¡nOrolo[2,3b]pyrid¡n-1 (6 / 7)-i)-amine (1.20 g, 2.59 mmol) in 100 ml of methanol and add 10% palladium on carbon (240 mg) under nitrogen protection. Replace the hydrogen and stir at room temperature in a hydrogen atmosphere for 16 h. Filter and wash the filter mass with 20 ml of methanol. Next, decompress and concentrate the solution to obtain the compound / ^-(e-toluene sulfonimidazo[4,5-c(]p¡rrolo[2,3-b]p¡r¡n-1 (6 / 7)-¡l)propane-1,2-diamine (1.16 g, 98% yield).1H NMR (400 MHz, CDCI3) 5 8.88 (s, 1H), 8.11 (d, J= 8.4 Hz, 2H), 7.96 (s, 1H), 7.76 (d, J = 3.9 Hz, 1 H), 7.26 (d, J = 8.4 Hz, 5H), 7.10 (d, J = 4.0 Hz, 1H), 6.06 (s, 1H), 3.39 - 3.29 (m, 1H), 3.02 (dd, J = 13.2, 3.6 Hz, 1H), 2.65 (dd, J = 13.2, 9.2 Hz, 1H), 2.35 (s, 3H), 0.92 (d, J= 6.2 Hz, 3H). LCMS ESI(+)m / z: 385.1 (M+1) . Step F: Dissolve compound A / 2-(6-toluene sulfonimidazo[4,5-c(|p¡rrolo[2,3-¿)]p¡r¡n-1 (6 / 7)yl)propane-1,2-diamine (1.16 g, 3.02 mmol) in 50 ml of methanol and add paraformaldehyde (109 mg, 3.62 mmol). Heat to 70 °C and stir for 16 h. Cool to room temperature and perform suction filtration. Subsequently, wash with 10 ml of methanol. Next, remove the solvent by decompressing and concentrating the filtrate to obtain the compound 1(5-methylimidazole alkanes-1-yl)-6-p-toluene sulfonyl-1,6-dihydroimidazolidine [4,5-c]pyrrolo[2,3b]pindine (1.28 g, 100% yield). 1H NMR (400 MHz, CDCI3) 5 8.73 (s, 1H), 8.57 (s, 1H), 8.01 (d, J = 7.7 Hz, 2H), 7.88 (dd, J = 21.5, 3.9 Hz, 1H), 7.39 (d, J = 7.7 Hz, 2H), 7.24 (d, J= 8.7 Hz,1 H), 4.40 - 4.24 (m, 1H), 4.15 - 4.01 (m, 1H), 3.87 - 3.72 (m, 1H), 3.71 - 3.49 (m, 1H), 3.22 (dd, J = 15.9, 8.6 Hz, 1H), 2.32 (s, 3H), 1.55 - 1.44 (m, 1H). LCMS ESI(+)m / z: 397.1 (M+1. Step G: nr Lrnn / zznz / B / Yi Dissolve the compound 1-(5-methylimidazolidin-1-yl)-6-p-toluene sulfonyl-1,6-dihydroimidazol[4,5-c]pyrrolo[2,3-β]pyridine (400 mg, 1.01 mmol) in 9 mL of methanol and add 2 N sodium hydroxide solution (3.0 mL, 6.0 mmol). Stir the mixture at 35 °C for 40 h. Then, dilute the reaction solution with 15 mL of water, remove the methanol by decompression and concentration. Extract with ethyl acetate (3 x 6 mL), fuse the organic phases, wash the organic phases with 5 mL of saturated brine, and dry with anhydrous sodium sulfate. Finally, perform suction filtration to remove the solvent. Finally, the crude compound 1-(5-methylimidazolidin-1-yl)-1,6-dihydroimidazo[4,5c(|pyrrolo[2,3-b]pridine (223 mg, 91% yield) is obtained. LCMS ESI(+)m / z: 243.1 (M+1). Step H: Dissolve the compound 1-(5-methylimidazolidin-1-yl)-1,6-dihydroimidazol-[4,5-c]pyrrolo[2,3b]pyridine (100 mg, 0.41 mmol) in 6 ml of dichloromethane, and then successively add cyanoacetic acid (42 mg, 0.50 mmol), HOBT (78 mg, 0.58 mmol), 4-dimethylaminopyridine (81 mg, 0.66 mmol) and EDCI (127 mg, 0.66 mmol) under nitrogen protection and an ice bath. Shake at room temperature for 16 h, decompress and concentrate the solution. Finally, the compound 3-(4-methyl-3-(imidazo[4,5-c(]pyrrolo[2,3-b]pridin1 (6 / - / )-imidazolin-1 -yl)-3-oxypropanitrile (40 mg, 31% yield) was obtained by silica column chromatography and high-performance liquid chromatography.1H NMR (400 MHz, DMSO-cfe) δ 11.91 (s, 1H), 8.60 (s, 1H), 8.45 (s, 1H), 7.47 (s, 1H), 6.72 (d, J = 16.2 Hz, 1H), 5.03 - 4.80 (m, 2H), 4.21 - 3.92 (m, 4H), 3.44 - 3.38 (m, 1H), 3.31 - 3.23 (m, 1H), 1.09 - 0.88 (m, 3H). LCMS ESI(+)m / z: 310.1 (M+1). Example 31 or nr Lrnn / zznz / B / Yi 3-(3-(¡midazo[4,5-c(|pyrrolo[2,3-b]pyr¡din-1 (6F / )-yl)¡m¡dazol¡na-1 -yl)-3-oxopropionitrile The specific implementation methods are as follows: Step A: Dissolve the tert-butyl carbamate (6-toluene sulfonyl imidazo[4,5-c(1-pyrrolo[2,3b]pindin-1(6-)-yl) (4.00 g, 9.36 mmol) in 400 mL of acetone, add sodium hydroxide (787 mg, 14.0 mmol) powder, and stir at room temperature for 10 min. Then add ethyl 2-bromoacetate (4.69 g, 28.1 mmol) to the reaction solution and stir at room temperature for 1.5 h. Filter the reaction solution and wash the filter media with dichloromethane (400 mL). Then decompress and concentrate the filtrate, subjecting the residue to silica column chromatography to obtain the compound 2-(tert-butoxycarbonyl)(6-ptoluene sulfonyl 1H NMR (400 MHz, CDCI3) 2H), 7.81 (d, J = 3.9 Hz, 1H), 7.29 (d, J = 8.4 Hz, 2H), 6.72 (d, J= 4.0 Hz, 1H), 5.17-4.78 (m, 1H), 4.33 - 4.17 (m, 2H), 4.15 - 3.96 (m, 1H), 2.36 (s, 3H), 1.62 - 1.36 (m, 3H), 1.35 - 1.15 (m, 9H). LCMS ESI(+)m / z: 514.1 (M+1). Paso B: Dissolve the compound 2-((tert-butoxycarbonyl)(6-p-toluene sulfonyl imidazo[4,5c(|pyrrolo[2,3-b]pyridine-1(6- / )-i)amino)methylacetate (4.34 g, 8.45 mmol) in 45 mL of a dichloromethane / methanol solvent mixture (10:1 by volume). Then add 15 mL of 4 N hydrogen chloride dioxane solution in an ice bath. Heat the mixture to room temperature and stir for 16 h under nitrogen protection. Subsequently, decompress and concentrate the reaction solution. Add 30 mL of saturated sodium bicarbonate solution and stir for 5 min. Extract with ethyl acetate (3 x 30 mL), fuse the organic phases, and wash with 10 mL of saturated brine. Next, dry with anhydrous sodium sulfate. Filter the filtrate by suction to obtain the compound 2-((6-p-toluene sulfonyl imidazo[4,5-olpyrolo[2,3-t>]prodin-1 (6 / - / )-i)amino)ethyl methylacetate (3.49 g, 100% yield).1H NMR (400 MHz, CDCI3) δ 8.85 (s, 1H), 8.10 (d, J= 8.4 Hz, 2H), 7.78 (d, J= 4.0 Hz, 1H), 7.24 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 4.0 Hz, 1 H), 5.73 (s, 1H),4.26 (q, J = 7.2 Hz, 2H), 3.95 (d, J= 4.9 Hz, 2H), 2.35 (s, 3H), 1.27 (t, J = 7.2 Hz, 3H).LCMS ESI(+)m / z: 414.0(M+1). Paso C: Dissolve the compound ethyl methyl 2-(((6-p-toluene sulfonyl imidazo[4,5-c(]pyrrolo[2,3b]pyridine-1 (6 / - / )-1)amino)methyl acetate (3.49 g, 4.96 mmol) in 100 mL of ethanol. Add sodium borohydride (958 mg, 25.3 mmol) in an ice bath under nitrogen protection. Stir the mixture at room temperature for 16 h. Then, dropwise add 1 N dilute hydrochloric acid solution to the reaction solution at 0 °C, adjust the reaction solution to neutrality, decompress and evaporate to remove the solvent, then extract the solution with ethyl acetate (3 x 50 mL), combine the organic phases, wash with 30 mL of saturated brine, and dry with anhydrous sodium sulfate. By removing the By solvent decompression and concentration and the application of silica column chromatography, the compound 2-((6-p-toluene sulfonyl imidazo[4,5-c(]pyrrolo[2,3-b]pridina-1 (6H)1)amino)ethyl-1 -ol (2.98 g, 95% yield) is obtained.LCMS ESI(+)m / z: 372.0(M+1). Step D: Add the compound 2-((6-p-toluene sulfonyl imidazo[4,5-c(]pyrrolo[2,3-b]pyridin-1(6H)yl)amino)ethyl-1-ol (2.98 g, 8.02 mmol), DBU (6.11 g, 40.1 mmol), and DPPA (6.62 g, 24.1 mmol) to a final volume of 100 mL of methylbenzene. Raise the temperature to 110 °C and stir for 1 h. Subsequently, decompress and concentrate the reaction solution, and subject the residues to silica column chromatography to obtain the compound N-(1-azida-2-yl)-6-p-toluene sulfonyl imidazo[4,5-c(]pyrrolo[2,3-b]pyridin-1(6H)-1)-amine (1.16 g, 36% efficiency).1H NMR (400 MHz, CDCI3) δ 8.86 (s, 1H), 8.11 (d, J= 8.4 Hz, 2H), 8.00 (s, 1 H), 7.80 (d, J = 4.0 Hz, 1H), 7.26 (d, J = 8.4 Hz, 2H), 6.94 (d, J = 4.0 Hz, 1H), 5.40 (t, J= 5.2 Hz, 1H), 3.61 - 3.54 (m, 2H), 3.45-3.38 (m, 2H), 2.35 (s, 3H). LCMS ESI(+)m / z: 397.1 (M+1). Step E: Dissolve the compound N-(1-azida-2-yl)-6-p-toluene sulfonyl imidazo[4,5-c(1-pyrrolo[2,3b]pyridin-1 (6-)-1)-amine] (1.06 g, 2.59 mmol) in 60 mL of methanol and add 10% palladium on carbon (212 mg) under nitrogen protection. Replace the hydrogen and stir the mixture at room temperature for 16 h in a hydrogen atmosphere. Then, perform suction filtration and wash the filter media with 20 mL of methanol. Finally, by decompression and concentration, the crude compound A / 2-(6-p-toluene sulfonyl imidazo[4,5-c(]pyrrolo[2,3-b]pridin-1 (6 / - / )-1)ethane-1,2-diamine (1.16 g, 100% yield) is obtained. LCMS ESI (+) m / z: 371.1 (M+1). Step F: Dissolve compound A / 2-(6-p-toluene sulfonyl imidazo[4,5-G(]pyrrolo[2,3-b]pyridine-1(6H)yl)ethane-1,2-diamine (1.16 g, 3.13 mmol) in 50 mL of methanol and then add paraformaldehyde (113 mg, 3.76 mmol). Heat to 70 °C and stir for 16 h. Cool to room temperature, filter by suction, and wash with 10 mL of methanol. Finally, decompress and evaporate the filtrate to remove the solvent, which helps to obtain compound 1-(imidazolidin-1-yl)-6-p-toluene sulfonyl-1,6-dihydroimidazol[4,5-c / ]pyrrolo[2,3b]pyridine (1.16 g, 97% of performance). LCMS ESI(+)m / z: 383.1 (M+1). Step G: Dissolve the compound 1-(imidazolidin-1-yl)-6-p-toluene sulfonyl-1,6-dihydroimidazo[4,5c(|pyrrolo[2,3-b]pyridine] (400 mg, 1.05 mmol) in 9 mL of methanol and add a 2 N sodium hydroxide solution (3.0 mL, 6.0 mmol). Stir at room temperature for 7 h. Then, dilute the reaction solution with 10 mL of water, decompress, and evaporate the methanol. Subsequently, extract the residues three times with 15 mL of ethyl acetate. Combine the organic phases, wash with 5 mL of saturated brine, and dry with anhydrous sodium sulfate. Then, perform suction filtration and remove the solvent by decompression and evaporation. Following these steps, the compound is obtained. crude 1-(5-imidazolidin-1 -yl)-1,6dihydro¡m¡dazo[4,5-c(]pyrrolo[2,3-b]pyr¡dine (277 mg, crude yield 100 %). LCMS ESI(+)m / z: 229.1 (M+1). Step H: nr Lrnn / zznz / B / Yi Dissolve the compound 1-(5-imidazolidine-1-yl)-1,6-dihydroimidazol[4,5-c]pyrrolo[2,3b]pine (100 mg, 0.44 mmol) in 6 ml of dichloromethane. Then, successively add cyanoacetic acid (45 mg, 0.53 mmol), HOBT (83 mg, 0.61 mmol), 4-dimethylaminopyridine (86 mg, 0.70 mmol), and EDCI (134 mg, 0.70 mmol) under nitrogen protection and an ice bath. Stir at room temperature for 16 h. Next, decompress and concentrate at reduced temperature, and then apply silica gel column chromatography and HPLC preparation to obtain the compound 3-(3-(imidazo[4,5c(]pyrrolo[2,3-b]pridina-1 (6 / - / )-1l)imidazoline-1 -1l)-3-oxopropionitril (40 mg, 30% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.88 (s, 1H), 8.58 (s, 1H), 8.39 - 8.32 (m, 1H), 7.50 - 7.43 (m, 1H), 6.77 - 6.70 (m, 1H)), 4.95 - 4.79 (m, 2H), 4.19 - 3.99 (m, 2H), 3.86 - 3.74 (m, 4H). LCMS ESI(+)m / z: 296.1 (M+1). Example 32 (fi)-3-(4-et¡l-3-(¡m¡dazo[4,5-c(]p¡rrolo[2,3-b]p¡r¡d¡n-1 (6 / 7)-¡l)im idazoline-1 -il)-3oxopropionitrileThe specific implementation methods are as follows: Step A: Dissolve the D-2-aminobutyric acid compound (25.0 g, 242 mmol) in 200 ml of methanol and add thionyl chloride (35.2 ml, 485 mmol) under nitrogen protection in an ice bath. Stir the mixture in an ice bath for 1 h, then heat to 70 °C and stir for 3 h. After the reaction, cool to room temperature. Finally, decompress and concentrate to obtain the methyl ester hydrochloride compound of D-2-aminobutyric acid (37.2 g, 100% yield).1H NMR (400 MHz, DMSO-d6) δ 8.68 (s, 3H), 3.96 (s, 1H), 3.75 (s, 3H), 1.90 - 1.80 (m, 2H), 0.92 (t, J = 7.5 Hz, 3H). LCMS ESI(+)m / z: 117.1 (M+1). Step B: Dissolve the compound D-2-aminobutyric acid methyl ester hydrochloride (10.0 g, 65.1 mmol) in 200 mL of tetrahydrofuran and successively add triethylamine (9.05 mL, 65.1 mmol) and benzaldehyde (7.60 g, 71.6 mmol) at room temperature. Stir at 30 °C for 48 h. Then filter and wash the filter media with 75 mL of tetrahydrofuran. Subsequently, decompress and concentrate the filtrate and dissolve it in 200 mL of methanol. Under an ice bath, successively add sodium borohydride (2.71 g, 71.6 mmol) in portions with stirring for 3 h. Subsequently, neutralize the reaction with 1 N dilute hydrochloric acid and adjust the pH to neutral. After these steps, extract with ethyl acetate (3 x 50 ml), fuse the organic phases, wash with 50 ml of saturated brine, dry with anhydrous sodium sulfate, decompress and concentrate. Finally, obtain the methyl ester of the compound D-2-benzylaminobutyric acid by silica column chromatography (11).4 g, 84 % de rendimiento).1H NMR (400 MHz, CDCI3) 5 7.38 - 7.20 (m, 5H), 3.81 (d, J = 13.0 Hz, 1H), 3.72 (s, 3H), 3.64 (d, J= 13.0 Hz, 1H), 3.23 (t, J = 6.5 Hz, 1H), 1.74 - 1.62 (m, 2H),0.94 (t, J= 7.4 Hz, 3H). LCMS ESI(+)m / z: 208.1 (M+1). Paso C: Dissolve the D-2-benaminobutyrate compound (11.4 g, 55.0 mmol) in 150 mL of dichloromethane, followed by the addition of sodium nitrite (5.69 g, 82.5 mmol) and ptoluenesulfonic acid (15.7 g, 82.5 mmol) monohydrate at room temperature. Stir at 30 °C for 2 h, filter, and wash the filter media with 50 mL of dichloromethane. Then, decompress and concentrate the filtrate. Next, stratify the residue in 100 mL of ethyl acetate and 50 mL of water. Separate the organic phase and extract with ethyl acetate (3 x 10 mL). Then, fuse the organic phases, wash them with 30 mL of saturated salt water, and dry with anhydrous sodium sulfate. Decompress and concentrate the solution to obtain the compound D-2-((Nbenzyl-Nnitroso)amino)butyrate methyl (12.3 g, 95% yield).1H NMR (400 MHz, CDCI3) δ 7.41 - 7.25 (m, 3.8H), 7.11 (m, 1.2H), 5.42 - 5.25 (m, 0.9H), 5.00 (d, J = 14.8 Hz, 0.6H), 4.95 (dd, J = 9.4, 6.0 Hz, 0.6H), 4.73 (t, J= 7.5 Hz, 0.4H), 4.59 (d, J= 14.8 Hz, 0.6H), 3.61 (s, 1.8H), 3.46 (s, 1.2H), 2.29 - 1.90 (m, 1.6H), 1.75 - 1.57 (m, 0.5H), 0.87 (t, J = 7.4 Hz, 1.9H), 0.81 (dt, J =28.3, 7.4 Hz, 3H), 0.74 (t, J = 7.5 Hz, 1.2H). LCMS ESI(+)m / z:. nr Lrnn / zznz / B / Yi 237.1 (M+1). Paso D: Suspend lithium aluminum hydride (3.21 g, 84.7 mmol) in 100 mL of diethyl ether and dropwise add 10 mL of diethyl ether solution containing methyl D-2-((N-benzyl-N-nitroso)amino)butyrate (5.00 g, 21.2 mmol) under nitrogen at room temperature, maintaining the drop rate until reflux. Stir at 40 °C for 0.5 h. Then, neutralize the ice bath with 3.2 mL of water, 3.2 mL of 15% sodium hydroxide solution, and 9.6 mL of water. Stir at room temperature for 5 minutes. Separate the organic phases, dry with anhydrous sodium sulfate, filter, and concentrate the filtrate. Next, the oily substance obtained ( / 7)-2-(1-benzylhydrazyl)butan-1-ol is used directly for the following reaction.1H NMR (400 MHz, CDCI3) δ 7.397.26 (m, 5H), 3.88-3.66 (m, 4H), 2.72-2.62 (m, 1H), 1.74-1.62 (m, 1H), CDCI3 δ 7.39-7.26 (m, 5H), 3.88-3.66 (m, 4H), 2.72-2.62 (m, 1H), 1.74-1.62 (m, 1H), 1.59 1.47 (m, 1 h), 0.98 (t, J = 7.5 Hz, 3 h). El LCMS ESI (+) m / z: 195.1 (m + 1). Paso E: Dissolve the crude compound ( / 7)-2-(1-benzylhydrazine)butan-1-ol from the previous step in 100 ml of isopropanol and successively add / V, / V-diisopropylethylamine (10.2 ml, 56.9 mmol) and the compound 4-chloro-5-nitro-1-p-toluene sulfonyl-1 / 7-pyrrolo[2,3-Σ>]pyridine (5.00 g, 14.2 mmol). Heat to 85 °C under nitrogen protection. Then stir and react for 16 h. Subsequently, concentrate the reaction solution and apply silica column chromatography to obtain the compound ( / 7)-2-(1-benzyl-2-(5-nitro-1-p-toluene sulfonyl-1 Hpyrrolo[2,3-o]pyridin-4-yl)hydrazine)-butan-1 -ol (5.91 g, two-step yield of 82%).1H NMR (400 MHz, CDCI3) δ 10.01 (d, J = 112.2 Hz, 1H), 9.00 (d, J= 5.2 Hz, 1H), 8.02 (dd, J = 8.4, 4.3 Hz, 2H), 7.55 - 7.41 (m, 2H), 7.33 - 7.06 (m, 7H), 4.29 - 3.68 (m, 4H), 3.10 - 2.90 (m, 1H), 2.40 (s, 3H), 1.87 - 1.42 (m, 2H), 0.96 (dt, J = 36.8, 7.5 Hz, 3H). LCMS ESI(+)m / z: 510.0 (M+1). Step F: Add the compound (fi)-2-(1-benzyl-2-(5-nitro-1-p-toluene sulphyl-1 / 7-pyrrole[2,3-b]pyridine4-1)diazanyl)butan-ol (5.90 g, 11.6 mmol) to 120 mL of ethanol, followed by the addition of iron powder (12.9 g, 232 mmol) and saturated ammonium chloride (40 mL) at room temperature. Stir at 80 °C for 15 min. Filter by suction with hot diatomaceous earth, wash with 30 mL of methanol, and concentrate the filtrate. The residue is then partitioned between 60 mL of water and 60 mL of ethyl acetate. Subsequently, separate the organic phases by extracting the aqueous phase four times with 60 mL of ethyl acetate. After that, fuse the organic phases, wash with 30 ml of water and 30 ml of saturated brine. Then, dry with anhydrous sodium sulfate, decompress and concentrate. Finally, apply silica column chromatography nr Lrnn / zznz / B / Yi to obtain the compound (fí)-2-(1-benzyl-2-(5-amino-1-p-toluene sulfonyl-1 / 7-pyrrole[2,3¿>]p¡ñd¡n-4-¡l) diazanyl)-butan-1-ol (2.45 g, yield 44 %).1H NMR (400 MHz, CDCF) 5 7.99 (d, J = 8.4 Hz, 3H), 7.71 (s, 1 H), 7.45 (d, J = 4.1 Hz, 1H), 7.26 - 7.16 (m, 7H), 6.75 (d, J = 3.9 Hz, 1H), 5.77 (s, 1H), 4.03 - 3.90 (m, 2H), 3.89 - 3.64 (m,2H), 2.36 (s, 3H), 1.86 - 1.69 (m, 2H), 1.50 - 1.39 (m, 1H), 1.26 (t, J = 7.1 Hz, 1H), 0.95 (t, J = 7.6 Hz, 3H). LCMS ESI(+)m / z: 480.1 (M+1). Step G: Dissolve the compound (n)-2-(1-benzyl-2-(5-amino-1-p-toluene sulfonyl-1 / 7-pyrrole[2,3b]pindin-4-yl) diazanyl)butan-1-ol (480 mg, 1.0 mmol) in 6 ml of acetic acid and add triethyl protoformate (222 mg, 1.5 mmol) under nitrogen. Stir at 100 °C for 15 min and decompress the reaction solution to remove the solvent. Next, subject the residues to silica column chromatography to obtain the compound (n)-2(benzyl(6-toluene sulfonyl imidazo[4,5-c(]pyrrorol [2,3-o]pyridine-1 (6 / - / )-1)amino)butan-1 -ol (316 mg, 65% yield). LCMS ESI(+) M / z: 490.1 (m +1). Step H: Add the compound (fi)-2-(benzyl(6-p-toluene sulfonyl imidazo[4,5-c(1-pyrrolo[2,3]pindin-1 (6-)-1)amino)butan-1-ol (316 mg, 0.65 mmol), DBU (491 mg, 3.23 mmol), and DPPA (533 mg, 1.94 mmol) to 8 mL of methylbenzene under ice-bath cooling and nitrogen protection. Heat to 100 °C and stir for 16 h, decompress, and concentrate the reaction solution. Subsequently, subject the residues to silica column chromatography to obtain the compound (fi)-N-(1-azida-2-1)-N-benzyl-6-p-toluene sulfonyl imidazo[4,5-c]pyrrolo[ 2,3-¿>]p¡ñd¡n-1 (6 / - / )-¡l)amine (216 mg, 65% yield). LCMS ESI(+)m / z: 515.2(M+1). Step I: Dissolve the compound ( / 7)-N-(1-azidina-2-1l)-N-benzyl-6-p-toluene sulfonyl imidazo[4,5c(1-pyrrolo[2,3-γ)]pridina-1 (6 / - / )-1l)amine (167 mg, 0.33 mmol) in 8 mL of dichloromethane and add anhydrous aluminum chloride (346 mg, 2.6 mmol) under nitrogen protection. Then, stir the mixture at room temperature for 1 h. Add 10 mL of saturated sodium bicarbonate to the reaction solution and stir for 5 min. Extract the compound three times with 15 mL of dichloromethane, mix the organic phase, wash with 10 mL of saturated saline solution, and dry with anhydrous sodium sulfate. Decompress and concentrate the filtrate. Finally, subject the residues to silica gel column chromatography to obtain the compound (A?)-N-(1-azidine-2-yl)-6-toluene sulfonyl imidazo[4,5-c(]pyrrolo[2,3£>]pyridine-1 (6 / - / )-yl)amine (89 mg, 62% yield).1H NMR (400 MHz, CDCI3) δ 8.90 (s, 1H), 8.22 (s, 1H), 8.12 (d, J = 8.4 Hz, 2H), 7.83 (d, J= 4.0 Hz, 1H), 7.28 (d, 2H), 7.03 (d, J = 4.0 Hz, 1 H), 5.65 (s, 1H),3.68 (dd, J = 12.0, 2.8 Hz, 1 H), 3.50 - 3.33 (m, 2H), 2.36 (s, 3H), 1.54 -1.44 (m, 2H), 0.93 (t, J = 7.5 Hz, 3H). LCMS ESI(+)m / z: 425.0 (M+1). nr Lrnn / zznz / B / Yi Step J: Dissolve the compound ( / 7)-N-(1-azidin-2-1l)-6-p-toluene sulfonyl imidazo[4,5c(|p¡rrolo[2,3-b]p¡r¡n-1 (6 / 7)-1l) amine (86 mg, 2.59 mmol) in 6 ml of methanol and add 10% palladium on carbon (43 mg) under nitrogen protection. Replace the hydrogen and stir the mixture under a hydrogen atmosphere at 35 °C for 2 h. Perform suction filtration, wash with 10 ml of methanol. Subsequently, decompress and concentrate the filtrate to obtain the compound ( / 7)-A / 2-(6-p-toluene sulfonyl imidazo[4,5-c(|p¡rrolo[2,3-b]p¡r¡n-1(6 / 7)-¡l)butane-1, 2-diamine (79 mg, 100% yield). LCMS ESI (+) m / z: 399.1 (M+1). Step K: Dissolve the compound (Z7)-A / 2-(6-pP-toluene sulfonyl imidazo[4,5-c(]pyrrolo[2,3-b]pyridine1(6 / 7)-1)butane-1,2-diamine (79 mg, 0.20 mmol) in 6 mL of methanol and add paraformaldehyde (7 mg, 0.2 mmol). Heat to 70 °C and stir for 16 h. Cool to room temperature, filter by suction, and wash with 5 mL of methanol. Decompress and evaporate the filtrate to remove the solvent, which helps to obtain the compound ( / 7)-1-(5-ethylimidazolidine-1-1)6-toluene sulfonyl-1,6-dihydroimidazol[4,5-c / ]pyrrolo[2,3-b]pyridine (81 mg, yield of 100 %).1H NMR (400 MHz, CDCI3) δ 8.94 - 8.77 (m, 1H), 8.13 - 8.07 (m, 2H), 7.79 - 7.67 (m, 1H), 7.28 - 7.24 (m, 1H), 7.08 (m, 1H), 4.53 - 3.97 (m, 2H), 3.80 - 3.37 (m, 3H), 2.42 - 2.30 (m, 3H), 1.83 -1.59 (m, 2H), 0.96 - 0.74 (m, 3H). LCMS ESI(+)m / z: 411.1 (M+1). Step L: Dissolve the compound ( / 7)-1-(5-ethylimidazolane-1-yl)-6-p-toluene sulfonyl-1,6-dihydroimidazol[4,5-c(1-pyrrolo[2,3-b]pyridine] (50 mg, 0.12 mmol) in 6 mL of methanol and add 2 N sodium hydroxide solution (1.5 mL, 3.0 mmol). Stir at 30 °C for 16 h. Dilute the reaction solution with 10 mL of water and remove the methanol by decompression and evaporation. Extract the residue three times with 15 mL of ethyl acetate. Then, fuse the organic phases, wash with 5 mL of saturated salt water, and dry with anhydrous sodium sulfate. Perform suction filtration to remove the solvent. Finally, obtain the crude compound ( / 7)-1 (5-ethyl imidazolane-1-yl)-1,6-dihydroimidazol[4,5-c / ]pyrrolo[2,3bjpyridine (31 mg, 100% yield). LCMS ESI(+)m / z: 257.1 (M+1). Step M: Dissolve the compound ( / 7)-1 -(5-ethylimidazolidine-1-yl)-1,6-dihydroimidazol-[4,5c(|pyrrolo[2,3-γ)]pyridine (31 mg, 0.14 mmol) in 6 ml of dichloromethane and then successively add cyanoacetic acid (15 mg, 0.17 mmol), HOBT (27 mg, 0.20 mmol), 4-dimethylaminopyridine (28 mg, 0.23 mmol) and EDCI (44 mg, 0.23 mmol) under nitrogen protection and an ice bath. Shake at room temperature for 16 h. Then decompress and concentrate the solution. Finally, by silica column chromatography and HPLC, prepare the compound (fi)-3-(4-ethyl-3-(im¡dazo[4,5-^pyrrolo[2,3-b]p¡r¡din-1 (6 / 7) nr Lrnn / zznz / E / YiAi ¡lo)im¡dazolína-1 -yl)-3-oxypropanítrile (12 mg, yield 26 %).1H NMR (400 MHz, DMSO-cfc) δ 11.89 (s, 1H), 8.87 - 8.03 (m, 2H), 7.47 (s, 1H), 6.70 (s, 1H), 5.05 - 4.69 (m, 2H), 4.30 - 3.68 (m, 4H), 3.56 - 3.41 (m, 1 H),1.54 - 1.27 (m, 2H), 0.85 - 0.68 (m, 3H). LCMS ESI(+)m / z: 324.1 (M+1). nr Lrnn / zznz / B / Yi Example 33 2-cyano-N-(1 -(imidazo[4,5-d|pyrrolo[2,3-t>] pyridine-1 (6 / - / )-¡l)pyrrolidine-3-¡l)acetamide The specific implementation methods are as follows: Dissolve terebutyl pyrrolidine-3-ylcarbamate (4.33 g, 23.3 mmol) in 30 mL of acetic acid and 10 mL of water. Gradually add dropwise (20 mL) an aqueous solution containing sodium nitrite (3.21 g, 46.6 mmol) at 0 °C. Then heat to room temperature and stir for 18 h under nitrogen protection. After the reaction, neutralize the solution by adding water at 0 °C, extract three times with ethyl acetate (240 mL), filter, centrifuge, and purify to obtain (1-nitrosopyrrolidine-3-yl) terebutyl carbamate (4.58 g, 93% yield). LCMS ESI(+)m / z: 216.1 (M+1). Step B: Suspend the compound (1-nitrosopyrrolidine-3-yl) tert-butyl carbamate (4.58 g, 21.3 mmol), zinc powder (13.8 g, 213 mmol) in acetic acid (5 mL) and methanol (50 mL). Stir the solution at room temperature for 2 h under nitrogen protection. After the reaction, filter and centrifuge to obtain the crude substance (1-aminopyrrolidine-3-yl) tert-butyl carbamate (4.28 g, 100% yield). LCMS ESI(+)m / z: 202.1 (M+1). Step C: Dissolve the compound (1-aminopyrrolidine-3-yl) tert-butyl carbamate (7.75 g, 22 mmol) in 100 ml of isopropanol, followed by the addition of (1-aminopyrrolidine-3-yl) tert-butyl carbamate (4.28 g, 21.3 mmol) and AA / V-diisopropylethylamine (11 g, 85.3 mmol). Heat to 100 °C and stir for 20 h. After the reaction, centrifuge and purify by column chromatography to obtain the compound (1-((5-nitro-1-p-toluene sulfonyl-1-1 / 7-pyrrole[2,3-b]pyridin-4yl)amino)pyridin-3-1l) tert-butyl carbamate (6.6 g, 60% yield). LCMS ESI(+)m / z: 517.1 (M+1). Step D: Suspend the compound 1-((5-nitro-1-p-toluene sulfonyl-1-1 / 7-pyrrole[2,3-b]pyridine-4-yl)amino)pyridine-3-yl)Boc-amide (1.5 g, 2.9 mmol), iron powder (977 mg, 17.4 mmol) and ammonium chloride (311 mg, 5.8 mmol) in 12 ml of ethanol and 4 ml of water. Under nitrogen protection, heat to 75 °C and stir for 1 h. After the reaction, filter, centrifuge and purify by column chromatography to obtain the product 1-((5-amino-1-p-toluene sulfonyl-1 -1H-pyrrol[2,3-b]pyridine-4-ilo)amino)pyridine-3-ilo)tere-butyl carbamate (770 mg, 55 % yield). LCMS ESI(+)m / z: 487.1. Step E: Dissolve the carbamate compound 1-((5-amino-1-p-toluene sulfonyl-1-1 / 7-pyrrolo[2,3]pyridine-4-yl)amino)pyridine-3-yl)tert-butyl (770 mg, 1.58 mmol), triethyl orthoformate (1 ml) and pyridine hydrochloride (18 mg, 0.16 mmol) in 20 ml of methylbenzene. Heat to 115 °C and stir for 2 h under nitrogen protection. After the reaction, centrifuge and purify by column chromatography to obtain the compound (1-(6-p-toluene sulfonyl imidazo[4,5c(|p¡pyrolo[2,3-b]p¡r¡n-1 (6 / - / )-¡l) pyridin-3-yl)tert-butyl carbamate (700 mg, 89 % yield). LCMS ESI(+)m / z: 497.1. Step F: Dissolve the compound (1-(6-p-toluene sulfonyl imidazo[4,5-c]pyrolo[2,3-β]pyridin-1(6H)yl)pyridin-3-yl) Boc-amide (700 mg, 1.41 mmol) in 10 mL of dichloromethane. Then add trifluoroacetic acid (2 mL) at 0 °C and stir at room temperature for 5 h under nitrogen protection. After the reaction, centrifuge to obtain the crude compound 1-(6-p-toluene sulfonyl imidazo[4,5-d]pyrolo[2,3-b]pyridin-1(6 / 7)-β)pyridin-3-ammonia triflate (560 mg, 100% yield). LCMS ESI(+)m / z: 397.1 (M+1). Step G: Dissolve the compound 1-(6-p-toluene sulfonyl imidazo[4,5-c(|pyrrolo[2,3-b]pyridin-1 (6 / 7)yl)pyridin-3-amino trifluoromethanesulfonate (360 mg, 0.91 mmol) in 10 mL of methanol. Then, add aqueous sodium hydroxide solution (2 N, 3 mL) at 0 °C. Stir the mixture at 30 °C for 18 h under nitrogen protection. After the reaction is complete, add 20 mL of water, adjust the pH to 8–9, extract with dichloromethane (6 x 50 mL), merge the organic phases, dry with anhydrous sodium sulfate, filter, centrifuge, and purify by column chromatography to obtain compound 1 -(¡midazo[4,5-c(|p¡rrolo[2,3-b]p¡r¡d¡n-1 (6H)-yl)p¡r¡d¡n-3amino (140 mg, 64% yield). LCMS ESI(+)m / z: 243.1 (M+1). Step H: Dissolve the compound 1-(imidazo[4,5-c(]pyrrolo[2,3-t>]pyridine-1(6 / - / )-1)pyridine-3-amino (70 mg, 0.29 mmol), 2-cyanoacetic acid (29 mg, 0.35 mmol), and HATU (165 mg, 0.43 mmol) in 5 mL of A / ,A / -dimethylformamide. Then add V,A / -diisopropylethylamine (112 mg, 0.87 mmol) at 0 °C. Stir at room temperature for 16 h under nitrogen protection. After the reaction is complete, add 20 mL of water and extract with ethyl acetate (3 x 50 mL). Merge the organic phases, dry with anhydrous sodium sulfate, filter, centrifuge, and purify using high-efficiency liquid-phase preparation. to obtain the compound 2-cyano-N-(1(imidazo[4,5-c(|pyrrolo[2,3-b]pyr¡din-1 (6 / - / )-¡l)pyrro¡din-3-¡l)acetam¡de (30 mg, 34 % yield).1H NMR (400 MHz, DMSO-d6) 5 11.88 (s, 1H),8.76 (d, J = 6.8 Hz, 1H), 8.57 (s, 1H), 8.46 (s, 1H), 7.47 (t, J= 3.0 Hz, 1H), 6.75 (dd, J = 3.6, 2.0Hz, 1H), 4.56 - 4.48 (m, 1H), 3.70 (d, J = 1.4 Hz,2H), 3.68 - 3.63 (m, 1H), 3.56 - 3.50 (m, 1H), 3.45 - 3.39 (m, 1H), 3.27 3.24 (m, 1H), 2.50 - 2.44 (m, 1H), 1.99 - 1.90 (m, 1H). LCMS ESI(+)m / z: 310.1 (M+1). Example 34 HN^CN N— / NH 2-((1-(imidazo[4,5-c(]pyrrolo[2,3-b]pyrrolidn-1 (6 / - / )-l)pyrrolidn-3-l)amino)aceton¡trol nr Lrnn / zznz / B / Yi Step A: Dissolve 1-(imidazo[4,5-c]pyrrolo[2,3-β]pyridin-1(6β-β)-β1)pyridin-3-amino (70 mg, 0.29 mmol) and bromoacetonitrile (42 mg, 0.35 mmol) in 5 ml of Aβ,Aβ-dimethylformamide, followed by the addition of triethylamine (88 mg, 0.87 mmol) at 0 °C. Stir the solution at room temperature for 16 h under nitrogen protection. Once the reaction is complete, add 20 ml of water, extract with dichloromethane (5*50 ml), fuse the organic phases, dry with anhydrous sodium sulfate, filter, centrifuge and purify by HPLC preparation to obtain the compound 2-((1(imidazo[4,5-c(|p¡pyrlo[2,3-b]p¡r¡n-1 (6 / - / )-¡l)pyrrol¡n-3-¡l)amino)acetonitrilo (12 mg, 15 % yield).1H NMR (400 MHz, CD3OD-Ó4) δ 9.03 (s, 1H), 9.85 (s, 1H), 7.66 (d, J = 3.4 Hz,1 H), 7.20 (d, J = 3.4 Hz, 1H), 4.09 (s, 2H), 4.07 - 4.00 (m, 1H), 3.89 - 3.84 (m, 1H), 3.75 3.69 (m, 1H), 3.65 - 3.58 (m, 2H), 2.66 - 2.58 (m, 1H), 2.24 - 2.16 (m, 1H). LCMS ESI(+)m / z: 282.1 (M+1) . nc Lrnn / zznz / B / Yu (3 S, 5R)-5-ethyl¡l-1-(¡m¡dazo[4,5-c(]pyrrole[2,3-¿>]pyr¡dina (6 H)-yl) pyrrolidin-3-carbonitrile The specific implementation methods are as follows: TBDPSO»· MsO'· Step A: Dissolve the compound (2S,4R)-N-Cbz-2-ethyl ester-4-pyrrolidinol carboxylate (20.0 g, 71.6 mmol) in 70 mL of A / ,A / -dimethylformamide. Add imidazole (10.7 mmol, 158 mmol) and TBDPSCI (23.6 g, 85.9 mmol) at room temperature and stir for 16 h. Pour the reaction solution into water (700 mL), extract with ethyl acetate (3 x 60 mL), combine the organic phases, wash with saturated brine (30 mL), dry with anhydrous sodium sulfate, and filter by suction. Subsequently, decompress and concentrate. Finally, subject the residues to silica column chromatography to obtain the compound (2S,4R)-N-Cbz-2-carboxylic acid ethyl ester of pyrrolidine-4-O-TBDPS (34.3 g, 92% yield).1H NMR (400 MHz, CDCI3) δ 7.65 - 7.56 (m, 4H), 7.46 - 7.30 (m, 11H), 5.23 - 5.04 (m, 2H), 4.60 - 4.47 (m, 1H), 4.41 (m, 1H), 3.70 - 3.47 (s, 3H), 3.65 - 3.49 (m, 2H), 2.29 - 2.21 (m, 1H), 1.93 - 1.83 (m, 1H), 1.03 (s, 9H). LCMS ESI(+)m / z: 518.2(M+1). Step B: Dissolve the compound (2S,4R)-N-Cbz-2-ethyl ester-4-O-TBDPS pyrrolidine (10.0 g, 19.3 mmol) in 80 mL of ethanol (10:1 by volume). Then, add sodium borohydride (2.19 g, 58.0 mmol) in parts in an ice bath. Heat to room temperature and stir for 16 h. Neutralize the reaction with 1 N hydrochloric acid solution. Subsequently, decompress and concentrate the reaction solution. Extract three times with methanol / ethyl acetate mixed solvent (volume ratio 10:1, 200 mL). Combine the organic phases, wash with 100 mL of saturated brine, and dry with anhydrous sodium sulfate. Next, suction filtration and concentration of the filtrate to obtain the compound (2S,4R)-N-Cbz-2-hydroxymethyl-4-0-TBDPS pyrrolidine (8.92 g, 94% yield).1H NMR (400 MHz, CDCI3) δ 7.67 - 7.56 (m, 4H), 7.46 - 7.29 (m, 11H), 5.21 - 5.09 (m, 2H), 4.38 - 4.25 (m, 2H), 3.74 - 3.50 (m, 3H), 3.31 - 3.20 (m, 1H), 2.08 - 1.97 (m, 1H), 1.56 - 1.45 (m, 1H), 1.03 (s, 9H). Paso C: Dissolve the compound (2S,4R)-N-Cbz-2-hydroxymethyl-4-O-TBDPS pyrrolidine (23.0 g, 4.96 mmol) in 700 mL of dichloromethane. Add Dess-Martin oxidant (29.9 g, 70.5 mmol) at room temperature. Stir at room temperature for 1 h. Filter through diatomaceous earth and wash with 50 mL of dichloromethane. Then add saturated sodium bicarbonate (200 mL) to the filtrate, followed by stirring for 30 minutes. Next, perform suction filtration, separate the organic phases, and extract the aqueous phase twice with dichloromethane (100 mL). Combine the organic phases, wash with 30 mL of brine, and dry with anhydrous sodium sulfate. After these steps, decompress and evaporate to remove the solvent. Finally, silica column chromatography was applied to obtain the compound (2S,4R)-N-Cbz-2-carbaldehyde-4-O-TBDPS pyrrolidine (14.0 g, 61% yield).1H NMR (400 MHz, CDCh) δ 9.45 (dd, J = 57.2, 2.9 Hz, 1H), 7.68 - 7.55 (m, 4H), 7.49 - 7.29 (m, 11 H), 5.25 - 5.09 (m, 2H), 4.57 - 4.34 (m, 2H), 3.74 - 3.34 (m, 2H), 2.10 (t, J = 10.3 Hz, 1H), 1.88 1.77 (m, 1H), 1.05 (s, 9H). LCMS ESI(+)m / z: 488.2(M+1). Step D: Add potassium tert-butoxide (6.44 g, 57.4 mmol) to the tetrahydrofuran solvent (150 mL) of methyltriphenylphosphorus (20.5 g, 57.4 mmol) in a nitrogen-protected ice bath. Heat to 30 °C and stir for 30 min. Cool the reaction solution to 0 °C. Then, dropwise add a solution of the compound (2S,4R)-N-Cbz-2-carbaldehyde-4 nr Lrnn / zznz / B / Yi O-TBDPS pyrrolidine (14.0 g, 28.7 mmol) in tetrahydrogenated pyrrolidine (30 mL). Maintain temperature and stir for 1 h. Add water (150 mL) and EA (150 mL) to the reaction solution. Separate the organic phases and extract the aqueous phase twice with ethyl acetate (150 mL). Then, fuse the organic phases, wash with water (100 mL) and saturated brine (50 mL), dry with anhydrous sodium sulfate, and perform suction filtration. Next, decompress and evaporate the solvent, finally obtaining the compound (2S,4R)-N-CBZ-2-vinylpyrrolian 4-O-TBDPS (13.0 g, 93% yield) by silica column chromatography.1H NMR (400 MHz, CDCI3) 5 7.73 - 7.57 (m, 4H), 7.49 - 7.27 (m, 11H), 5.77 - 5.58 (m, 1H), 5.22 - 4.90 (m, 4H), 4.61 - 4.42 (m, 1H), 4.39 - 4.31 (m, 1H), 3.64 - 3.45 (m, 1H), 3.46 - 3.28 (m, 1H), 2.18 - 2.05 (m, 1H), 1.78 - 1.62 (m, 1H), 1.04 (s, 9H). LCMS ESI(+)m / z: 487.2(M+1). Step E: Add dropwise the crude pyrrolian (2S,4R)-N-CBZ-2-vinyl-4-O-TBDPS compound (20 ml) obtained in the last reaction to a 1.0 M tetrahydrofuran solution (53.5 ml, 53.5 mmol) of n-butylammonium fluoride trihydrate and stir at room temperature for 16 h. Then decompress and concentrate the solution. Finally, silica column chromatography was applied to obtain the compound (2S,4R)-N-CBZ-2-vinyl-4-pyrrolidonol (6.15 g, 93% yield).1H NMR (400 MHz, CDCI3) δ 7.42 - 7.27 (m, 5H), 5.86 - 5.67 (m, 1H), 5.25 - 5.00 (m, 4H), 4.57 - 4.40 (m, 2H), 3.70 - 3.47 (m, 2H), 2.21 - 2.06 (m, 1H), 1.97 - 1.86 (m, 1H). LCMS ESI(+)m / z: 248.1 (M+1). Step F: Dissolve the compound (2S,4R)-N-Cbz-2-vinyl-4-pyrrolidinol (2.00 g, 8.09 mmol) in 50 mL of dichloromethane, followed by the dropwise addition of triethylamine (2.25 mL, 16.2 mmol) and methylsulfonyl chloride (1.39 g, 12.1 mmol) under nitrogen protection in an ice bath. Stir under an ice bath for 3 h. Then add water (50 mL) and mix for 15 min. Add ethyl acetate (150 mL), separate the organic phases, wash twice with water (30 mL) and saturated brine (30 mL), dry with anhydrous sodium sulfate, and filter by suction. Through these steps the crude compound (2S,4R)-N-Cbz-2-vinyl-4-pyrrolidine methanesulfonate (2.63 g, 100% yield) is obtained.1H NMR (400 MHz, CDCI3) δ 7.45 - 7.28 (m, 5H), 5.88 - 5.66 (m, 1H), 5.28 - 5.04 (m, 5H), 4.60 - 4.46 (m, 1H), 4.06 - 3.84 (m, 1H), 3.74 - 3.61 (m, 1H), 3.00 (s, 3H), 2.57 - 2.41 (m, 1H), 2.13 - 2.01 (m, 1H). Step G: Dissolve the compound (2S,4R)-N-CBZ-2-vinyl-4-mesylate (2.63 g, 8.08 mmol) in 50 mL of anhydrous A / ,A / -dimethylformamide (50 mL), followed by the addition of a sodium cyanide solution (1.19 g, 24.3 mmol) under nitrogen. Stir at 80 °C for 7 h, then stir at 100 °C for 2 h. Pour the reaction solution into 300 mL of water, then extract with ethyl acetate (3 x 50 mL) and merge the organic phases. Subsequently, wash with water (50 mL) and salt-saturated water (50 mL), dry with anhydrous sodium sulfate, and perform suction and filtration. Finally, obtain the compound (2S,4S)-N-CBZ2-vinyl-4-cyano-pyrrolidine (1.17 g, 56% yield) by silica gel column chromatography.1H NMR (400 MHz, CDCI3) δ 7.43 - 7.29 (m, 6H), 5.95 - 5.81 (m, 1H), 5.34 - 5.06 (m, 4H), 4.50 - 4.39 (m, 1H), 4.08 - 3.89 (m, 1H), 3.71 - 3.62 (m, 1H), 3.14 - 3.03 (m, 1H), 2.58 - 2.47 (m, 1H), 2.17 - 2.03 (m, 1H). LCMS ESI(+)m / z: 257.1 (M+1) . Step H: Dissolve the compound (2S,4S)-N-Cbz-2-vinyl-4-cyanopyrrolidine (1.17 g, 4.56 mmol) in 30 mL of methanol, followed by the addition of 10% palladium on carbon (234 mg) under nitrogen protection. Replace the hydrogen. Stir at room temperature for 16 h. Perform suction filtration, washing twice with 10 mL of methanol. Then decompress and concentrate the filtrate to obtain the compound (3S,5R)-5-ethylpyrrolidine-3-methylcyanide (567 mg, 100% yield). LCMS ESI(+)m / z: 125.1 (M+1). Step I: Dissolve the compound (3S,5R)-5-ethylpyrrolidine-3-methylcyanide (456 mg, 4.57 mmol) in 25 ml of dichloromethane and sequentially add sodium nitrite (347 mg, 5.03 mmol) and p-toluenesulfonic acid monohydrate (847 mg, 5.03 mmol) at room temperature. Shake for 3 h, filter, wash the filter mass with 20 ml of dichloromethane, decompress and concentrate the filtrate, and finally perform silica column chromatography to obtain the compound (3S,5R)-1-nitroso-5-ethylpyrrolidine-3-methyl cyanide (210 mg, 24% yield). 1H NMR (400 MHz, CDCI3) δ 4.52 - 4.40 (m, 1H), 4.31 - 4.19 (m, 1H), 3.74 - 3.65 (m, 1H), 3.20 - 3.09 (m, 1H), 2.75 - 2.63 (m, 1H), 2.40 - 2.28 (m, 1H), 2.26 - 2.12 (m, 1H), 2.01 - 1.90 (m, 1H), 1.09 (t, J = 7.4 Hz, 3H). LCMS ESI(+)m / z: 128.1 (M+1). Step J: Dissolve the compound (3S,5R)-1-nitroso-5-ethylpyrrolidine-3-methylcyanide (210 mg, 1.37 mmol) in 6 mL of methanol and add zinc powder (896 mg, 13.7 mmol) at room temperature. Then, add acetic acid (2 mL) dropwise. Stir at 30 °C for 2 h. Subsequently, perform suction filtration of the reaction solution. Next, wash the solution with 5 mL of methanol and concentrate the filtrate. Then, extract the residue with 15 mL of dichloromethane, followed by suction filtration, and concentrate the filtrate. Finally, the oily substance obtained (3S,5R)-1-amino-5-ethylpyrrolidine-3-methylcyanide is used directly in the following reaction. LCMS ESI(+)m / z: 140.1 (M+1). Step K: The crude compound (3S,5R)-1-amino-5-ethylpyrrolidine-3-methylcyanide from step nr Lrnn / zznz / B / Yi above is dissolved in 12 ml of isopropanol, and N,N-diisopropylethylamine (1.86 g, 14.4 mmol) and the compound 4-chloro-5-nitro-1-p-toluenesulfonyl-1-Hpyrrolo[2,3-β]pyridine (758 mg, 2.16 mmol) are successively added. Heat to 85 °C under nitrogen protection. Stir and react for 16 h. Subsequently, concentrate the reaction solution and apply silica column chromatography to obtain the compound (3S, 5R)-5-ethyl-1-((5-nitro-1-p-toluene sulfonyl-1 / 7-pyrrolo[2,3-ε]pyridine-4-yl)amino)pyrrolidine-3-cimetidine (282 mg, 43% yield).1H NMR (400 MHz, CDCI3) δ 9.17 (s, 1H), 8.08 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 4.0 Hz, 1 H), 7.47 (d, J = 4.0 Hz, 1 H), 7.31 (d, J = 8.1 Hz, 2H), 3.61 (d, J = 9.6 Hz, 1 H), 3.21 - 3.13 (m, 1H), 2.98 - 2.90 (m, 1H), 2.80 - 2.73 (m, 1H), 2.62 - 2.53 (m, 1H), 2.40 (s, 3H), 1.52 - 1.43 (m, 1H), 1.31 - 1.22 (m, 2H), 0.87 (t, J = 7.5 Hz, 3H). LCMS ESI(+)m / z: 455.1 (M+1) . Paso L: Add the compound (3S,5R)-5-ethyl-1-((5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3]pindin-4-i)amino)pyrrolidine-3-methyl cyanide (250 mg, 0.55 mmol) to 12 mL of ethanol, followed by the sequential addition of iron powder (922 mg, 16.5 mmol) and saturated ammonium chloride (2 mL) at room temperature. Stir at 80 °C and react for 0.5 h. Filter with diatomaceous earth while hot, wash with 10 mL of methanol, and concentrate the filtrate. The residue is then partitioned between 6 mL of water and 20 mL of ethyl acetate. Separate the organic phases and extract the aqueous phase twice with 20 mL of ethyl acetate. Combine the organic phases, wash with 10 mL of saturated salt water, and dry with anhydrous sodium sulfate. Finally, decompress and concentrate to obtain the crude product of the compound (3S,5R)-5-ethyl-1((5-amino-1-p-toluene sulfonyl-1 / 7-pyrrorol [2,3-o]pyridine-4-1)amino)pyrrolidine-3-cimetidine, which is used directly for the next step.LCMS ESI(+)m / z: 425.1 (M+1) . Paso M: Add the crude product of the compound (3S,5R)-5-ethyl-1-((5-amino-1-p-toluenesulfonyl1 / 7-pyrrolo[2,3-b]pyridine-4-1)amino)pyridine-3-methyl cyanide, triethyl orthoformate (122 mg, 0.82 mmol) and pyridine hydrochloride (6 mg, 0.05 mmol) to 15 ml of methylbenzene. Heat to 115°C under nitrogen and stir for 2 h. Decompress and evaporate the reaction solution to remove the solvent. Finally, subject the residues to silica column chromatography to obtain the compound (3S,5R)-5-ethyl-1-(6-p-toluene sulfonyl imidazo[4,5c(|pyrrolo[2,3-b]pyridine-1 (6 / - / )-l)pyrrolidine-3-methylcyanide (82 mg, 34% yield).1H NMR (400 MHz, CDCh) 5 8.90 (s, 1H), 8.23 ​​- 8.08 (m, 3H), 7.81 (s, 1H), 7.29 (d, J = 8.0 Hz, 2H), 7.00 (s, 1H), 3.86 - 3.72 (m, 1H), 3.60 - 3.27 (m, 3H), 2.74 - 2.63 (m, 1H), 2.36 (s, 3H), 2.19 2.09 (m, 1H), 1.52 - 1.40 (m, 2H), 0.80 (t, J = 7.5 Hz, 3H). LCMS ESI(+)m / z: 435.1 (M+1) . Step N: nr Lrnn / zznz / B / Yi Dissolve the compound (3S,5R)-5-ethyl-1-(6-p-toluene sulfonyl imidazo[4,5-c(]pyrrolo[2,3b]phydn-1 (6 / - / )-l)pyrrole-3-methyl cyanide (79 mg, 0.18 mmol) in 6 mL of methanol and add 1 N sodium hydroxide solution (2.0 mL, 2.0 mmol). Stir at 30 °C for 7 h. Dilute the reaction solution with 10 mL of water. Then, decompress and evaporate the solution to remove the methanol. Extract the residue four times with 10 mL of ethyl acetate. Combine the organic phases, wash with 10 mL of saturated brine, dry with anhydrous sodium sulfate, and filter by suction. Decompress and evaporate to remove the solvent. Subsequently, prepare the residues with HPLC to obtain the compound (3S,5R)-5-ethyl-1-(m¡dazo[4,5c(|p¡rrol¡o[2,3-b]p¡r¡n-1 (6 / - / )-¡l)pyrrol¡dina-3-methylnitrile (20 mg, 40% yield).1H NMR (400 MHz, DMSO-cfe) δ 11.85 (s, 1H), 9.10 - 8.01 (m, 2H), 7.46 (s, 1H), 6.76 (s, 1H), 3.92 - 3.52 (m, 4H), 2.67 (s, 1H), 1.98 - 1.87 (m, 1H), 1.40 - 1.26 (m, 2H), 0.72 (t, J = 7.4 Hz, 3H). LCMS ESI(+)m / z: 281.2 (M+1). Example 36 nr Lrnn / zznz / B / Yi 2- ((5R)-5-ethyl-1 -(imidazo[4,5-c(|p¡rrolo[2,3-b]p¡r¡d¡n-1 (6 / - / )-¡l)p¡rrol¡din-3-¡l)aceton¡thlo The specific implementation methods are as follows: Step A: Dissolve the compound (2S,4R)-N-Cbz-2-vinyl-4-hydroxypyrrolidine (3.50 g, 14.2 mmol) in Add 200 ml of methanol and 10% palladium on carbon (700 mg) under nitrogen protection. Replace the hydrogen. Stir at room temperature for 16 h. Perform suction filtration, wash twice with 20 ml of methanol. Finally, decompress and concentrate the filtrate to obtain the compound (2S,4R)-2-ethyl-4-hydroxypyrrolidine (1.63 g, 100% yield).1H NMR (400 MHz, CDCI3) 5 4.42 (t, J = 5.0 Hz, 1H), 3.37 - 3.27 (m, 1H), 3.19 (dd, J = 11.9, 4.7 Hz, 1 H), 2.92 (d, J= 11.9 Hz, 1H), 1.95 (dd, J= 13.5, 6.4 Hz, 1H), 1.62 - 1.37 (m, 3H), 0.95 (t, J = 7.4 Hz, 3H). LCMS ESI(+)m / z: 116.1 (M+1). Step B: Dissolve the compound (2S,4R)-2-ethyl-4-hydroxypyrrolidine (1.63 g, 14.2 mmol) in 70 ml of dichloromethane, followed by sodium nitrite (1.46 g, 21.2 mmol) and ptoluenesulfonic acid monohydrate (4.04 g, 21.2 mmol) at room temperature. Stir the mixture for 3 minutes and wash the filter mass with 20 ml of dichloromethane. Next, decompress and concentrate the filtrate to obtain the compound (2S,4R)-1-nitroso-2-ethyl-4-hydroxypyrrolidine (1.78 g, 87% yield) by silica gel column chromatography. 1H NMR (400 MHz, CDCI3) δ 4.63 - 4.52 (m, 2H), 3.86 (d, J = 15.8 Hz, 1H), 3.61 (ddd, J = 15.5, 4.8, 1.7 Hz, 1 H), 2.37 - 2.26 (m, 2H), 1.96- 1.74 (m, 3H), 1.04 (t, J = 7.5 Hz, 3H). LCMS ESI(+)m / z: 145.1 (M+1). Step C: Dissolve the compound (2S,4R)-1-nitroso-2-ethyl-4-hydroxypyrrolidine (950 mg, 6.59 mmol) in 45 mL of methanol and sequentially add zinc powder (8.62 g, 132 mmol) and acetic acid dropwise (9 mL) at room temperature. Stir the mixture at 30 °C for 20 min. Perform suction filtration of the reaction solution, wash with 5 mL of methanol, and concentrate the filtrate. The resulting oily substance (2S,4R)-1-amino-2-ethyl-4-hydroxypyrrolidine is then used directly in the following reaction. LCMS ESI(+)m / z: 131.1 (M+1). Step D: Dissolve the crude product compound from the previous step (2S,4R)-1-amino-2-ethyl-4-hydroxypyrrolidine in 50 ml of isopropyl alcohol and successively add the compounds A / ,A / -diisopropylethylamine (4.70 ml, 26.3 mmol) and 4-chloro-5-nitro-1-p-toluene sulfonyl-1 / 7-pyrrolio[2,3-b]pyridine (3.01 g, 8.56 mmol). Heat to 85 °C under nitrogen protection. Stir and react for 16 h. Next, concentrate the reaction solution and apply silica column chromatography to obtain the compound (3R,5R)-5-ethyl-1-((5-nitro-1 / 7-ptoluene sulfonyl-1-[2,3-ε]pyrrole and phdin-4-i)amino)pyrrolidine-3-methyl cyanide (1.61 g, 55% yield).1H NMR (400 MHz, CDCI3) 5 9.46 (s, 1H), 9.07 (s, 1H), 8.07 (d, J= 8.4 Hz, 2H), 7.51 (t, J = 4.9 Hz, 1H), 7.35 - 7.28 (m, 3H), 4.53 (d, J = 5.5 Hz, 1H), 3.67 (dd, J = 11.0, 5.5 Hz, 1H), 3.19 - 3.09 (m, 1H), 2.76 (dd, J= 11.1,3.4 Hz, 1H), 2.40 (s, 3H), 2.13 - 2.05 (m, 1H), 1.84 - 1.74 (m, 1H), 1.68 - 1.62 (m, 2H), 1.40 - 1.27 (m, 1H), 0.84 (t, J = 7.5 Hz, 3H). LCMS ESI(+)m / z: 446.1 (M+1). Step E: nr Lrnn / zznz / B / Yi Add the compound (3fi,5fi)-5-ethyl-1-((5-nitro-1-p-toluenesulfonyl-1 / 7-pyrrolo[2,3b]pyridine-4-1)amino)pyridine-3-methyl cyanide (1.61 g, 3.61 mmol) to 80 mL of ethanol, followed by the sequential addition of iron powder (6.05 g, 108 mmol) and saturated ammonium chloride (20 mL) at room temperature. Stir at 80 °C for 20 min. Filter through diatomaceous earth while hot, wash with 10 mL of methanol, and concentrate the filtrate. The residue is then partitioned between 50 mL of water and 50 mL of ethyl acetate. Separate the organic phase and extract the aqueous phase twice with 50 mL of ethyl acetate. Combine the organic phases, wash with 10 ml of saturated brine and dry with anhydrous sodium sulfate. Step F: Dissolve the compound (3F?,5fí-5-ethyl-1-(5-amino-1-p-toluene sulfoyl-1 / 7-pyrrolo[2,3b]pyridin-4-yl)amino)pyrrolidine-3-methylcyanide (75 mg, 0.18 mmol) in 1 ml of acetic acid and add triethyl protoformate (40 mg, 0.27 mmol) under nitrogen. Stir at 100 °C for 5 minutes under nitrogen. Decompress and evaporate the reaction solution to remove the solvent. Finally, subject the residues to silica column chromatography (pure ethyl acetate) to obtain the compound (3R,5R)-5-ethyl-1-(6-p-toluene sulfonyl imidazo[4,5c(|p¡pyrrolo[2,3-b]p¡r¡n-1 (6 / - / )-¡l)pyrrol¡din-3-ol (55 mg, 72% yield). LCMS ESI(+)m / z: 426.1 (M+1). Step G: Dissolve the compound (3F,5F)-5-ethyl-1-(6-p-toluene sulfonyl imidazo[4,5-c(1-pyrrolo[2,3b]pyridin-1 (^A7)-yl)pyrrole-3-ol (55 mg, 0.13 mmol) in 10 mL of dichloromethane and add Dess Martin oxidant (112 mg, 0.26 mmol) at room temperature. Mix at room temperature. Filter by suction with diatomaceous earth and wash with 10 mL of dichloromethane. Add saturated sodium bicarbonate (10 mL) to the filtrate and stir for 30 min. Then, perform suction filtration, separate the organic phases, and extract the aqueous phases twice with dichloromethane (10 mL). Next, fuse the organic phases and wash with 5 mL of saline solution. Dry with anhydrous sodium sulfate, remove the solvent by decompression and evaporation. Subsequently, silica column chromatography was applied to obtain the compound (3R,5R)-5-ethyl-1-(6-p-toluene sulfonimidazo[4,5-c(]pyrrolo[2,3b]pyridine-1 (6 / - / )-1)pyrrolidine-3-ketone (25 mg, 45% yield). LCMS ESI(+)m / z: 424.1 (M+1) . Paso H: Dissolve diethyl(cyanomethyl)phosphonate (67 mg, 0.38 mmol) in 8 mL of tetrahydrofuran and add 60% sodium hydrogen (15 mg, 0.38 mmol) under nitrogen in an ice bath. Stir at room temperature for 0.5 h. Under a nitrogen-protected ice bath, add the tetrahydrofuran compound solution (1 mL) of the compound (3R,5R)-5-ethyl-1-(6-ptoluene sulfonyl imidazo[4,5-d]pyrrolo[2,3-b]pyridine-1(6H)-yl)pyridine-3-ketone (80 mg, 0.19 mmol). Stir for 2 h in an ice bath. Add 5 ml of saturated ammonium chloride solution, raise the temperature to room temperature and stir for 5 min. Then, extract with ethyl acetate (3x5 ml), fuse the organic phases, wash with 3 ml of saturated saline solution, and dry with anhydrous sodium sulfate.Subsequently, decompress and concentrate the crude compound (n)-2-(5-ethyl-1-(6-p-toluene sulfonyl imidazo[4,5-d]pyrrolo[2,3-b]pyridine-1 (6 / - / )l)pyrrolodina-3-ylidene)acetonithol, which is used directly in the next step. LCMS ESI(+)m / z: 447.1 (M+1). Step I: Dissolve the crude product (R)-2-(5-ethyl-1-(6-p-toluene sulfonyl imidazo[4,5c(pyrrolo[2,3-β]pyridine-1 (6β-β)-β)pyrrolidine-3-lydeno)acetonithol in 10% methanol and add 10% palladium on carbon (84 mg) under nitrogen protection. Replace the hydrogen. Stir at room temperature for 16 h. Perform suction filtration, wash twice with 5 mL of methanol. Then compress and concentrate the filtrate. Finally, apply silica gel column chromatography to obtain the compound 2((5R)-5-ethyl-1-(6-p-toluene sulfonyl imidazo[4,5-β]pyrrolo[2,3-β]pyridine-1 (6 / - / )-¡l)pyrrol¡din-3yl)acetonitrile (67 mg, 79% yield). LCMS ESI(+)m / z: 449.2 (M+1). Step J: Dissolve the compound 2-((5R)-5-ethyl-1-(6-p-toluene sulfonyl imidazo[4,5-c]pyrrolo[2,3b]pyrrolidine-1 (6 / - / )-1)pyrrolidine-3-1)acetonitrile (30 mg, 0.06 mmol) in 3 mL of methanol and add 1 N sodium hydroxide solution (1.0 mL, 1.0 mmol). Stir at 30 °C for 6 h. Extract the residues four times with 5 mL of ethyl acetate. Then combine the organic phases and wash with 1 mL of saturated saline solution. Dry with anhydrous sodium sulfate, filter by suction, and remove the solvent by decompression and evaporation. After these steps, prepare the residues by silica column chromatography and high-performance liquid chromatography to obtain the compounds 2-((3S,5F?)-5-ethyl-1-(imidazo[4,5c(]pyrrolo[2,3-b]pyridin-1 (6 / - / )-1)pyrrolididin-3-1)acetonitrile (36-1, 10 mg, yield of 58%) and 2-((3F?,5fí)-5-ethyl-1-(imidazo[4,5-c / |pyrrolo[2,3-b]pyridin-1 (6 / - / )-1)pyrrolididin-3-1)acetonitrile (36-2, 8 mg, yield of 20%). Compuesto 36-1:2-((3S,5F?)-5-etil-1 -(imidazo[4,5-c / ]pirrolo[2,3 -b]piñdin-1 (6H)il)p¡rrolidin-3-il)acetonitrilo: 1H NMR (400 MHz, DMSO-d6) δ 11.79 (s, 1H), 9.10 - 7.84 (m, 2H), 7.42 (s, 1H), 6.84 (s, 1H), 3.94 - 3.44 (m, 2H), 3.37 - 3.25 (m, 2H), 3.05 - 2.71 (m, 3H), 1.52 -1.40 (m, 1H), 1.35 1.19 (m, 2H), 0.69 (t, J = 7.5 Hz, 3H). LCMS ESI(+)m / z: 295.1 (M+1). Compuesto 36-2: 2-((3F?,5F?)-5-etil-1 -(imidazo[4,5-c / ]pirrolo[2,3 -b]piñdin-1 (6H)il)pirrolidin-3-il)acetonitrilo: 1H NMR (400 MHz, DMSO-d6) δ 11.79 (s, 1H), 9.10 - 7.84 (m, 2H), 7.42 (s, 1H), 6.84 nr Lrnn / zznz / B / Yi (s, 1 Η), 3.94 - 3.44 (m, 2H), 3.37 - 3.25 (m, 2H), 3.05 - 2.71 (m, 3H), 1.52 -1.40 (m, 1H), 1.35 1.19 (m, 2H), 0.69 (t, J = 7.5 Hz, 3H).LCMS ESI(+)m / z: 295.1 (M+1). Example 37 Detecting the activation of hidden mole vulnerabilities in the Cinasa JAK experimental schema 1. Preparation of reagents (1) kinase reaction buffer solution Prepare the kinase reaction buffer solution with the following components: HEPES 50 mM, pH 7.5, EGTA 1 mM, MgCI2 10 mM, DTT 2 mM, Tween20 at 0.01%. (2) 1X detection buffer solution To prepare the detection buffer solution, dilute the 10X detection buffer solution to 1X with 9:1 deionized water (3) 4X kinase solution Dilute JAK to the final concentration 4X with the JAK reaction buffer solution (JAK1:40nM, JAK2: 0.5 nM) (4) 4X substrate solution Dilute the ULight™-JAK-1 substrate (Tyr1023) to 200 nM with the kinase reaction buffer solution (final concentration: 50 nM) (5) 4X ATP solution Dilute ATP to the final concentration 4X with the kinase reaction buffer solution (JAK1: 160 μM, JAK2: 40 μM) (6) Compound 4X test solution DMSO dissolves the test compound in a 10 mM stock solution, and then prepares it to the desired concentration with a 3-fold serial dilution, establishing 10 concentration points for each compound. Furthermore, the final concentration range of the test compound is: 10 μM - 0.5 nM (7) 4X Enzyme Reaction Termination Fluid The 1X test buffer solution dissolves EDTA to 40 mM (final EDTA concentration: 10 mM) (8) 4X antibody detection solution The 1X buffer solution dilutes the Eu-labeled antibody (antiphosphotyrosine (PT66)) to 8 nM (final antibody concentration: 2 nM) 2. Experimental Procedure (1) Successively add 2.5 µL of 4X JAK solution and 2.5 µL of diluted 4X test compound solution at different concentrations to microporous plate 384 and set up 2 multi-wells for each concentration. Meanwhile, set up the enzyme solution blank control group and the negative control group (DMSO group). (2) Shake the 384 well plate, mix the enzymes and compounds, centrifuge at 1000 rpm for 1 minute and incubate at room temperature for 60 minutes. (3) Add 2.5 pL of 4X substrate solution to a 384 well plate and centrifuge at 1000 rpm for 1 min. (4) Add 2.5 pL of ATP 4X solution to the 384 multi-well plate and centrifuge at 1000 rpm for 1 minute to start the enzymatic reaction. (5) JAK1 reacts at room temperature for 2 h and JAK2 reacts at room temperature for 1 h. (6) The final concentrations of each group of the JAK1 reaction are: JAK1: 10 nM, substrate: 50 nM, ATP: 40 uM and the final concentration range of the test compound is: 10 pM-0.5 nM The final concentrations of each group of the JAK2 reaction are: JAK2: 0.125 nM, substrate: 50 nM, ATP: 10 pM and the final concentration range of the test compounds is: 10 pM - 0.5 nM (7) After the enzymatic reaction, add 5 pL of 4X enzyme reaction stop solution to each well of the 384 well plate, centrifuge at 1000 rpm for 1 minute and incubate at room temperature for 5 min. (8) Add 5 pL of 4X detection antibody solution to each well of a 384 well plate (the final concentration of the detection antibody is 2 nM), centrifuge at 1000 rpm for 1 minute and incubate at room temperature for 1 h. (9) After antibody incubation, measure the signal value of each well on an Envision plate reader nr Lrnn / zznz / B / Yi 3. Data Analysis (1) The percentage inhibition rate corresponding to each concentration of the tested compounds is calculated by taking the blank control group of the enzyme solution as an inhibition rate of 100% and the negative control group (DMSO group) as an inhibition rate of 0%. (2) A nonlinear regression analysis was performed in GraphPad Prism software on the logarithm of the test compound concentration and the corresponding percent inhibition rate to obtain the half-inhibitory concentration (IC50) of the test compound. The experimental results obtained are listed in Table 1. Table 1 Example JAK1 (IC50,nM) JAK2 (IC50,nM) Example JAK1 (IC50.nM) JAK2 (IC50.nM) 1 23.8 70.9 20 4.30 1.90 2 0.28 1.70 21 0.92 4.77 3 0.17 0.28 22 1.60 4.04 4 0.47 0.95 23 2.71 6.07 5 0.28 1.45 24 7.72 46.6 6 0.66 3.89 25 5.20 5.30 7 0.08 4.00 26 41.7 151 8 1.50 5.00 27 1.70 2.30 9 0.14 0.70 28 3.50 13.1 10 0.80 6.10 29 13.9 27.5 11 0.57 2.98 30 2.80 28.1 12 1.77 3.28 31 6.90 71.8 13 16.0 56.7 32 6.80 15.3 14 13.5 7.50 33 11.2 29.1 15 5.14 16.1 34 73.8 51.7 16 1.31 16.1 35 9.50 61.3 17 2.0 1.2 36-1 6.8 23.5 18 6.31 13.8 36-2 43.6 126.9 19 2.37 6.01

Claims

1. A cyano-substituted cyclic hydrazine derivative, characterized in that the cyclic hydrazine derivative is a compound represented by the following structural formula or its pharmaceutically acceptable stereoisomer, geometric isomer, tautomer, racemate, hydrate, solvate, metabolite and salt or prodrug; nr Lrnn / zznz / B / Yi 2. A cyano-substituted cyclic hydrazine derivative, characterized in that the cyclic hydrazine derivative is a compound represented by the following structural formula or its pharmaceutically acceptable stereoisomer, geometric isomer, tautomer, racemate, hydrate, solvate, metabolite, and salt or prodrug; R1 R20 wherein, ring A is selected from cyclic groups having the following structure; R1 is one or more substituents that are the same or different; R1 is selected from hydrogen, alkyl; R10 is selected from cyano or a cyano-terminated group; R2 is selected from hydrogen, substituted or unsubstituted alkyl, amino, amino-substituted; R20 is selected from hydrogen, an amino protecting group. nc Lrnn / zznz / B / Yu 3. The cyano-substituted cyclic hydrazine derivative of claim 2, characterized in that the cyclic hydrazine derivative is a compound having the following structure: wherein, n is selected from a natural number from 1 to 3; X is selected from substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, -(CH2)mN(R3)-, -(CH2)mC(O)N(R3)-, -(CH2)mC(O)-; the bond between X and ring A is a single or double bond; R3 is selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl; and m is selected from a natural number from 1 to 3.

4. The cyano-substituted cyclic hydrazine derivative of claim 2, characterized in that the cyclic hydrazine derivative is a compound having the following structure: wherein A, X, R1 and R2 are as defined above; Y is selected from GR4, N; R4 is selected from hydrogen, hydroxyl, substituted or unsubstituted alkyl and substituted or unsubstituted alkoxy.

5. The cyano-substituted cyclic hydrazine derivative of claim 2, characterized in that the cyclic hydrazine derivative is a compound having the following structure: nr Lrnn / zznz / E / YiA wherein a is 0,1,2,3; Rw is selected from the cyano-terminated group.

6. The cyano-substituted cyclic hydrazine derivative of claim 2, characterized in that the cyclic hydrazine derivative is a compound having the following structure: wherein, Z is selected from substituted or unsubstituted alkylene; R5 is selected from hydrogen, substituted or unsubstituted alkyl, and substituted or unsubstituted heteroalkyl.

7. The cyano-substituted cyclic hydrazine derivative of claim 2, characterized in that the cyclic hydrazine derivative is a compound having the following structure, or its stereoisomer, isotopic isomer, salt: CN wherein, R5 is selected from hydrogen, methyl.

8. A method for preparing the cyano-substituted cyclic hydrazine derivative of any one of claims 2 to 7, characterized in that the method comprises the following process steps: S1. taking 11-1 as a starting material and nitrosylating the NH group thereon to form the nitroso product II-2; S2. converting the nitroso product II-2 into compound II-3 via a reduction reaction; S3. reacting compound 11-3 with compound 11-4 under alkaline conditions to obtain compound 11-5; S4. reducing the nitro group in compound 11-5 to amino by hydrogenation to obtain compound 11-6; S5. subjecting compound 11-6 to a cyclization reaction to obtain compound nr Lrnn / zznz / B / Yi H-7; S6. deprotecting compound 11-7 to obtain the target product; where, the structures from 11-1 to H-7 are as follows: Γ A ) 11-1 ' -„^NH Rl'' -'X^ Γ A j -2 ' NO R1^ '->Tr1 r A ] n-3 NH2 11-7 9. A pharmaceutical composition characterized in that it comprises the cyano-substituted cyclic hydrazine derivative of any one of claims 1 to 8 and at least one of the pharmaceutically acceptable carriers, excipients, diluents, adjuvants or vehicles; wherein the amount of the cyano-substituted cyclic hydrazine derivative is 0.0199.9% of the total mass of the pharmaceutical composition.

10. The pharmaceutical composition of claim 9, characterized in that the pharmaceutical composition contains additional therapeutic agents, and the additional therapeutic agents are selected from anti-inflammatory drugs, immunomodulatory or immunosuppressive agents, neurotrophic factors, active agents for the treatment of cardiovascular diseases, active agents for the treatment of diabetes, and active agents for the treatment of autoimmune diseases.

11. The use of the compound of any of claims 1 to 8 or the pharmaceutical composition of claim 9 or 10 in the preparation of a medicament, characterized in that: the medicament is used to prevent, manage, treat or alleviate autoimmune diseases or proliferative diseases of a patient and / or to inhibit or regulate protein kinase activity.